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Abstract 
The present dissertation investigates the influence of brand as well as substance-related 
marketing attributes on prescription pharmaceutical sales within a state-controlled market. For 
this purpose, a systematic literature review was conducted in the first instance, during which 
knowledge about the most relevant research within this field was gathered. Consequently, 
over 538 publications were reviewed and indicated as being potentially relevant, leading to an 
eventual count of 98 core publications. However, most of these studies had been conducted in 
the mainly unrestricted US market. These findings were then summarised and statistically 
evaluated. In a second step, based on the literature review, a qualitative study, containing 
focus and Delphi groups, was then performed. The participants in these studies were involved 
in pharmaceutical marketing within a state-controlled prescriptions pharmaceuticals market. 
Consequently, the findings were slightly different to those derived by the systematic literature 
review. Based on this second step, seven hypotheses were proposed. In the third step, these 
hypotheses were tested, using collected data and a secondary market dataset provided by a 
market research institute. A statistical analysis was then performed, applying descriptive as 
well as multiple regression analytical methods. The evaluation of the results resulted in a 
conceptual model of physician targeting, leading to several theoretical, methodological and 
managerial implications. 
 
Keywords: Pharmaceutical Prescriptions Marketing, State-Regulated Market, Marketing Mix, 
Order-of-entry, Systematic literature review, Focus Group Technique, Delphi Group 
Technique, Secondary Data, Multiple Regression  
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Executive Summary 
The pharmaceutical market is experiencing significantly increased research and development 
costs, as well as price and other competitive pressures. Consequently, the entire industry has 
moved into a difficult economic environment. At the same time, marketing expenditure are 
increasing significantly in comparison to product development costs, meaning that the use of 
marketing in the pharmaceutical sector is of considerable interest. Furthermore, it has been 
shown that on the one hand a decline in “product innovation” has taken place, whereas on the 
other hand an increase in competition is happening within the pharmaceutical marketplace, 
thus pressurising pharmaceutical companies to increase their marketing expenditure and the 
effectiveness of their marketing measures. Despite the increased popularity in research into 
pharmaceutical marketing, there are still many undiscovered areas, particularly as most of the 
research has been conducted in a non-state-regulated market. Furthermore, there is room for 
further research in order to derive a “physician-targeting” model and to gain a better insight 
into product design-related areas. Consequently, scholarly research exploring pharmaceutical 
marketing is rather piecemeal and has tended to focus on various very specific issues, so 
research into this area is overdue.  
 
Therefore, in a first step, a systematic review of the literature relevant to pharmaceutical 
marketing was conducted. Databases of scientific literature were systematically scanned, and 
in total 538 publications were identified as potentially relevant. After a systematic literature 
selection process, the results of 98 final core publications were evaluated and analysed using 
descriptive statistics. It was found that the order-of-entry effect is critical in the sector, 
indicating that the early entrant has an advantage, as the early entrant defines the market 
standard, whereas the late entrant can benefit from the experience and promotional activities 
made by the early entrant in order to prepare the market. This leads to the conclusion that both 
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strategies are a feasible option. Based on a strategic decision, marketing activities have to be 
set accordingly, taking regulatory limitations into account. Consequently, according to the 
literature, the most relevant factors for product design are innovativeness, efficacy and 
branding, as well as qualities such as safety. In addition, it was revealed that a low price 
strategy is not necessarily effective. Regarding promotion, it was determined that personal 
selling, prescriber-directed advertisement (DTP), sampling and word-of-mouth-related 
activities are of high relevance. Distributional issues were not considered highly in the 
research. In total, 21 relevant marketing criteria and their sub-criteria were indicated. 
 
Having gathered the actual scientific knowledge and indicated the research gaps, and in order 
to investigate essential marketing success factors, a qualitative focus study employing five 
Swiss healthcare professionals in middle and senior management positions was conducted. 
The focus group study set-up was based on the conclusions of the systematic literature 
review, and they were asked to express their personal opinions regarding the importance of 
various factors that might influence the turnover of prescription drugs. This two-hour 
roundtable interview was tape-recorded, following which a transcript was produced and the 
content was analysed. As a result, 11 relevant marketing variables and their 24 attributes were 
derived.  
 
In order to increase the validity of the results from the focus group study, a Delphi group 
study was additionally conducted, employing a different group of eleven pharmaceutical 
marketing experts. The Delphi group was designed on the basis of the focus group findings. 
This study contained three steps. In the first step, a questionnaire containing open questions 
was sent to the participants. The returned answers were then analysed and a second 
questionnaire, containing closed, Likert-type scale questions, was created and distributed. In 
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the final step, the participants were asked to re-evaluate their answers from the previous round 
where a high level of disagreement was present, in order to reach a consensus within the 
group. In total, 17 variables were derived and ranked according to their importance within 
their marketing categories (4Ps). This study concluded that successful marketing has to 
consider appropriate product properties, including issues such as efficacy, safety and a 
promotion policy that takes opinion leaders and personal selling into account. In a next step, 
and based on these results, seven hypotheses were derived and a conceptual model of 
“physician-targeting” presented. 
 
The aim of this step was to test the proposed hypothesis. For this purpose, a secondary dataset 
containing five prescription classes, with 37 substances from 108 medical products, for the 
period 1995 to 2005 from the state-regulated Swiss market were used. However, despite 
incomplete informational content, additional data had to be gathered from alternative sources, 
so an online survey of 80 Swiss pharmacists and 6,000 medical doctors (costumers) was 
conducted. In a next step, all data were collated and tested for their quality, by applying 
descriptive statistical methods, and then they were prepared for further analysis. The analysis 
indicated different sales (revenue) curve slopes and different sales increases/decreases within 
the same time period. Consequently, an additional variable as an indicator for the slope (beta 
value), in addition to the existing dependent “average sales” variable, was implemented. 
Furthermore, the analysis revealed a two-level data structure, containing a brand and a 
substance level. As a result, the data had to be aggregated accordingly, in order to perform a 
multiple regression analysis. A test of the analysis result for reliability showed a positive 
outcome.  
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Evaluating the statistical results of the multiple regression analysis revealed that the order-of-
entry effect does not have an influence on sales, whereas a positive relation to sales increases 
(beta) was indicated. This means that it is not essential to be early to the market, and a later 
market entry is also a feasible alternative. Despite finding a positive relation between the 
“marketing expenditure” and sales, high multicollinearity between expenses involved in 
personal selling, mailing and advertising was revealed, leading to the conclusion that no 
differentiation is made when implementing these marketing instruments. Regarding product 
design it was shown that “drug interaction” has a negative relation to “beta sales”, leading to 
the conclusion that higher drug interactions reduce sales, which is supported by the scientific 
literature. Furthermore, the results showed a positive relation between “perceived quality” on 
the one hand and a positive relation with “side-effects” on the other. This rather spurious 
result led to the conclusion that prescribers (costumers) are either not or very badly informed, 
or they do not care about “side-effects”. Furthermore, a positive relation between “average 
price” and sales was found, leading to the conclusion that prescribers (costumers) prefer to 
choose the more expensive medication to suit personal financial benefit.  
 
This dissertation has derived some implications for marketers, policymakers and researchers. 
Therefore, the following guidance can be given to marketers in state-regulated prescription 
drugs markets: (1) It is not essential to be first to market; (2) Enhance prescribers 
(costumers)’ perceived quality; (3) A high price policy is beneficial for sales; (4) Apply 
specific promotional measures; and (5) Maintain strong marketing activities during the launch 
phase. On the other hand, policymakers should: (1) Inhibit prescribers (costumers)’ medical 
drug price-related prescription practice by banning the practice of self-dispensing physicians; 
(2) Negotiate lower medical prices; (3) Inhibit companies’ promotional activities; and (4) 
Educational programmes as well as systems on medical drug information for prescribers 
 9 
(costumers) should be implemented. These opposing interests result in a conflict between 
marketers and policymakers. However, because of rising costs in healthcare, the role of 
policymakers will become ever more important. Nevertheless, this dissertation has also 
revealed new potential research areas. These are:  
(1) Factors influencing perceived quality; (2) Price elasticity of prescription pharmaceutical 
marketing demand models (3) Generalisation of research results; (4) The role of distribution 
and the order-of-market entry; and (5) Relevant factors for product policy. 
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1. Introduction 
 
1.1. Pharmaceutical Market 
‘The importance of the pharmaceutical industry is set to grow further within developed 
nations as an aging population profile combines with diminishing pension funds to introduce 
the prospect of not only living longer but having to remain economically active for longer’ 
(Black and Tagg, 2007, p348). 
The pharmaceutical industry has shown enormous and innovative strength because of the 
sustained demand for novel therapies and in response to intense competitive pressures. In the 
past this has led repeatedly to new research processes which have culminated in the 
development of new products. Nevertheless, even though trends in sales of pharmaceuticals in 
recent years have continuously increased, and despite the demographic growth trend which 
portends a growing elderly population in need of nursing care, pharmaceutical sales (revenue) 
will certainly not continue to grow so strongly because of the persistent explosion of costs in 
the health sector and the resultant pressure that will follow this growth in costs 
(Blechschmidt, 2003; Schulenburg, Kulp et al., 2003).  
Worldwide spending on pharmaceuticals, the largest component of the life sciences industry, 
was estimated in 2005 to be $565.9 billion, growing at 5.2% and 7.1% annually in the United 
States and Europe (EFPIA, 2006). ‘In fact, nine of the largest US pharmaceutical companies 
spent $45.4 billion on sales (revenue), marketing and administration in 2001. This is twice the 
amount that these companies spent on research and development’ (Black and Tagg, 2007, 
p348; Families USA, 2003). In 2002, the twelve largest pharmaceutical companies between 
them accounted for approximately about half of the total market volume (see Table 1-1) 
(Burckhardt, 2003).  
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Rank Company Country Revenue 
(Billion $) 
Market 
Share  
 
Table 1-1: Global sales (revenue) of medications, 2003 (Burckhardt, 2003)  
 
Despite the massive investment in pharmaceutical research, the industry is experiencing 
significant problems of decreasing productivity relating to new and existing drugs 
(Datamonitor, 2007; Nichols, 1994; Ruffolo, 2004). Schmid and James (2001) suggested that 
this declining productivity is due at least partly to the fact that simple disease targets have 
been addressed, and firms are now left with targets that are much more difficult to address 
from traditional chemistry perspectives, or where their role in disease is not well understood. 
This can be underlined by the statement made in Dr Marcia Angell’s  (2005, p75) 
controversial book “The Truth About the Drug Companies” that in the ‘five years 1998 
through 2002, 415 new drugs were approved by the United States Food and Drug 
Administration (FDA), of which only 14% were classified by the FDA as truly innovative. A 
further 9% were old drugs that had been changed in some way to appear, in the FDA’s view, 
significantly improved. The remaining 77% were classified as being no better than drugs 
already on the market, or as treating the same condition as drugs already in existence – termed 
“me-too” drugs’ (see also www.fda.gov). In addition, it has been highlighted by Angell (2005, 
p80) that ‘me-too drugs are made by competing companies, who create their own versions of 
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blockbuster drugs to cut into a market that has already proved both lucrative and expandable’. 
For example, in addition to Prilosec and Nexium, there are three other competing proton 
pump inhibitors on the market. Probably the most popular family of me-too drugs (copies of 
the original drugs) is the statins1 (Kritz, 2001; Rowland, 2003). As stated by Angell (2005, 
p81), ‘the original statin, Merck’s Mevacor, appeared in 1987, and other companies were 
quick to produce their own statins. Mevacor was joined by the same company’s me-too drug, 
Zocor, Pfizer’s Lipitor, Bristol-Myers’ Squibb’s Pravachol, Novartis’s Lescol and 
AstraZeneca’s Crestor in 2003’.  
Jarvis (2001) reported that there is a widening gap between increasing research and 
development spending and the decreasing number of new products actually reaching the 
market. The survival probability of therapeutic inventions – only 1 in 5,000 to 10,000 new 
inventions eventually makes it to market – leads to life sciences development portfolios being 
uniquely shaped as funnels (Ding and Eliashberg, 2002; Grewal et al., 2008; Jaakkola and 
Renko, 2007; Schweitzer, 1997). Furthermore, according to the United States Securities and 
Exchange Commission (SEC) and shareholder reports for 2001, the biggest drug companies 
spent on average of about 35% of their revenues on “Marketing and Administration” (Henry 
J. Kaiser, 2004; Public, 2003). In fact, the ‘large pharmaceutical companies spent much more 
on marketing in 2002 than on R&D’ (Angell, 2005, p122), which is illustrated by Hollon’s 
(1999) quote that sets out the critical role of marketing and product innovation within the 
prescription drugs market: 
‘The winners in the prescription drugs market are not going to be the ones with the patents or 
products, but those that are the best marketers’ (Hollon, 1999, p384). 
As a result, the impact of marketing activities on pharmaceutical sales (revenue) is worthy of 
investigation, and one would expect the vast amount of research on marketing in the past half-
                                                 
1
 Drugs used to lower blood cholesterol levels. 
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century would offer significant insights into this area. In fact, in recent years, marketing 
scholars appear to have become much more interested in pharmaceutical marketing. For 
Stremersch (2008, p232), ‘the Health and Marketing area is probably one of the richest in 
unstudied phenomena that the marketing discipline has ever seen in its history’. He sees 
evidence that ‘Health and Marketing is starting to gain firm ground as a new research field 
defined by its application area’ (Stremersch, 2008, p229). This is evidenced by the appearance 
of pharmaceutical marketing research in the discipline’s top journal – The Journal of 
Marketing (e.g. Narayanan, Desiraju, and Chintagunta, 2004; Stremersch and Van Dyck, 
2009) – as well as a recent special issue of The International Journal of Research in Marketing 
(Stremersch, 2008), another top-level journal. In fact, a dedicated outlet, The International 
Journal of Pharmaceutical and Healthcare Marketing, appeared in 2007, although this was 
balanced by the apparent demise of The Journal of Pharmaceutical Marketing and 
Management in 2008. The relevance of this discipline is also justified by the vast range of 
specialised professional pharmaceutical marketing conferences such as The Annual 
Healthcare New Media Marketing Conference; The Annual Multicultural Pharmaceutical and 
Healthcare Marketing Conference; The Annual Public Relations & Communications Summit; 
APMRG; CDC’s National Conference on Health Communication, Marketing, and Media; The 
DigiPharm Europe Conference; The Digital Pharma Conference; The e-Patient Connections 
Conference; The Eye for Pharma Conference, KOL Europe Conference; The mHealth 
Conference; The PharmaMarketing Summit; The Social Communications & Healthcare 
Conference and The Social Media for the Pharmaceutical Industry Conference. Furthermore, 
increasing expertise on Health and Marketing among faculties, combined with high societal 
demand, has induced schools such as Columbia University; Deemed University, New Delhi; 
Fairleigh Dickinson University; Middlesex University; Saint Joseph's University, The George 
Washington University; University of California; University of Illinois; University of 
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Mississippi; University of Phoenix and University of Washington to offer healthcare 
marketing degree programmes.  
Furthermore, ‘sceptics may argue that there is nothing new to studying promotional 
effectiveness; however, the health context is unique and may yield unique responsiveness’ 
(Kremer et al., 2008; Stremersch, 2008, p232). According to Singh and Smith (2005), the 
effectiveness of pharmaceutical promotional expenditure appears to be heterogeneous, 
depending on a wide range of variables. Existing generalisations of the effectiveness of 
marketing instruments cannot be generally employed (e.g. Albers et al., 2008; Assmus et al., 
1984; Bijmolt et al., 2005; Tellis, 1988; Tellis and Ambler, 2007; Vakratsas and Ambler, 
1999) because the pharmaceutical industry differs from markets in at least three important 
aspects. First, the pharmaceutical industry markets in a provider-patient (consumer) structure, 
where the physician has a unique gatekeeping function (Stremersch and Van Dyck, 2009). 
Furthermore, the pharmaceutical industry has to market to both physicians (costumers) and 
patients (consumers) (Ding and Eliashberg, 2008). Second, in comparison with other 
industries such as engineering, manufacturing and knowledge-intensive services (BIS, 2007), 
the pharmaceutical industry spends a large percentage of its revenues on marketing than on 
research and development (R&D) (Gagnon and Lexchin, 2008). Third, the pharmaceutical 
industry requires specialised marketing knowledge such as new product development, life 
cycle management and marketing management (Stremersch and Van Dyck, 2009).  
As well as its clear commercial and social importance, scholarly interest in the pharmaceutical 
sector is presumably driven by the fact that the pharmaceutical market exhibits several 
peculiarities in comparison to the industrial and consumer markets that marketing research 
has tended to investigate in the past. Pharmaceutical marketing is not only relevant, but it also 
raises new questions. In particular, the complex tripartite relationship (3P-triangle) (see figure 
1-1) in prescription drug marketing, between a) the party who pays for the drug (in most cases 
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the health insurer or the state), b) the patient (consumer) who actually uses the drug and c) the 
prescriber of the drug, is a critical influence.  
 
 
 
Health Insurances / Authorities 
(payers) 
Physicians 
(prescribers) 
Patients 
(users) 
 
Figure 1-1: Illustration of the tripartite relationship in prescription drug marketing  
 
Thus, this specific business area is faced with the unique situation that the actual purchase 
decision is not made by the payer or the user (consumer), but by the prescriber, i.e. the 
physician (costumer) (Ding and Eliashberg, 2008; Gonul and Carter, 2001; Groves et al., 
2003; Harms et al., 2002). White et al. (2004, p66) show that ‘doctors (costumers) remain the 
indispensable arbiter of care in the eyes of the consumer and, in terms of patient (consumer) 
care, doctor (costumer)-patient (consumer) relationships are substantially unaffected by drug 
marketers’ investment in consumer promotion’. However, ‘it has also been shown that neither 
physicians (costumers) nor patients (consumers) are immune to the effects of marketing’ 
(Hollon, 1999, p384). These conflicting opinions are in need of a systematic attempt at 
reconciliation. Furthermore, the ‘Health and Marketing field is also an intrinsically unstable 
environment’ (Stremersch, 2008, p233), characterised by the continuous changes of 
regulations, new discoveries and new health treatments.  
Finally, it can be stated that ‘the practical relevance of research questions in the Health and 
Marketing field to firms can easily be appreciated if one considers that life sciences firms 
often spend a large amount of their revenues on promoting their therapies’ (Stremersch, 2008, 
p233; see also Kremer et al., 2008). Furthermore, ‘rising healthcare costs have become a 
major public concern in recent years and prescription drugs represent a significant component 
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of such costs, with shares ranging from 4% in the United States (US) to nearly 18% in France 
and Italy’ (Gonzalez et al., 2008, p247; see also Kyle, 2003). 
 
1.1.1. Marketing in the Pharmaceutical Sector 
An analysis of the situation in the pharmaceutical market is a pre-condition to being able to 
set up a marketing concept. In the following section an overview of the market situation and 
relevant pharmaceutical marketing strategies is therefore given, in order to be able to deduce 
the required goals of this research. 
Except for the USA, most countries have a strongly regulated market, which is certainly the 
case with the Swiss health system (Gallay, 2002). As an example, upper limits for prices for 
medication are mandated by (Federal) legislation.  
Since the public in general and health insurance companies in particular are no longer 
prepared to accept highly or overpriced medicines, or even increases in pricing for minimal 
therapeutic advances, the price leeway for many pharmaceutical companies has grown smaller 
and has thus led to lower revenues (see also Gonzalez et al., 2008). This has forced companies 
to reduce their costs, e.g. by cutting back on their marketing communication budgets or taking 
other measures to improve their margins. Although this approach is well-known in the 
industry, there are still some restraints involved in this shift. In particular, losses made in 
market shares in the mass markets are practically impossible to recover (Kotler and Keller, 
2006). Since the possible measures for cost reduction are limited, new ways to increase sales 
(revenue) have to be found.  
In the pharmaceutical sector, two predominant strategic trends have become apparent in 
recent years (Dogramatzis, 2002). While companies such as Novartis continue to concentrate 
on the mass market, organisations such as Roche have chosen to follow the path of 
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specialising in products used in cases with less prevalent indications (market niche segment 
strategy), primarily in the area of oncology (Fibig and Hutt, 2003). The advantages of the 
latter approach are obvious: smaller sales teams, as fewer medical specialists are needed, and 
smaller marketing outlays, since the majority of patients (consumers) with such serious 
illnesses are already well-informed. In contrast, the manufacturers of products used for the 
more prevalent conditions suffer from the enormous marketing expenditure needed to 
differentiate themselves from the competition and attract the attention of doctors (costumers) 
and patients (consumers) alike.  
Furthermore, the decision of the order-of-market entry appears to have a decisive influence 
upon sales. This phenomenon can be illustrated by sales (revenue) figures taken from the 
PDE5-inhibitiors market. As a first entrant, the Pfizer company launched in March 1998 its 
blockbuster product Viagra (sildenafil) (see also Angell, 2005) and has generated since then 
total sales (revenue) of more than over $8 billion. In late 2002, Levitra (vardenafil), which 
was jointly developed by Bayer and Glaxo SmithKline, entered the market. In February 2003, 
as a third entrant, the Icos company and its sales partner Eli Lilly launched Cialis (tadalafil). 
As clearly shown in Figure 1-2, the sales of the medical drugs that have entered the market 
later are remarkably lower. At this point it should be noted that the efficacy of all three 
substances is quite similar (Gresser and Gleiter, 2002; Moore, 2005). This illustrative 
example shows quite clearly the relevance of the order-of-market entry taking place within a 
specific prescription pharmaceutical market.  
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Figure 1-2: PDE5-Inhibitors international sales (revenue) developments  
(Source: www.sec.gov, taken from applicable business reports) 
 
In the past, companies realised that the sales of life-saving and life-prolonging medication 
were related largely in proportion to the respective marketing measures employed. As a 
consequence, as described by Angell (2005, p126), the pharmaceutical industry in the United 
States has increased the number of its salespersonnel to 88,000 [one per every five to six 
physicians (costumers)]. At the same time, neither the number of products promoted nor the 
number of practising doctors (costumers) changed in a remotely similar way to the number of 
salesforce personnel. The absolute rise in research expenses and advances in genetics has not 
led to the expected volume of more innovative medications. The forecast increase, driven by 
advances in human genetics, from about 500 to over 30,000 “target points” as leads for 
product generation is far from becoming reality. This leads to the situation where evermore 
products with effects that are difficult to differentiate are being offered in the same 
therapeutic areas (see also Angell, 2005).  
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This illustrative example demonstrates the relevance of order-of-market entry within this 
specific market for sales (revenue) success. However, it can also be assumed that this is not 
the only decisive factor, as indicated by the gradual sales (revenue) increase of a later entrant 
(Cialis).  
 
1.1.2. The Marketing Mix Concept 
Marketing is defined by the American Marketing Association (AMA) as ‘the activity, set of 
institutions, and processes for creating, communicating, delivering, and exchanging offerings 
that have value for customers, clients, partners, and society at large’.2  Effectively, marketing 
is an attempt to modify behaviour and hopefully stimulate demand (see also Smith, 1983). 
McCarthy and Perreault (1960) proposed a fundamental conceptual marketing approach 
termed the ‘4Ps’, which is generally accepted within consumer goods circles. The 4Ps refer to 
four marketing instrument areas: product (includes product design, package, brand, service), 
place (distribution channels), promotion (personal selling, advertising, sales (revenue) 
promotion, publicity) and price (see also Frey, 1956; Kotler, 1976). In addition, Borden 
(1965, p368) defined ‘the “marketing mix” as the interrelationship among the marketing 
decision variables (marketing instruments)’. Furthermore, according to Balachandran and 
Gensch (1974, p160), ‘one of the most challenging questions is how to determine the 
optimum marketing mix’.  
In addition, for Liberman and Rotarius (2001, p23), ‘the nature of the healthcare environment 
requires the addition of a fifth factor – partners’. This addition recognises that the modern 
healthcare industry is defined by the unprecedented number of interorganisational 
collaborations taking place (Rotarius, 1997). Furthermore, Harms et al. (2002, p147) 
concluded that the ‘future of pharmaceutical marketing depends on the ability to involve 
                                                 
2
 This definition was approved by the American Marketing Association (AMA) in October 2007 
(www.marketingpower.com) 
 29 
clinicians, patients (consumers), politicians, insurance companies, media, the general public 
and all healthcare professionals’. They proposed a “4 + 3P” (with the addition of positioning, 
politics and patients (consumers)) marketing mix approach. 
Despite this being a popular field of research in the past, it has been proved not to be so 
popular in the last twenty years. The application of the marketing mix concept by marketing 
practitioners (costumers) is common practice and can be found in most of the marketing text 
books described (see also Kotler, 1998). However, most of the recent research in the 
pharmaceutical marketing area has focused on specific topics such as product design, 
promotion, pricing or distribution (see also Chapter 2). There have been isolated studies 
where researchers have investigated the conceptual marketing mix framework in a general 
context of multinational corporations, applying a systematic review (Brinik and Bowman, 
2007). However, no published empirical study has investigated the marketing mix in a 
pharmaceutical marketing context. Interestingly, Stremersch and Van Dyck (2009), in the 
Journal of Marketing, published research directions similar to those indicated in this thesis. In 
fact, they highlighted that there is a need for further research within the area of therapy 
launch, investigating market entry timing as well as salesforce and communication 
management within the area of therapy promotion. As will be discussed later, there is a need 
to revaluate this concept in today’s prescription pharmaceuticals environment, in order to 
close this gap in pharmaceutical marketing research. Consequently, the optimum marketing 
mix still remains a critical issue for today’s research. There is a further need for research on 
this subject in pharmaceutical marketing, marketing instruments and “physician-targeting” 
models especially.  
For services marketing, this approach was expanded with an additional three marketing mix 
variables (people, process and physical evidence, see also Booms and Bitner, 1981; 
Vandermerwe and Rada, 1988). Similar to other industries, in pharmaceutical marketing it 
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can be assumed that not all of the decision variables have the same relevance. However, 
according to Balachandran and Gensch (1974, p160), ‘one of the most challenging questions 
is how to determine the optimum marketing mix’. The parameters of the marketing mix are 
given by the marketing concept, which in turn relies upon marketing research to define 
market segment, its size and to ensure that the objectives of the marketing are satisfied by 
controllable parameter of the marketing mix. To satisfy these needs, the marketing team 
makes decisions about many marketing mix parameters (Kotler, 1998). 
 
1.1.3. The Market for Pharmaceuticals  
In order to investigate pharmaceutical marketing, it is essential to be aware of the current 
market environment and to be familiar with the market of prescription drugs. Therefore, in the 
first stage, the most relevant healthcare systems are presented and their implications for the 
pharmaceutical business discussed. In a second stage (see Paragraph 1.1.6.), a general market 
model is presented. 
A number of different health systems have emerged worldwide (Reinhardt et al., 2002). 
Moreover, modes of marketing vary across different health systems. The marketing concept 
has to consider the actual market environment, which means that appropriate new marketing 
strategies must be developed for each market (Cooper and Kleinschmidt, 1993; Liberman and 
Rotarius, 2001). It is therefore essential to be familiar with the several country-specific 
peculiarities exhibited by pharmaceutical markets. In this section, a number of different health 
systems (see Table 1-2), along with corresponding advantages and disadvantages peculiar to 
the state and region, are presented. As an illustration, two different (non-British) health 
systems, one with a relatively unregulated (financed by private insurances) and one with a 
highly regulated (financed by social insurance) market structure are discussed. 
 Table 1-2: Overview of the most important health systems (Gallay, 2002) 
 
The American unregulated pharmaceutical market, by private insurances financed, is one of 
the few that allows the relatively free setting of prices. In contrast to many other health 
systems, as shown in Table 1-2, the American system is distinguished by its customer 
orientation. It is run with a commercial focus and contains many more market elements, and 
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the high value placed on quality assurance is especially important. A further major difference 
lies in the fact that in the USA there is no insurance requirement and no central 
administration. Although the American health system is one of the most expensive in the 
world, almost 16% of all Americans are uninsured. Of those who are insured, 60% are insured 
through their employers; 12% through other private insurance; 13% supported by Medicaid 
(special insurance for the poor) and 15% through Medicare (insurance for the retired and for 
those over 65 years old). Medicare is financed by a wage tax, and Medicaid is supported by 
the Federal government and individual states (see Figure 1-3). Unfortunately, medication 
costs which are not set by the state are not always covered by insurance, a situation that leads 
to financial problems for many. However, there has recently been a new healthcare reform 
introduced by the Obama administration in order to improve this situation (see also 
www.whitehouse.gov).  
 
Figure 1-3: The American health system (partly OECD Secretariat, 2003) 
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By contrast, the Swiss medication market, for example, is very highly regulated (see also 
Kocher and Oggier, 2007) (c.f. Figure 1-4). Special rules are established by health insurance 
law, in order to compensate the provider of services (the rules include costs that will be 
assumed by the health fund). The list of approved medications created for this purpose 
determines the composition of a medication and its price. For the purposes of basic insurance, 
compensation is paid only for those medications found on the approved list. These 
medications can be obtained by the insured person directly from the pharmacist or from many 
physicians (costumers)’ practices (again, a complicated regulation). Pharmacists are 
remunerated for their services with a fixed-fee form of compensation (this applies only for 
prescription drugs) (Apothekenverband, 2003), which is independent of the sales price. There 
is a lack of incentives for efficiency on the part of patients (consumers) and providers, so the 
more doctors (costumers) prescribe and examine, the more they earn. Then there is also little 
incentive for insurance companies to develop much vaunted innovative, lower-cost insurance 
policies. In addition, there is the strict prohibition of parallel imports of drugs, resulting in 
punitively high drug prices compared to those in the EU. This has resulted in a mantra in 
Swiss healthcare politics that healthcare in Switzerland is of good quality but quite expensive. 
Indeed, according to OECD statistics, Switzerland operates the third most expensive system 
in the world – behind only the USA and Germany (Civitas, 2002). This creates an attractive 
pharmaceutical market environment. According to Business Monitor Report (2009), the 
overall size of the Swiss market and high per-capita spend on drugs continues to be one of the 
key attractions.  
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Figure 1-4: The Swiss health system (partly Office federal de la statistique, 2005) 
 
As a result, it can be stated, for state-regulated markets as well as other markets, that the 
market for healthcare provision and the perfect situation of supply matching demand is almost 
never reached. This is because the market for healthcare fails to meet some of the basic 
assumptions necessary for a perfectly competitive market. There are a number of reasons for 
market failure in relation to healthcare (Elliott and Payne, 2005, p10): 
• Imperfect information on the quality and price of the healthcare good (service). 
• Moral hazard: some form of insurance cover makes one less careful. 
• Agency relationship between patients (consumers) and healthcare providers as a result 
of an asymmetry of information [typically, the doctor (costumer) knows more than the 
patient (consumer)]. 
• Supplier-induced demand: providers with a superior knowledge about health and 
healthcare interventions are therefore in a position to influence demand for them. 
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These four examples show why a market failure is a potential problem in relation to 
healthcare provision and the introduction of drugs. The automatic outcome of a perfect market 
is efficiency, and the identification of market failures is important because it may lead to 
inefficiency in the healthcare market.  
Most scientific pharmaceutical marketing and related studies focus on the US market. 
According to Copper and Kleinschmidt (1993, p91), ‘it is viewed as a problem, that studies 
tend to have a one-country (or even one-region) focus (in this case the US market)’. In the 
present research, only a minority of studies (refer also to Chapter 2) have investigated a non-
US market (c.f. Table 1-3). This conclusion is supported by Birnik and Bowman (2007, 
p317), who note that ‘extant research has largely focused on the advanced economies of the 
US, Japan and Western Europe’. Furthermore, Birnik and Bowman (2007, p317) conclude 
that ‘this literature is thus prone to the same geographic bias found in a great deal of 
published research’. However, it has to be considered that because of the different market 
structures, these findings mainly apply to the specific investigated market. In addition, it has 
to be noted that the US market, as previously discussed, is substantively different to most 
Western markets, both in the nature of payment and the promotional environment. So far, few 
published studies which investigate a state-controlled market, such as Belgium, Finland, 
France, Germany, Japan, Netherlands and Switzerland, financed by combined state and 
private funding, are available (see Table 1-3). Furthermore, state-controlled markets have 
different peculiarities regarding governmental management, as well regulations that are 
implemented. Consequently, the results derived from scientific research performed on the 
basis of one specific country cannot be fully generalised to other markets. However, as 
emphasised by Stremersch (2008, p233), the ‘primary goal of scholarly research in 
pharmaceutical marketing should not be to derive theories that can be generalized perfectly to 
all situations’. In other words, there is a need for specific context-related research. 
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Markets Number of 
Publications 
found 
Main Author 
Central 
America 
1 Rojas (2009) 
China 1 Chen (2007) 
Belgium 1 Parsons (1981) 
France 1 Lilien (1990) 
Italy 1 Coscelli (2000) 
Netherlands 4 Cohen (2007); Leeflang (2008); Stremersch (2009); 
Venkataraman (2007) 
Sweden 1 Jönsson (2001) 
non-US 1 Vakratsas (2008)  
UK 3 Flechter (1989); Gillis (1998); Greenhalgh (2004) 
UK, Finland 1 Jaakkola (2007) 
US 56 Aaker (1985); Ambady (2006); Andaleeb (1996); Avorn Chern-
Hartley (1982); Azoulay (2002); Berndt (1994); Berndt (2003); 
Bond (1977); Boulding (1990); Bowman (1996); Brown (1994); 
Buzzell (1975); Cooley (2009); Chen (2007); Dao (1984); 
Donohue (2004); Ellison (1997); Goetzinger (2007); Golder 
(1993); Gonul (2001); Hauser (1990); Huff (1994); Iizuka (2002); 
Kardes (1992); Kalyanaram (2009); Kalyanaram (2008); Lambkin 
(1988); Lim (2008); Lurie (1990); Manchanda (2005); 
Manchanda (2004); Michaels (1985); Mizik (2004); Narayanan 
(2004); Parsons (1981); Pauwels (2004); Rice (2009); Rizzo 
(1999); Robinson (1985); Robinson (1988); Rosenthal (2002); 
Saxe (1982); Shankar (1998); Stern (1998); Tellis (1996); Urban 
(1986); White (2004) 
US, Canada, 
Europe 
9 Bijwaard (2008); Cooper (1993); Han (2005); Lexchin (2009); 
Lexchin (2006); Mintzes (2003); Mintzes (2002); Wittink (2002); 
Wong-Rieger (2009)  
Table 1-3: Overview of investigated markets 
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1.1.4. Definition of a general Prescription Drug Market System Model 
Taking the previously discussed basis of existing general conceptual marketing knowledge, a 
universally applicable market model can be set up, which is adapted from Kuehn (2003) (see 
original in Appendix 1). This takes the marketing concept and the market environment into 
consideration and represents a pharmaceutical market (see Figure 1-5), in order to understand 
the potential parameters and their interactions, the market and the current conditions.  
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Company 
 
Figure 1-5: Prescription drug market system model [Source: based on Kuehn (2003)] 
 
As the market system clearly illustrates (Figure 1-5), costumers (in this case physicians) play 
a central role within the market, but unlike most markets studied in prior marketing research, 
they are a completely separate entity to the actual users (consumer) of the product [patients 
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(consumers)]. This statement is supported by Wright and Lundstrom (2004), who revealed 
that the primary link between buying and selling firms, sales people, have considerable 
influence on the buyer’s perceptions of the seller’s reliability, the value of the seller’s services 
and, consequently, the buyer’s interest in continuing the relationship. This leads to the 
conclusion that the interaction between the physician (costumer) and salesperson is of central 
relevance within pharmaceutical marketing. As there is no standardised definition, the process 
of approaching and dealing with potential and existent customers is named “physician-
targeting” in the present work. Furthermore, Nickum (2007) concludes that because 
traditional sales models are not the best approach for reaching a more diversified audience, 
pharmaceutical marketing marketers are rethinking the way they design and deploy their field 
sales organisations. These converging needs have forced the pharmaceutical industry to re-
examine and begin redesigning their sales models in both the primary care and specialty 
markets. The focus of these efforts has been to better understand the prescribing universe, in 
order to strengthen physician (costumer)-company relationships.  
Furthermore, additional factors influencing the market should also be briefly discussed at this 
point. These are, according to Kuehn’s (2003) definition (see also figure 1-5): ‘competitors’, 
‘distributors’, ‘opinion leaders’ and ‘consumers’. It has to be emphasized, as it has already 
previously been discussed (see Paragraph 1.1.), that a tripartite relationship (prescribers, users 
and payers) is in the ‘consumer’ box present. In addition to this it has to be noted that (as 
indicated in illustration 1-5), ‘internal factors’ (please refer to Daft, 2011), ‘external factors’ 
(based on the PEST model; please refer to Middleton, 2003) as well as ‘external competition 
forces’ (based on the Porter’s 5 forces model; Porter, 1979) influence the pharmaceutical 
market behaviour. 
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As previously indicated, in prescription drug marketing the interaction between the costumer 
(physician) and salesperson plays a central role because it is essential for sales (revenue) 
success. Therefore, in the present work, this process will be termed “physician-targeting”.  
In the next section of this chapter, a summary of the first few paragraphs will be given and the 
relevant conclusions will be drawn. This will help to indicate the research gaps as well as 
research objectives. 
 
1.1.5. Synthesis and Conclusions 
In the first part of this chapter a description of the pharmaceutical sector and the role of 
marketing, as well as the latest and most relevant scholarly research, was made. It was 
highlighted that there is a need for further research, as indicated by the scientific literature. In 
a next step, the most fundamental marketing strategies that take place within the prescription 
pharmaceutical sector and the strategic relevance of order-of-market entry for sales (revenue) 
were mentioned. The marketing mix concept (interrelationship among the marketing 
instruments) was then presented and the associated literature discussed. This led to the 
conclusion that, in order to define an appropriate marketing mix and to perform research 
within the prescription pharmaceuticals sector, further knowledge about the market, especially 
its peculiarities, its environment and the sales process, is required. For this purpose, four 
fundamentally characteristic healthcare systems were presented and an overview of 
pharmaceutical markets was given. The properties of non-state-regulated as well as of state-
regulated markets were then discussed. Based on this overview, a prescription 
pharmaceuticals market model was presented and the resulting market failures were 
described. Furthermore, it is also necessary to understand the actual process that takes place 
when potential prescribers (customers) are approached in order to reach their personal 
 41 
commitment to prescribing a specific medical drug to their patients (consumers). This process 
is termed “physician-targeting” (see also Raisch, 1996). 
Firstly, there is a widening worldwide gap between increasing research and development 
spending and the decreasing number of new products actually reaching the market (Jarvis, 
2001). In fact, the ‘large pharmaceutical companies spent much more on marketing in 2002 
than on research and development’ (Angell, 2005, p122). As a consequence, as described by 
(Angell, 2005), the pharmaceutical industry in the United States has increased the number of 
its salespersonnel over the past decade.  
Secondly, in most countries, the marketing of medications is strongly regulated and inefficient 
and leads to a number of markets failures. Elliott and Payne (2005, p10) identified four 
failures, namely (1) Imperfect information; (2) Moral hazard; (3) The agency relationship 
between patients (consumers) and healthcare providers (asymmetry of information) and (4) 
Supplier-induced demand. Moreover, modes of marketing vary across different health 
systems (Gallay, 2002), which means that, for each market, appropriate new strategies must 
be developed (Cooper and Kleinschmidt, 1993; Liberman and Rotarius, 2001).  
Thirdly, the development of a marketing strategy follows from prevailing market conditions 
and a clearly laid out general company strategy. In the pharmaceutical sector, there are two 
predominant strategic directions (Dogramatzis, 2002). While companies such as Novartis 
continue to concentrate on the mass market, companies such as Roche have chosen to follow 
the path of specialising in products used in cases with less prevalent indications (market niche 
segment strategy), primarily in the area of oncology (Fibig and Hutt, 2003). However, there is 
no generally applicable strategic approach in the pharmaceutical industry, but there are 
nonetheless factors that should be considered to achieve company success (Harms et al., 
2002).  
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Fourthly, it is concluded that the process of “physician-targeting” plays an essential role in the 
success of pharmaceutical marketing.  
 
1.2. The Research Gap 
Thus, as marketing expenditure for pharmaceutical firms increase, and firms begin to rely on 
the influence of marketing to influence the performance (revenue) of drugs in an increasingly 
crowded market space (see also Buckley, 2004; Levy, 1994; Greene, 2007), questions 
regarding the most efficient marketing instruments are raised. At the same time, from a 
theoretical perspective, the prescription drugs market is an interesting market to study because 
of its unique characteristics, such as high regulation and complex relationships between the 
payer, prescriber and user (consumer). Furthermore, because of its unique health context, 
investigations of the marketing mix and promotional effectiveness may yield unique 
responses (see also Kremer et al., 2008). Moreover, as stated by Stremersch (2008, p233), ‘the 
moderators of such effectiveness may be specific to the health context’ (see also 
Venkataraman and Stremersch, 2007).  
As already stated, Stremersch and Van Dyck (2009) published in the Journal of Marketing 
similar research directions as indicated in this thesis. We see a further need for research about 
the marketing mix (interrelationship among the four marketing instruments) in pharmaceutical 
marketing, marketing instruments and especially “physician-targeting” models. The reliability 
of this preliminary generalisation could be increased through meta-analysis (Stremersch and 
Van Dyck, 2009, p13), which would enable companies to adapt their current “physician-
targeting” concept based on the market and strategic requirements. This would involve 
considering the most essential marketing instruments and ensuring an appropriate marketing 
mix is set up. Furthermore, there is a necessity to develop a “physician-targeting” model 
(Stremersch and Van Dyck, 2009) that considers the mean effect of personal selling on brand 
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prescriptions, product properties and salespersons. As Stremersch and Van Dyck (2009, p13) 
concluded, the opportunity lies in developing “physician-targeting” models based on volume, 
physician (costumer) responsiveness to detailing and competitive detailing patterns (see also 
Dong et al., 2008). The necessity for more research in this area is also stated by Ryerson 
(2008), who refers to Churchill et al.’s (1985) meta-analysis of 393 studies and 36 
dissertations to determine the level of predictability of sales performance. According to 
Ryerson (2008, p181), ‘these results were “unimpressive” and have propelled researchers to 
submit to the challenge of uncovering significant factors, which lead to the determination of 
sales performance. As a result, 30 years later, new models are still being developed for this 
same reason’.  
As previously stated, the pharmaceutical industry has been forced to re-examine and begin 
redesigning its sales models (Nickum, 2007). The focus of these efforts is to better understand 
the prescribing universe, strengthen physician (costumer)-company relationships and, 
consequently, improve the process that takes place when a physician (costumer) is targeted by 
a salesperson, in order to gain successful sales (revenue). For this purpose, an appropriate 
“marketing mix” has to be designed. As previously stated, Borden (1965, p368) defines ‘the 
“marketing mix” as the interrelationship among the marketing decision variables’. However, 
according to Balachandran and Gensch (1974, p160), it is ‘one of the most challenging 
questions how to determine the optimum marketing mix’. Birnik and Bowman (2007, p317) 
proposed that it ‘would be valuable if future studies used qualitative research methodologies 
to capture the richness of both marketing mix standardization decisions and implementation’.  
Furthermore, most of the available studies have investigated the variation of marketing mix 
variables in the less regulated US market (Berndt et al., 1997; Berndt et al., 2002; Berndt et 
al., 2003; Bowman and Gatignon, 1996; Bond and Lean, 1977; Golder and Tellis, 1993; 
Lieberman and Montgomery, 1988; Lilien and Eunsang, 1990; Moore et al., 1991; Robinson 
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and Fornell, 1985; Tellis and Golder, 1996; Urban et al., 1986; Vernon, 1971). As already 
stated, the extant research has largely focused on the advanced economies of the US, Japan 
and Western Europe (mainly the UK, France, Italy and Belgium but not Switzerland). 
Consequently, there is a geographically-related bias in some of the published research (Birnik 
and Bowman, 2007, p317).  
In comparison to other industries, the pharmaceutical industry has some unique properties, as 
discussed, which make it a good example for isolating and studying single success factors. 
For example, price regulations rule out many rebate tactics and also exclude most of the sales 
promotion tools available to marketers in other markets. The economic success of the 
pharmaceutical industry depends on innovative products and successful marketing and sales 
activities. Furthermore, increased competition and the large variety and complexity of 
products in the pharmaceutical industry demand the services of a well-educated and 
professional salesforce in the field (see Paragraph 1.1.). This is generally true for many 
businesses, but especially for the pharmaceutical industry. In order to gather further 
knowledge about the “physician-targeting” process, one emphasis of the research should be 
on specific marketing instrument product design (especially quality) and promotion. At this 
point it should be emphasised that one aim of scholarly research should be not only to 
generalise theories but also to develop models with a specific context to their socioeconomic 
institutional and cultural environment (Steenkamp, 2005). 
Finally, in addition to stronger theoretical links, Birnik and Bowman (2007, p316) would also 
welcome studies that aim to derive managerial prescriptions. It has to be noted that 
‘marketing managers are under increasing pressure to assess and communicate the impact of 
marketing expenditure on financial outcomes’ (Lehmann, 2004, p75). Furthermore, the 
‘insights from such studies could improve management decision-making and help to justify 
the amount and allocation of their marketing budgets’ (Kremer et al., 2008, p236). According 
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to Rod et al. (2007, p175), ‘drug manufacturers on both sides of the Atlantic are increasingly 
interested in identifying those marketing investments (i.e. those forms of pharmaceutical 
promotion) that generate a positive ROI (return on investment)’. In addition, Birnik and 
Bowman (2007, p316) stated that ‘the current body of literature is vast in richness but full of 
contradictory findings. As a result, it is not obvious how to distil “best evidence” for use by 
management practitioners (costumers)’. 
The findings of this work will contribute to the domain of pharmaceutical marketing, more 
specifically to marketing strategy. According to Hooley et al., (2008, p35), the marketing mix 
proportion is the outcome of the marketing strategy process and can therefore be considered 
as a key element.  
 
1.3. Research Objectives 
The objectives of the present study are threefold, and follow on from the previous discussion. 
Essentially, the objectives are focused on eliciting theoretical and empirical evidence 
regarding pharmaceutical marketing instruments and their substantive consequences. More 
specifically, the three objectives of this study are: 
1. To conceptualise and delineate the dimensionality of pharmaceutical marketing mix 
instruments that are used when physicians (costumers) are targeted. 
2. To investigate the influence of product- (especially quality) and promotion-mix 
related factors on “physician-targeting”, thus leading to an increase in sales (revenue). 
3. To develop a valid and reliable model of “physician-targeting” in the sector of 
prescription pharmaceuticals for marketing managers. 
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The attainment of these three objectives is important for a number of reasons, which together 
form the anticipated theoretical contribution of the thesis.  
In order to provide a theoretical contribution, in regard to the existing research gaps (see 1.2), 
the attainment of objective one will contribute to pharmaceutical marketing by 
conceptualising a number of novel constructs, as well as their factors and interactions which 
may be of importance to “physician-targeting” models. A key benefit of such a review is the 
provision of guidance for planning future studies such as measurement items for further 
standardised studies. Objective one’s achievement is crucial, since, without a robust 
delineation of the relevant constructs pertaining to pharmaceutical marketing (whether 
literature- or field-based), it is difficult for researchers to even speculate as to how to develop 
a “physician-targeting” model. The uniqueness of the Swiss prescription pharmaceutical 
market in terms of governmentally fixed prescription pharmaceutical pricing, almost non-
existent competition from other markets and the lack of price awareness when a drug choice 
is made by prescribers (costumers), patients (consumers) and insurance companies is another 
benefit of this study (see 1.1.3).  
There are also a number of practical contributions to be gained by the successful undertaking 
of the present study. Earlier works and reviews have tended to have a limited perspective on a 
single aspect of marketing or sales (revenue) in the sector. Thus, they do not cover adequately 
all aspects of the conceptual framework of “physician-targeting”. These findings will also be 
adaptable to other similar state-regulated markets such as Belgium, Finland, France, 
Germany, Japan and the Netherlands (see 1.1.3). 
Furthermore, as a managerial contribution, theoretical light will be shed on the extent of 
pharmaceutical market penetration and to develop a qualitative evaluation, which will result 
in specific recommendations for marketing managers. The resulting conceptual model of the 
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prescription pharmaceutical marketing process could serve as a decision-making tool for 
marketing managers when applied to modelling simulation software. 
This research will make the following contributions: 
• To provide a description of the pelicularities of the state-regulated Swiss prescription 
pharmaceuticals market. 
• Reveal the relevance of the important pharmaceutical marketing factors. 
• Develop a “physician-targeting” model. 
• To provide support for existing theoretical frameworks. 
• To contribute to marketing strategy theory. 
• To provide practical recommendations for marketing managers and policy makers. 
• To deliver directions for further academic research. 
 
1.4. An Outline of the Thesis’ Structure 
In the first stage of this work, a general overview of worldwide valid marketing 
methodologies will be given. In order to narrow the focus, the study will be limited to one 
state-regulated market, the Swiss prescription pharmaceutical market, in the second stage.  
The thesis is structured into seven chapters, including the present one.  
Chapter 2 focuses on assessing the relevant conceptual and empirical literature regarding 
pharmaceutical marketing, especially “physician-targeting”. In order to carry out this 
investigation, a systematic literature review will be performed. Here, research in 
pharmaceutical marketing, psychology and other relevant disciplines is examined in order to 
gain an insight into pharmaceutical marketing and the key variables of importance. Within 
each particular stream of research, comment is made on the understanding it can offer to the 
 48 
task in hand and any particular areas where it may lack explanatory power. In the first 
instance, the theoretical construct of order-of-market entry will be discussed. In a second step, 
established pharmaceutical marketing instruments will be discussed. 
Chapter 3 describes the qualitative surveys that are performed for this work. Essentially, a 
qualitative study of “physician-targeting” is described, in order to draw out insights into 
“physician-targeting”. For this purpose, a focus group study is set up, taking the conclusions 
derived from the systematic literature review into account. The focus group study provides the 
outcome of the effort to provide field-based evidence regarding “physician-targeting”.  
Chapter 4 conducts the second step of the qualitative surveys, the Delphi group study, which 
is set up on the basis of the findings derived from the focus group study. Based on the 
outcome, a conceptual model and formal hypotheses are presented. In conclusion, it is argued 
that, in order to gain more specific awareness of “physician-targeting”, these literature-based 
hypotheses need to be examined in light of field data. 
Chapter 5 applies a quantitative market data analysis, in order to test the proposed hypotheses. 
For this purpose, a secondary market dataset containing five state-regulated medical drug 
classes, provided by a market research company as well as gathered from alternative sources, 
are prepared for statistical analysis. However, because of missing information, additional data 
are collected. These data are then collated for their quality tested and for their structure 
analysed using descriptive statistics. A multiple regression analysis is then applied. 
Chapter 6 synthesises the relevant findings outlined in the previous sections. In particular, the 
significance of the findings to existing theory and methods is examined in depth.  
Following this, in Chapter 7, the implications of “physician-targeting” for marketers and 
policymakers are discussed in detail, and several practical recommendations regarding 
“physician-targeting” are advanced. Finally, the limitations of the study are outlined, and 
following on from this a number of recommendations for future research are presented.
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2. Success Factors in Pharmaceutical Marketing:  
A Systematic Literature Review 
 
2.1. Introduction 
In this chapter, the current scientific marketing literature, as well as specific marketing 
instruments, and their relevance to the pharmaceutical marketing and personal selling context 
are explored. An overall picture of existing evidence-based strategies and pharmaceutical 
marketing concepts will be derived and a provision of guidance for planning further studies 
will be provided.  
In the first part, problem statements are discussed and research objectives stated. An overview 
of the theoretical background of the systematic literature review is given, the applied method 
justified and the research procedure described. In the second part of this chapter, a brief 
summary of the research methods applied by the reviewed publications is provided. The 
findings are then presented in a logical, systematic order. The applied structural framework is 
based on the order-of-entry and the 4Ps marketing mix model. First of all, the order-of-entry 
concept regarding the most relevant findings is discussed. It is argued that the effect of order-
of-entry is only apparent because of habit formation and the risk that appears for consumers 
when trying a new brand. Consequently, different marketing strategies have to be applied for 
both the first entrant and the late entrant. In the second stage, the marketing mix concept and 
the most relevant findings regarding prescription pharmaceutical marketing and product 
differentiation criteria such as innovativeness, branding and quality are discussed. In 
combination with this, an adequate pricing strategy has to be employed. For promotion, it is 
concluded that word-of-mouth, information, advertising, personal selling and sampling for 
both direct-to-consumer and direct-to-prescriber promotion are the most essential instruments. 
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Distribution, as another marketing mix attribute, has not been given very much attention in 
pharmaceutical marketing research so far, so the topic is not addressed herein. Finally, all 
marketing factors are listed and ranked according to their relevance, a brief summary is given 
and the implications for further research are discussed. 
 
2.2. Problem Statement and Objectives 
As previously described, “Marketing” is generally defined as the ‘process of planning and 
executing the conception, pricing, promotion, and distribution of ideas, goods, and services, to 
create exchanges that satisfy individual and organisational objectives’ (Marketing News, 
1985, p1). Furthermore, it can also be described as an attempt to modify behaviour and to 
stimulate demand (see also Smith, 1983). In order to reach these aims, a “marketing concept” 
has to be set up, which relies upon marketing research in order to define market segment, their 
size, and to ensure that the marketing objectives are satisfied by controllable parameters in the 
marketing mix (Kotler, 2006). These parameters refer, as it has been previously discussed, to 
four “marketing mix instruments” (4Ps), namely product (includes product design, package, 
brand and service), place (distribution channels), promotion (personal selling, advertising, 
sales promotion and publicity) and price (see also Bowman and Gatignon, 1996; Borden, 
1965; Berndt et al., 1997; Frey, 1956; Kotler, 2006; Rizzo, 1999; Ghosh et al., 1983; 
Balachandran and Gensch, 1974). 
In the product design area of pharmaceutical products, product innovativeness, efficacy, 
branding and qualities such as safety and tolerability appear to be the key success factors 
(Smith, 1983; Fletcher, 1989; Dogramatis, 2002). However, for Cooper and Kleinschmidt 
(1993, p110), criteria such as ‘product innovativeness and entry order have a modest impact 
on success’. Nevertheless, according to Hollon (1999, p384), ‘the winners in the prescription 
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drug market are not going to be those with the best patent protection for their products but 
those that are the best marketers’. Furthermore, Gonul et al. (2001, p90) find that the 
‘effectiveness of direct promotional efforts to physicians (costumers) can be enhanced by 
more specific segmentation, targeting and positioning contingent on the intrinsic brand 
preferences demonstrated by certain healthcare professionals’. Furthermore, as stated by 
Azoulay (2002, p555), it is assumed that ‘advertising is more effective when combined with a 
superior bundle of product-quality attributes’ (see also Berndt et al., 1997). For personal 
selling, one can refer to Gonul et al.’s (2001, p89) study, which showed that the ‘scope of 
personal selling should be carefully scheduled in terms of frequency, length of visits, and 
number of free samples given away to optimise the company’s effectiveness of direct 
promotion efforts and expenses’. Place (distribution), as another marketing instrument, does 
not appear to play such an essential and important role in marketing success, at least 
according to some researchers (Cooper and Kleinschmidt, 1993; Ghosh et al., 1983; Smith, 
1983).  
It has to be emphasised that three parties are involved when purchasing prescription drugs: (1) 
the prescriber and usually a decision-maker [doctor (costumer)]; (2) the consumer [patient 
(consumer)] and (3) the payer (e.g. an insurance policy) (Jaakkola and Renko, 2007). 
Consequently, ‘the ones, who make the decisions are not identical with those, who receive the 
service and/or pay for it’ (Harms et al., 2002, p147). Therefore, a “price” policy might play a 
less important role within the area of the prescription drug market, and it is even likely that 
‘payers pay higher prices as a result of the higher advertising that occurs in the industry’ 
(Rizzo, 1999, p89) and/or because of a more innovative product (Dao, 1984).  
Since the sales (revenue) of the leading therapeutic categories of the total pharmaceutical 
market sales predominate, most pharmaceutical companies conduct research in closely related 
therapeutic areas (Scrip, 2001). These companies often employ similar technological 
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approaches, which inevitably leads to strong competition in these market segments and results 
in a race to be first to market. Several researchers (Berndt et al., 1997; Berndt et al., 2002; 
Berndt et al., 2003; Bowman and Gatignon, 1996; Bond and Lean, 1977; Golder and Tellis, 
1993; Lieberman and Montgomery, 1988; Lilien and Eunsang, 1990; Moore et al., 1991; 
Robinson and Fornell, 1985; Tellis and Golder, 1996; Urban et al., 1986; Vernon, 1971) have 
shown the relevance of early market entry within the pharmaceutical business. In a landmark 
study, Bond and Lean (1977) analysed the therapeutic group of diuretics (which promote 
diuresis) and angina pectoris3. They found that later entrants with higher expenditure on 
marketing and lower priced drugs were not able to defeat the market leader (see also Ghosh et 
al., 1983). However, they concluded that promotion (advertising) is essential for sales 
(revenue) success. Product quality and price were added to the mix later by Berndt et al. 
(1997). These researchers also showed that later entrants with a much more innovative 
product (preparation with better therapeutic properties) were able to defeat the market 
pioneer. It can be concluded that order-of-entry is relevant for market success, but it is not the 
only strategy that can be employed to become a market leader. Similarly, Tellis and Golder 
(1996, p73) concluded that ‘market pioneering is neither necessary nor sufficient for long-
term success and leadership’.  
The objectives of the present chapter follow on from the previous discussion. Essentially, they 
focus on eliciting theoretical and empirical evidence regarding pharmaceutical marketing 
instruments and their substantive consequences. More specifically, the two main objectives of 
the Systematic Literature Review are: 
 
                                                 
3
 Angina pectoris is severe chest pain due to ischemia (a lack of blood and hence oxygen supply) of the heart 
muscle, generally due to an obstruction or spasm of the coronary arteries (the heart’s blood vessels) 
(MerckMedicus.com, Dorland's Medical Dictionary, Retrieved May, 2010). 
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1. To conceptualise and delineate the dimensionality of pharmaceutical marketing 
instruments used when physicians (costumers) are targeted. The marketing factors 
most salient to success in the unique context of the pharmaceutical industry will be 
identified. More specifically, the most relevant pharmaceutical marketing factors have 
to be identified. In addition this, another aim is to familiarize with the most important 
marketing literature. 
2. To investigate the influence of pharmaceutical marketing instruments on  
“physician-targeting”, leading to an increase in sales (revenue). More specifically, the 
possible interactions between the various previously identified marketing factors and 
their relevance for sales success according to literature have to be explored. 
 
In order to carry out this investigation, a systematic literature review is performed. In the first 
section, the methodological approach of this review is described. Following this, the most 
relevant findings derived from the review are summarised, described and, finally, according 
to their relevance, evaluated and rated. 
 
2.3. Literature Review Method  
‘Systematic reviews have become increasingly common in recent years’, as highlighted by 
Shojania et al. (2007, p224). In addition, systematic reviews are recommended by researchers 
as a superior source of evidence regarding the state of current knowledge in a general field, or 
to substantiate the existence or otherwise of a given relationship (Mulrow et al., 1997; 
Shojania et al., 2007). According to Petticrew and Roberts (2006, p2), a ‘systematic review is 
especially useful when a general overall picture of the evidence in a topic area is needed to 
direct future research efforts, or when an accurate picture of past research and past 
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methodological approaches is required’. Consequently, as well as being appropriate in this 
instance, the systematic review is popular in the medical field and is becoming increasingly 
popular in management. In fact, around 2,500 new systematic reviews are indexed annually 
on Medline (Moher et al., 2007; Whitlock et al., 2008).  
An extended literature search and evaluation process, conducted in a systematic manner, is a 
key distinction between traditional literature reviews and systematic reviews. Systematic 
reviews are summaries of the available research evidence. Such methods are aimed at 
reducing bias and chance effects to provide more reliable information on which to make 
decisions (Antman et al., 1992; Kleijnen and Knipschild, 1992). Thus, in order to identify all 
relevant literature within major databases, and also to secure other relevant material, 
sometimes described as grey literature (Savoie et al., 2003), conventional systematic extended 
literature review methods as detailed within the next paragraph were used.  
However, it has been stated by Moyer et al. (2007, p448) that ‘there is no standard definition 
of a systematic review’. Consequently, different approaches to systematic reviews can be 
found in the literature (James et al., 2004; Li Pan Wo, 1997; Petticrew and Roberts, 2006) and 
are normally adapted according to their requirements. In order to perform a systematic review, 
a journal database and library access, an investigator and an advisory group are required. In 
this case, the outcome objectives for assessment (i.e. the search terms) were set at the start of 
the project. Table 2-1 shows the systematic procedure followed. As can be seen, each step 
feeds into the next and the focus becomes more and more exact, akin to a funnelling process. 
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Step 1 - General literature search
● Search term:  Pharmaceutical Marketing
● Databases:  EBSCO, Emerald, ABI Inform, NEBIS and Google
● Hits:  126
Step 2 - Literature review (narrative process)
Identification of the most important marketing criteria
● Identified criteria:  distribution, promotion, product, price, product diffusion, market system, 
word-of-mouth and order-of-entry effects
Step 3 - Redefined literature search
● Search terms:  distribution, promotion, product, price, product diffusion, market system, 
word of mouth and order-of-entry effects
● Databases:  BioMed Central; Business Insights; Cambridge Journals Online; Directory of 
Open Access Journals; EBSCO; Emerald Fulltext; Highwire Press; Ingenta; Oxford Journals;
Jstor; Nber; ProQuest; PubMed; Royal Society of Chemistry Journals; ScienceDirect; 
SpringerLink (MetaPress); Swetwise; Taylor and Francis (informaworld); Wiley 
InterScience; google; journal catalogues; news articles; text books; grey literature
● Hits:  538
Step 4 - Ranking of papers according to their relevance (own definition)
Criteria: Description: Ranked:
5 star Core paper 4
4 star Important Findings and good methodology 57
3 star Some interesting findings and figures 100
2 star Interesting research methods applied 217
1 star Not relevant to subject 286
Step 5 - Pearl fishing
Identification of new relevant references (cited more than twice) within the 5 and 4 star papers
● Hits:  92 papers out of total 1814 citations identified  
Step 6 - Ranking of “pearl fishing” papers according to their relevance
Criteria: Description: Ranked: Total:
5 star Core paper 91 95
4 star Important Findings and good methodology 1 58
Step 7 - Ranking of papers according to their impact factor
● Criteria:  Number of citations 
● Database:  ISI Web of Science citation index  
● Hits:  103 papers identified
Step 8 - Assessing the remaining studies and key factors identification
● Criteria:  Study, Year, Intervention, Study population, Study design, Primary reference and
secondary reference, Sample size, Response rate, Follow-up rate, Follow-up (months),
Validity score, Findings, Conclusion, Key factors
● Given the substantial changes in health care and pharmaceutical industries into account, the
search was limited to papers published in the last 25 years . Older paper were only considered,
if containing substantial statements or being viewed as core paper within their subject area.
Step 9 - Examination of content of similar studies
Step 10 - Evaluating and compiling of selected publications 
● 170 citations out of 98 publications indicated
Step 11 - Structuring of information
● Coding scheme based on Order-of-Entry Model and 4P-Concept
Step 12 - Presentation and evaluation of citations
● Ranking of the criteria within each category according to their number of citations
● Calculation of relative importance
 
Table 2-1: The systematic literature review flow chart 
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Each stage was subject to an analysis according to a set of criteria. In the first stage, the key 
criterion was to find general preliminary literature in order to set the parameters for more 
detailed searches in the future. Thus, a broad search of ‘pharmaceutical marketing’ yielded 
126 results, which were the input into the first narrative (second) step. This step involved a 
review with the aim of identifying the most important criteria for pharmaceutical marketing 
success. Following this, each criterion was used as a term in a dedicated search, resulting in 
528 hits in total. The cut-off point was reached when searches did not add to the tally of 
included studies (Petticrew and Roberts, 2006). The gathered publications were then 
subjected to an extensive literature review (third step).  
In a fourth step, publications were viewed and ranked according to their relevance to the 
research task. It should be noted that the procedure of a systematic literature review has to be 
adapted to the requirements given by the study task (for similar methods see also Biermann et 
al., 1999; Mullins and Spence, 2003; Wasson et al., 1993). In order to determine the study’s 
appropriateness regarding the research questions, a checklist to assess the derived publications 
was set up. The following criteria were defined (for further explanations, please refer to 
Appendix 2): (a) five-star paper (indicated as a core paper within the subject area, shows high 
relevance regarding to the research question); (b) four-star (study has some important findings 
and good methodology); (c) three-star (some interesting, but less essential findings and 
figures can be found); (d) two-star (regarding ongoing research, only interesting research 
methods applied) and (e) one-star (not relevant to the subject at all).  
In total, 4 five-star, 57 four-star, 100 three-star, 91 two-star and 286 one-star publications 
were rated. For further research, only five- and four-star papers were considered. Next (the 
fifth step), the previously described procedure was followed for the ranking of papers 
uncovered by the ‘fishing’ stage, uncovering a further 92 papers from the 1,814 citations in 
the four- and five-star ranked papers taken from the fourth step and ranked according to their 
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relevance (see Appendix 2) (sixth step). In the seventh step, ISI citation impact was taken into 
account to rank the remaining papers.  
The remaining 103 publications were evaluated, and keywords were identified using a 
Microsoft Excel-based data extraction form. The criteria were: study, year, intervention, study 
population, study design, primary reference and secondary reference, sample size, response 
rate, follow-up rate, follow-up (months), validity score, findings, conclusion and key 
marketing factors. Taking the substantial changes in healthcare and pharmaceutical industries 
into account, the search was limited to papers published in the last 25 years. Older papers 
were only considered if they contained substantial statements or were viewed as a core paper 
(five- and four-star, see Appendix 2) within their subject area. As a result, five papers had to 
be excluded. The critical information from each paper was then collated and sorted, using a 
coding scheme as explained below (eighth step).  
The remaining top 98 papers were retained for further analysis and review. In order to make 
sure that no critical information was missed, the aim was to investigate the content of 
literature review studies containing the same research objectives (similar papers) (for research 
objectives, see Paragraph 2.2.). However, despite the many existing literature research studies 
in marketing, usually focusing on specific subject areas, no similar studies were found (ninth 
step).  
In fact, no study was found that has performed an overall literature review of pharmaceutical 
marketing as presented in this study (please refer also to Paragraph 1.1.2). The most extensive 
review of pharmaceutical marketing was performed by Kremer et al. (2008), investigating 
only the effectiveness of pharmaceutical promotional expenditure. Groves et al. (2002) also 
studied the prescription habits of physicians (costumers). Another literature review performed 
by Szymanski et al. (1995) analysed order-of-entry and its impact on business performance. 
Furthermore, the first-mover advantage was investigated by Kerin et al. (1992) and by Golder 
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and Tellis (1993) in a different study. Marketing mix standardisation in multinational 
corporations was investigated by Birnik and Bowman (2007), while the role of consumer 
behaviour in marketing was analysed by Foxall (1999). Churchill et al. (1985) studied the 
determinants of salesperson performance. This study has included these findings as far as 
relevant to the research today. 
In the tenth step, the selected 98 publications were evaluated and 170 essential citations 
compiled. The identified citations were then coded using a coding scheme that was based on 
the order-of-entry model and 4Ps concept. The applied criteria were (see also Kotler, 1998): 
order-of-entry, early entry, late entry, market share, market leader, market niches, consumer, 
patient (consumer), physician (costumer), habit formation, sales (revenue), marketing mix, 
product, product life cycle, innovativeness, product quality, brand, generics, patents, service 
quality, distribution, promotion, personal selling, perception, SOCO (scale of selling 
orientation versus customer orientation), advertising, DTP (direct-to-prescriber promotion), 
DTC (direct-to-consumer promotion, scientific information source, commercial information 
source, sampling, word-of-mouth, price, costs, market environment, non-product variables, 
time in market, competitive performance, market growth rate and strategies (eleventh step). 
The citations were finally sorted according to their defined criteria, presented in a structured 
text and based on the 4Ps marketing mix concept. After each section, the most important 
statements were summarised and a conceptual model was derived. In order to gain an 
overview of the relevance of the marketing factors, these criteria were counted and ranked. In 
order to ensure that no relevant information had been missed, the analysis was repeated.  
In the next section of this chapter, the results of the systematic literature review are presented. 
At first, a brief overview of the reviewed publications is given, focusing on methodologies 
used in prior work. Next, the findings are summarised and presented in a systematic order. As 
a starting point, order-of-entry is discussed, leading to the marketing mix instruments of 
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product, price and promotional design. Finally, an overview regarding the relevance of 
marketing instruments, indicated by the number of citations, is given in order to justify further 
research. 
 
2.4. Methodologies used by Previous Studies 
A summary listing of the applied methodologies used in the reviewed literature is provided in 
Table 2-2. This table classifies the literature into broad methodological categories, and within 
these categories reports the sample size and data source of each individual study (where it was 
possible to determine this information). Due to the diversity of samples used in the literature, 
it was necessary to describe the samples of each individual study rather than categorise them 
further. It is evident that most of the studies are based on surveys, suggesting that there is 
significant potential for additional work incorporating qualitative, experimental or modelling 
approaches to develop additional insights. 
Total 
Articles 
Method of 
Analysis 
Main Author, Sample Size and Data Source (if available) 
1 Case study Chen (2007) vitamin market 
49 Survey Aaker (1985) PIMS data; Andaleeb (1996) 400 physicians; Avorn (1982) 2 
drug classes, 100 physicians; Azoulay 2002) anti-ulcer market; Berndt (1994) 
3'500 physicians (IMS data); Bond (1977) 2 drug markets; Boulding (1990) 
3'250 evaluations of 340 business units (PIMS data); Bijwaard (2008) 16 
telecom markets; Bowman (1996) 5 categories; Brown (1994) 129 brands in 
34 different categories; Chen (2007) 3’000 adult patients; Coscelli (2000) 
75'000 observations; Dao (1984) 19 drug classes; Donohue (2004) 25'716 
subjects; Ellison (1997) IMS data; Flechter (1989) 187 firms; Gillis (1998) 87 
participants; Gonul (2001) 3 large datasets; Hauser (1990) ASSESSOR 
database; Huff (1994) 95 observations in 34 product categories; Iizuka (2002) 
NAMCS, CMR, IMS data; Jaakkola (2007) 45 interviews; Kalyanaram 
(2009) three therapeutic classes; Kalyanaram (2008) three therapeutic classes; 
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Kalyanaram (1992) 8 markets, 28 new brand entrants, 220 weeks; Lambkin 
(1988) 129 start-up companies and 187 businesses (PIMS data); Leeflang 
(2008) 49 brands 5 products; Lexchin (2009) 73 multiple dosage products; 
Lilien (1990) 112 observations; Lurie (1990) faculty of 7 universities; 
Manchanda (2004) 1'000 of 116'218 physicians; Mintzes (2003) 200 
physicians; Michaels (1985) 3'216 participants; Mitchell (1989) 5 subfields of 
medical diagnostic imaging industry, 30 years data entry; Mizik (2004) 
74'075 individual physicians; Narayanan (2004) US market; Parsons (1981) 
10 ethical drug products 14 sales territories; Pauwels (2004) 1100 Californian 
car dealers JDPA data; Rice (2009) 13 drugs; Rizzo (1999) IMS data; 
Robinson (1985) 500 observations (PIMS data); Rosenthal (2002) 12'000 
physicians (panel data); Rojas (2009) 17 large companies: Saxe (1982) 133 
sales people; Schwartz (1989) undefined; Shankar (1998) 13 brands 2 ethical 
drugs categories; Tellis (1996) PIMS and ASSESSOR database; Urban 
(1986) A.C. Nielsen market data; Vakratsas (2008) IMS and A.C. Nielsen 
market data; Venkataraman (2007) 2’774 physicians 39’880 months of 
observations large firm dataset; White (2004) 21'000 adults (MARS data); 
Wittink (2002) 392 branded drugs 21’436 observations 
2 Qualitative 
data 
analysis 
Cooley (2009) 14 participants; Cooper (1993) 21 companies;  
9 Essay Cohen (2007); Han (2005); Jönsson (2001); Lexchin (2006); Manchanda 
(2005); Mintzes (2002); Roth (2004); Stremersch (2009); Wong-Rieger 
(2009) 
3 Experiment Ambady (2006) 22 video clips; Kardes (1992) 46 and 40 MBA students 
13 Literature 
review 
Churchill (1985) 116 articles; Elling (2002) McKinsey Report; Golder (1993) 
450 articles and 250 books; Greenhalgh (2004) research areas; Groves (2002) 
15 articles; Kalyanaram (1995) undefined; Karakaya (2000) undefined; Kerin 
(1992) 13 articles; Kremer (2008) meta-analysis of 58 books +781 articles; 
Lieberman (1988) undefined; Lilien (1981) undefined; Manchanda (2005); 
Szymanski (1995) 67 articles 
5 Modelling Cohen (1987) model categorisation; Goetzinger (2007) 263 online 
respondent; Lim (2008) 71 time-series; Shankar (1997) 72 scenarios 
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10 Review 
paper 
Breuer (2003); Comanor (1979); Comanor (1986); Hill (1999); Hoch (1989); 
Hollon (1999); Hunt (1998); Jaffe (2000); Schwartz (1990); Trim (2005) 
2 Text book Dogramatis (2002); Bain (1956); Kotler (2006); Smith (1983) 
Table 2-2: Profile of analysed publications 
 
2.5. The Importance of Order-of-Entry in Pharmaceutical Marketing as a 
Theoretical Concept 
2.5.1. Order-of-Entry as a Fundamental Concept 
Most of the current literature on pharmaceutical marketing presupposes the order-of-entry 
model as a starting point in the conception of a marketing strategy (see also Castro and 
Chrisman, 1995; Rodriquez-Pinto et al., 2008). The theoretical order-of-entry concept and 
first-mover advantage are extensively discussed in the literature and can be applied in both 
general marketing and pharmaceutical marketing. Bain (1956) initiated the concept, which 
states that a general tendency of buyers to prefer established over new products may place 
potential later entrants at a disadvantage as compared to firms already established in the 
industry. Bain notes that firms entering later might have to accept a lower selling price and/or 
incur higher selling costs than existing firms, in order to persuade buyers to accept their 
products. Furthermore, according to Lambkin (1988, p137), ‘order-of-entry is systematically 
related to competitive performance, and this relationship is likely to be moderated by 
variations in the structures and strategies of the business in different entrant categories’. These 
findings are supported by Kalyanaram (2008), who investigated the order-of-entry effect in 
prescription (Rx) drugs markets. However, Kremer et al.’s (2008, p243) results show that the 
effect of ‘order-of-entry on promotional effectiveness is not significant’, confirming the 
findings of Shankar et al. (1998). 
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Furthermore, it was highlighted by Bijwaard et al. (2008, p246) that the ‘effect of order-of-
entry can be partly explained by the predominant importance of switching costs on the 
demand side’. Consequently, Bijwaard et al. (2008, p247) determined three relevant factors: 
(1) consumers have to make some initial investment in adapting to a seller’s product or 
services, (2) contractual costs imposed by the firm and (3) firm-specific learning on how to 
use the product (habit formation). Because of these switching costs, firms that already exist in 
the market benefit, as later firms have to convince consumers to switch. Furthermore, 
according to Coscelli (2000, p367), ‘patients (consumers)’ and physicians (costumers)’ 
prescribing behaviour exhibits a strong state of dependence, which declines as the number of 
months between two successive purchases/prescriptions grows larger’. In addition, Coscelli 
(2000, p351) found ‘significant evidence of doctor (costumer) and patient (consumer) 
“habits”, which imply that in markets in which brands are not allowed to compete on the basis 
of price, habit persistence can translate into persistent market shares’.  
In summary it can be said that many of the fundamental strategic concepts of pharmaceutical 
marketing are based on the order-of-entry effect, which is caused by the risks occurring and 
switching costs on the buyer side when trying a new, previously unknown brand/product. This 
leads to the formation of a habit towards existing brands/products, once a product/brand is 
accepted by the consumer. At this point, the brand cognition effect takes place.  
 
2.5.2. The Relation between Order-of-Entry, Market Share and Profitability 
The relation between order-of-entry, market share and profitability has been investigated by 
several researchers. Karakaya (2000, p9) revealed that ‘order-of-entry has an impact on the 
performance of firms including market share and profitability’. Berndt et al. (1997, p37) 
concluded that order-of-entry effects are very substantial for sales (revenue). Lilien and 
Eunsang (1990) linked turnover directly with order-of-entry. For Robinson and Fornell 
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(1985), order-of-entry is a major determinant of market share, too, which is supported by 
Szymanski and Troy (1995, p30), who found that ‘on average, order-of-entry exerts a 
significant and positive effect on market share’. In addition, Tellis and Golder (1996) revealed 
that an early market entry is relevant for market success, but that it is not the only strategy for 
becoming a market leader. Furthermore, Kalyanaram et al. (1995, p219) argued that order-of-
entry is not related to long-term survival rates, while Cooper and Kleinschmidt (1993, p110) 
stated that ‘order-of-entry does have a modest impact on success’. 
In addition, it has to be noted that it is not always better to have more market share, since 
changes in market share strongly influence costs (Comanor, 1986, p1207). This statement is 
supported by Boulding and Staelin (1990, p1160), who concluded that ‘companies with high 
market shares derive no superior market power except if they operate in environments with 
little buying power’. As a result, an optimum market share has to be aimed for. Consequently, 
more market share is not always better, as environmental factors and changes in market share 
most strongly influence price and costs.  
 
2.5.3. Order-of-Entry Model 
Combining the previously described factors – order-of-market entry, marketing efforts and 
sales (revenue) – an order-of-entry model can be derived. Several researchers have proposed a 
market share proportion rule (Urban et al., 1986; Berndt et al., 1997; Kalyanaram and Urban, 
1992; Lean and Bond, 1977 and Golder and Tellis, 1993), stating that early market leaders 
have a higher market share and concluding that relative to the nth product, the (n+1)th entrant 
can expect about 40% lower sales (revenue). Holding marketing mix elements constant, Table 
2-3 shows that the entrant’s forecasted market share divided by the pioneer’s market share 
roughly equals one divided by the square root of order-of-market entry (Kalyanaram et al., 
1995, p216).  
Table 2-3: Market share proportion of order-of-entry and market share for consumer packaged goods  
and prescription anti-ulcer drugs (Kalyanaram et al., 1995, p216) 
 
2.5.4. Early Market Entry as a Strategy 
As previously established, the literature strongly suggests that the early market entrant will 
benefit from the pioneering advantage when introducing a new product. The resulting habit 
formation will consequently define the product standard within a specific market segment. 
The pioneer advantage can be explained using a consumer integration perspective. As a result, 
Kardes and Kalyanaram (1992, p356) concluded that the ‘learning advantage conferred to the 
pioneering brand translates into more extreme and confidently held judgments of the pioneer’. 
Consequently, ‘judgments held with conviction are persistent over time and lead to a long-run 
pioneering advantage’ (Kardes and Kalyanaram, 1992, p356). For Brown and Lattin (1994, 
p1361), ‘pioneering advantage is also related to a brand’s length of time in the market: the 
longer the brand’s time in market, the greater its relative share advantage’. This statement is 
in support of Huff and Robinson’s (1994, p1376) findings, whereby ‘increasing lead time 
tends to increase the pioneer’s market share reward’. 
Early market entrants not only benefit from several advantages, but also they are faced with 
many potential disadvantages. For Tellis and Golder (1996, p74), market pioneering is a 
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necessary condition for attaining first-mover advantage and is conducive to achieving a 
dominant market share and abnormal returns, but ‘being first to the market by itself is neither 
necessary nor sufficient for enduring market leadership’. Furthermore, Kerin et al.’s. (1992, 
p48) literature synthesis showed that the ‘belief that entry order automatically endows first-
movers with immutable competitive advantages and later entrants with overwhelming 
disadvantages is naïve in light of conceptual and empirical evidence’. This statement is 
supported by Brown and Lattin, 1994, p1368), who concluded that ‘over time, some of the 
share advantage of the early entrant will be competed away’.  
In conclusion, we can refer to Lieberman’s and Montgomery’s (1988, p54) statement that 
‘pioneering carries both advantages and disadvantages’. A newcomer to the industry will not 
only be more likely to gain market share, but also to survive if he enters late. This is also 
supported by Lilien and Eunsang (1990, p580), who stated that ‘first entrants see high return 
if successful, but bear the risk of a lower overall likelihood of success than later entrants do’. 
This is supported by Lieberman and Montgomery (1988, p48), who indicated that 
‘mechanisms that promote first mover advantages include proprietary learning effects, 
patents, pre-emption of input factors and locations, and development of buyer switching costs. 
Conversely, first-mover disadvantages may result from uncertainty, shifts in technology or 
customer needs, and various types of organisational inertia’. Consequently, the first-mover 
strategy has its risks (Mitchell, 1989), and research shows that ‘forty-seven percent of market 
pioneers fail while only eleven percent of pioneers are current market leaders’ (Golder and 
Tellis, 1993, p169). Furthermore, it should be noted that in the pharmaceutical industry, entry 
time is not under the complete control of the firm. Additional factors (e.g. the drug approval 
process, progress in research and development, competitors’ research progress and strategic 
decisions regarding market entry (see also Subhash, 2009)) also play a role in the timing of 
drugs entry. 
 66 
In order to meet the market requirements of an early market entrant, and to ensure a 
successful product introduction, an innovative product and a specific marketing mix 
(considering product, price, promotion and place/distributional, see Trim and Hao, 2005) have 
to be created and pursued. As Tellis and Golder (1996) stated, innovativeness is essential for 
the early market entrant’s success. However, this advantage will be slowly chipped away due 
to the diffusion of innovativeness that takes place (Greenhalgh et al., 2004). The diffusion 
patterns of new prescription drugs were characterised by Vakratsas and Kolsarici (2008). 
Regarding promotion, for Cohen and Basu (1987), promotional strategies have a direct impact 
in the early stages of product perception and are likely to be of considerable importance. 
However, ‘there is a lack of marketing mix effectiveness on early market adoption that 
suggests that the pharmaceutical market has a pre-defined need for the product and adoption 
considerations are most likely based on efficacy of the product’ (Vakratsas and Kolsarici, 
2008, p291). Shankar’s (1997, p290) results show that the ‘shift in the pioneer’s equilibrium 
marketing mix allocation follows changes in its relative marketing mix effectiveness’. 
Therefore, Vakratsas and Kolsarici (2008, p290) suggest that, ‘due to persistent and severe 
symptoms suffered by a class of patients (consumers), an early market for prescription drugs 
is created. This market may be formed even before the launch of the product, due to well-
defined diagnosed needs of patients (consumers) forming this market’. 
Consequently, an early market entrant should emphasise promotional measures to ensure 
consumers’ habit formation. Therefore, ‘managers of pioneering brands should implement 
promotional and channel-related tactics that facilitate consumer learning’ (Kardes and 
Kalyanaram, 1992, p355). As a result, the main task of promotion lies in building up brand 
name recall effects. As consumers’ knowledge about the features and benefits of pioneer 
brands increases, the magnitude and duration of the pioneering advantage will also increase 
(Kardes and Kalyanaram, 1992). Thus, we can make reference to Hoch and Deighton’s (1989, 
p16) conclusions that ‘in the design of communication and promotional programs, and in 
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testing the effectiveness of new product concepts or advertising executions, learning must be 
accounted for not as something independent of marketing action, but as a process that 
marketing has the power to leverage in building brand attitudes and consumer loyalty’. 
Because of the previously described advantages, companies are aiming for an early market 
entry. In summary, it can be concluded that pharmaceutical promotion serves at least two 
functions, namely habit formation and the informational function (see also Leffler, 1981).  
 
2.5.5. Late Market Entry as a Strategy 
A late market entry strategy is a possible alternative to early market entry, even though later 
entrants are likely to be at a significant disadvantage in some areas (Brown and Lattin, 1994), 
but ‘the increase of the number of years of competitive rivalry helps later entrants slowly chip 
away at the pioneer’s market share’ (Huff and Robinson, 1994, p1370). A late entrant will 
perform better if he waits while early entrants test the products and markets, and then will 
benefit from these early entrants’ experience (Mitchell, 1989). In addition, late market 
entrants do not have the marketing costs incurred by early entrants, although they often 
escape the risk of product failure and gain some little benefit from earlier entrants’ advertising 
(Mitchell, 1989). 
For late entrants, there are two strategic options: (1) promoting themselves as variety 
enhancers and/or (2) gaining the cooperation of retailers in order to encourage side-by-side 
comparisons of their brands with existing market leaders (Kardes and Kalyanaram, 1992, 
p356). However, most of the late entrants are on a very small scale and not very innovative. 
As a result, the typical later market entrant does not represent a serious threat to the leading 
early market entrant (Robinson, 1988). Furthermore, ‘order-of-market-entry tends to decrease 
the market response to quality’ (Bowman and Gatignon, 1996, p238).  
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Consequently, a late market entrant has to implement an adapted marketing mix according to 
market requirements. Marketing mix decisions which can compensate for not being first were 
discussed by Comanor (1986). The disadvantage of being late can be overcome with a 
differentiated product strategy supported by promotions (see also Vakratsas and Kolsaricis, 
2008). Consequently, late entrants have to ‘shout louder to be heard’ (Robinson and Fornell, 
1985, p316). However, Bond and Lean (1977) concluded that advertising effectiveness is a 
decreasing function of order-of-entry into the market. This point is supported by Bowman and 
Gatignon (1996, p222), who revealed that ‘order-of-entry tends to decrease the market 
response to promotion’.  
The pricing policy plays an essential role for the late entrant, too. In particular, ‘later entrants 
are at a disadvantage in competing with price; they need to change price by a larger amount 
than earlier entrants to attain the same change in market share’ (Bowman and Gatignon, 1996, 
p238). This is especially the case when a me-too strategy is applied. These results are 
reinforced by Hauser and Wernerfelt (1990), whose findings revealed that the more brands a 
consumer takes into consideration, the more price-sensitive the consumer will be. There is an 
apparent relation between order-of-entry, product design, promotion, pricing and sales 
(revenue).  
In conclusion, for Lilien and Eunsang (1990, p580), the ‘tactical decision of entry time is a 
problem of balancing the risks of premature entry with the potential missed opportunity of 
late entry’. For Mitchell (1989, p99), ‘an industry incumbent will perform better if it waits 
while newcomers test the products and markets’. Therefore, practical guidelines were 
suggested by Lilien and Eunsang (1990, p580): (1) enter earlier when expected return is 
higher and (2) enter later when the market is evolving more rapidly. Furthermore, ‘pioneers 
may be businesses with skills and resources attuned to market leadership, whereas late 
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entrants may be attuned to being market nichers’ (Robinson and Fornell, 1985, p316). In sum, 
it can be stated that: 
1. Innovativeness is essential for an early market entrant’s success (see also Tellis and 
Golder, 1996). 
2. Managers of pioneering brands should implement promotional and channel-related 
tactics that facilitate consumer learning (habit formation) (Kardes and Kalyanaram, 
1992, p355). 
3. Late entrants have to shout louder to be heard (Robinson and Fornell, 1985, p316). 
4. Later entrants are at a disadvantage when competing with price; they need to change 
price by a larger amount than earlier entrants to attain the same change in market 
share (Bowman and Gatignon, 1996, p238). 
5. The disadvantage of being late can be overcome with a differentiated product strategy 
(see also Vakratsas and Kolsaricis, 2008). 
 
2.6. The Relevance of Product Mix and Pricing in Pharmaceutical Practice 
‘Product differentiation is an essential discriminator between winning and losing new 
products’ (Cooper and Kleinschmidt, 1993, p108). It is therefore considered key to successful 
marketing (see also Kotler, 2006 and 1998; Sharp et al., 2001) and may lead to significant 
buyer preference between established products and the products of new entrant firms (Kotler, 
2006). 
For Cooper and Kleinschmidt (1993), product differentiation can be reached by branding, by 
differences in the design or physical quality of competing products, by the efforts of sellers to 
distinguish their products through packaging and innovativeness and by offering value-added 
services to buyers, ‘designed to win the allegiance and loyalty of potential buyers’ (Bain 
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1956, p114; see also Chen and Burgers, 2007 and Kotler, 1998). Furthermore, as previously 
discussed, the marketing mix design depends largely on order-of-market entry. In the product 
design area of pharmaceutical products, product innovativeness, efficacy, branding and 
qualities such as safety (including tolerability) appear to be the key success factors (Smith, 
1983; Flechter, 1989; Dogramatzis, 2002). 
 
2.6.1. The Role of Product Mix Attributes  
The three most common product mix elements – innovativeness, quality and branding – 
applied in prescription drugs marketing, and their implications, are discussed in this 
paragraph.  
Product innovativeness is relevant for the early market entrant’s success (Tellis and Golder, 
1996) and essential in order to gain unique attributes, thus influencing the price level 
positively. Consequently, there is an importance attached to continuous innovation within the 
product category (Tellis and Golder, 1996). Nevertheless, according to Cooper and 
Kleinschmidt (1993, p110), ‘innovativeness has a modest impact on success’.  
Market features conducive to pharmaceutical innovation were investigated by Cohen (2007, 
p214). These are: ‘(1) more flexibility on the part of private insurers to deviate from the 
national formulary; (2) speedier reimbursement appraisals, and more (3) specific funding for 
certain highly innovative pharmaceutical products. On the other hand, other features are 
detrimental to drug innovation. These include (1) direct price controls, (2) reference pricing, 
and a (3) centralized nature of decision-making with respect to drug reimbursement’. In this 
context the impact of the WTO’s Trade-Related aspects of Intellectual Property Rights 
(TRIPs) Agreement, which makes the granting of patents for pharmaceuticals obligatory, has 
to be mentioned. Since previously many developing countries allowed only for limited patent 
protection in this area, this represents a significant change in the pharmaceutical sector. 
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However, as highlighted by Timmermans and Hutadjulu (2000, p1), ‘proponents believe this 
will lead to an increase in investment and research and development (R&D; innovativeness), 
yet numerous public health experts, as well as consumer groups, have expressed concern 
about the impact of the TRIPs Agreement on the availability and prices of drugs’. 
Product quality (efficacy, safety (including tolerability) has also been shown to play an 
important role in pricing. Gonul et al. (2001, p90) found evidence that, in general, ‘physicians 
(costumers)’ price sensitivity comes second to considerations about drug efficacy and patients 
(consumers)’ conditions’. Consequently, if the approved product has an advantage relative to 
other products, its market share increases (Berndt et al., 1997). 
Regarding branding, there are two fundamental strategic approaches apparent: (1) generic 
(usually non-branded products with chemically identical active ingredients (me-too strategy)) 
and/or (2) branded alternatives produced by different companies (branding strategy). In 
contrast, branding does influence pricing positively (Rice, 2009). The effectiveness of the me-
too strategy has been questioned by Schmalensee (1982). Consequently, as stated by Kremer 
et al. (2008, p244), ‘the price difference makes generics more attractive than branded 
products, positively influencing their marketing effectiveness’. In the literature, however, 
‘there is little consensus on the price elasticity of demand’ (Kremer et al., 2008, p236). 
Furthermore, Ellison et al. (1997, p426) also observed ‘fairly high demand elasticity between 
generic drug substitutes’. In conclusion it can be said that generic (me-too) and new 
innovative (improved) products tend to lead to price pressure on existing products (Dao, 
1984; Kremer et al., 2008).  
 
2.6.2. The Role of Pricing 
The influence of pricing in the pharmaceutical sector has been investigated by several 
researchers. Lexchin (2009, p145) highlighted that ‘doctors (costumers) are generally ignorant 
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both about the relative and absolute prices of medications’. However, this statement is 
questioned by Rice (2009, p184), who concluded that ‘HMO4 physicians (costumers) are 
more price sensitive in prescribing brand name substitutes than non-HMO physicians 
(costumers)’. 
Furthermore, according to Rojas (2009, p133), ‘there are significant differences in the prices 
of identical drugs across countries’. In prescription drugs markets (please refer also to Table 
1), where no regulation regarding the company’s pricing practice takes place (such as 
limitation by profit control, reference pricing regarding a competitor’s price, negative lists not 
paid by statutory health insurance, price freezes, price cuts, general practitioners (costumers)’ 
budgets, pharmaceutical expenditure ceilings, and generic promotion) two different pricing 
strategies are prevalent – a flat price strategy, where all strengths of the tablet have more or 
less the same price, and a monotonic price strategy, ‘where the price is more or less 
proportionate to the strength of the tablet’, as stated by Joensson (2001, p105). Lexchin (2009, 
p142) noted that ‘when monotonic pricing is used it leads to higher expenditure whereas flat 
pricing results in lower expenditure and offers public drug plans more predictability in 
expenditure’, since, regardless of the dosage prescribed, spending is the same. However, 
companies making scored tablets (e.g. to make pill splitting and dosing easier (Solomon, 
2007)) may feel that they ‘do need to use monotonic pricing since doctors (costumers) will 
not recognize the cost savings from splitting tablets’ (Lexchin, 2009). This supports Cooper 
and Kleinschmidts’ (1993, p109) conclusion that a ‘low-price strategy is in general not 
effective’. 
The regularly raised concern that “drugs are too expensive” was debated by Lexchin (2006). 
For Lexchin, actual drug prices are justified because new medicines are (1) an effective 
treatment and (2) cost-effective. On the other hand, for Lexchin (2006, p545), ‘(1) the claim 
                                                 
4
 Health Maintenance Organisation – an organisation that provides comprehensive healthcare to voluntarily 
enrolled individuals and families in a particular geographic area by member physicians with limited referral to 
outside specialists and which is financed by fixed periodic payments determined in advance (Webster, 2005).  
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that it costs more than $800 million (US) to bring a new drug to market is highly debatable; 
(2) most new drugs do not represent any substantial therapeutic advantage over existing 
products; (3) the prices companies charge include the $2.1 billion they spend promoting their 
medications’. However, as already mentioned by Han (2005, p150), the comments raised by 
Lexchin give little if any attention to the ‘risks and benefits of conducting large-scale research 
with scarce social and economic resources’. These conclusions are similar to those of Vernon 
et al. (2004, p2), who predicted that an ‘increase of governmental control on drug purchases 
will dramatically reduce both real drug prices and research and development (R&D) 
spending’. They estimated that real drug prices will decline by 67.5 per cent. Consequently, 
according to Vernon et al. (2004, p3), this will ‘reduce investment in R&D and lead to a loss 
of life and life expectancy of a great magnitude’. Furthermore, Vernon et al. (2004, p4) stated 
that ‘informed public policy debate should consider the trade-off between lower drug prices 
now and future health benefits lost because of lower R&D spending’ (see also U.S. 
Department of Commerce, 2004).  
 
2.7. The Relevance of Promotion in Pharmaceutical Practice 
The relevance of promotion in pharmaceutical marketing has been described by Bond and 
Lean (1977), who found a linear function between sales (revenue) and promotion. These 
findings are supported by Kremer et al. (2008, p244), who showed that ‘promotional 
expenditure have a significant and positive effect on sales in pharmaceutical markets’. 
However, this has also been questioned by Kremer et al. (2008, p235), who concluded that the 
‘main conclusion from studies on the product and disease category levels is that the 
effectiveness of promotional instruments remains unclear’. The conclusion of the 
heterogeneity of promotional expenditure effects is also supported by several researchers 
(Leeflang and Wieringa, 2008; Manchanda et al., 2005; Parsons and Abeele, 1981; 
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Venkataraman and Stremersch, 2007; Wittink, 2003). Furthermore, Kremer et al. (2008, 
p244) did not find ‘significant promotional elasticity differences between branded and generic 
products’. Some of these variations might be explained by the fact that personal selling 
primarily affects product share positively (Kremer et al., 2008, p244), while ‘DTC 
instruments have a positive effect on both product share and disease category sales (revenue)’ 
(Narayanan et al., 2004, p91).  
The influence of promotion on pricing has been investigated by several researchers. Rizzo 
(1999, p112) provided evidence that ‘product promotion inhibits price competition in the 
pharmaceutical industry, lowering price elasticities and leading to higher equilibrium prices’. 
Narayanan et al. (2004, p104) found ‘significant interaction effects between price and 
promotional expenditure, and quantify the impact of these interactions on personal selling, 
direct-to-consumer advertising and return on investment’. Rizzo (1999, p89) concluded that 
‘personal selling efforts systematically lower price sensitivity. As a result, it is likely that 
consumers pay higher prices as a result of the advertising that occurs in the industry’. 
In addition, another aspect to be considered is the informational content of promotion and its 
role in prescription behaviour. Azoulay (2002, p551) revealed that ‘product market 
competition in the pharmaceutical industry is shaped by both advertising rivalries and 
scientific rivalries’. A similar conclusion was made by Avorn et al. (1982), who performed a 
survey of actual prescribing practices. They revealed that physicians (costumers) were more 
influenced by scientific rather than commercial information sources. Furthermore, Azoulay 
(2002, p551) found evidence that in ‘prescription-drug markets both advertising and scientific 
information stemming from clinical trials can influence physicians (costumers)’ prescription 
choices’. However, Schwartz et al. (1989, p281) revealed that ‘physicians (costumers) also 
sometimes prescribed drugs at a rate far greater than that warranted by scientific evidence of 
their effectiveness’. Nevertheless, Roth et al. (2004) raised concerns about the validity of 
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scientific information as an information source because of apparent cases of data suppression 
or manipulation.  
 
2.7.1. Promotional Marketing Policies 
In pharmaceutical prescription drugs marketing, promotional marketing instruments can be 
divided into two main groups: (1) direct-to-consumer (DTC) and (2) direct-to-prescriber 
(DTP) promotion.  
Direct-to-consumer (DTC) promotion is the direct appeal to end consumers (users) by the 
pharmaceutical company. In DTC promotion, drug companies target prescription drugs 
directly at the public. This approach is based on the idea ‘that mass media marketing 
motivates patients (consumers) to visit their physicians (costumers) for previously untreated 
conditions’ (Donohue and Berndt, 2004, p123; see also Findlay, 2002; National Consumers 
League, 2006; Shaw, 2008). In addition, research also suggests that direct-to-consumer 
marketing messages serve as discussion starters between doctors (costumers) and patients 
(consumers) to a greater extent than they stimulate actual patient (consumer) demand for a 
particular treatment (White et al., 2004). According to Hunt (1998, p2), ‘patients (consumers) 
often initiate conversations with their physicians (costumers) about promoted medications and 
even ask for them. In jurisdictions where it is allowed, direct-to-consumer promotion has 
proved highly successful in stimulating consumer demand for prescription drugs’. In contrast, 
for Iizuka and Jin (2002, p2), DTC marketing has no effect on physicians (costumers)’ choice 
of prescription, but ‘may facilitate the communication between patients (consumers) and 
physicians (costumers)’. These findings are also underlined by Iizukas’ (2002) and Donohue 
and Berndt’s (2004) results, in that direct-to-consumer promotion leads to a large increase in 
the number of outpatient (consumer) drug visits (see also Chen, 2007), i.e. ‘a moderate 
increase in the time spent with physicians (costumers), but no effect on physicians 
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(costumers)’ specific choice among prescription drugs within the therapeutic class’ (Iizuka 
and Jin, 2002, p1). Most studies agree that “disease awareness” or “drug awareness” 
promotions lead to increases in consultations for targeted conditions. It is argued that ‘direct-
to-consumer information about pharmaceutical products serves an unmet patient (consumer) 
need’ (Wong-Rieger, 2009, p130), and it is stated that, through promotion, ‘drug companies 
can enable patients (consumers) to make better informed choices about their health and 
treatment’ (Mintzes, 2002, p908). On the other hand, ‘critics have argued that healthy patients 
(consumers) seeking physician (costumer) advice are a waste of healthcare resources; 
however, there is scant evidence that these consultations are inappropriate’ (Wong-Rieger, 
2009, p130). Therefore, it is concluded by Wong-Rieger (2009, p130) that ‘promotions do not 
lead to patients (consumers) getting inappropriate medications’.  
Nevertheless, in the literature, several researchers have raised their concerns regarding direct-
to-consumer promotion. Barbara Mintzes (2002, p908) argued that ‘direct-to-consumer 
(DTC) promotion risks medicalising normal human conditions, with the drug companies 
raking in increasingly healthy profits’. Mintzes (2002, p909) justified this by citing that ‘more 
than $2.5bn (£1.8bn; €2.9bn) were spent on direct-to-consumer marketing in the United States 
in 2001’, and concludes that ‘the cumulative message may be stronger than any individual 
campaign’. Furthermore, Mintzes et al.’s (2003) results suggest that more marketing leads to 
more requests for promoted medicines – and more prescriptions. Consequently, it can be 
established that ‘if direct-to-consumer promotion opens a conversation between patients 
(consumers) and physicians (costumers), that conversation is highly likely to end with a 
prescription, often despite physician (costumer) ambivalence about treatment choice’ 
(Mintzes et al., 2003, p405). For Kalyanaram (2009), there is a positive and significant effect 
attributed to DTC and market share. 
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In conclusion, Narayanan et al.’s (2004, p104) findings reveal that ‘direct-to-consumer 
marketing has a significant positive effect on both brand share and category sales (revenue)’. 
The effects of direct-to-consumer communication in the US market were measured by White 
et al. (2004) in an empirical study. White found that consumers valued physicians 
(costumers)’ opinions most (77%), followed by friends (57%), pharmacists (53%), nurses 
(48%), brochures (47%), magazine articles (42%), medical journals (38%) and newspaper 
articles (33%).  
Furthermore, it has to be noted that, in healthcare, ‘manufacturers are legally prohibited from 
communicating directly with their end customer [with the exception of New Zealand and the 
United States]’ (Stremersch, 2009, p5), so there is emphasis on other promotional activities 
(Rod et al., 2007).  
The Role of Direct-to-Prescriber (DTP) Promotion – Marketing efforts, typically directed 
toward physicians (costumers) by pharmaceutical companies, are defined as direct-to-
prescriber promotion (Manchanda and Honka, 2005). Kremer et al. (2008, p239) classified 
‘three DTP subgroups: personal selling, advertising, and other (including physician 
(costumer) meetings and events, direct mails and sampling)’. Furthermore, Kremer et al. 
(2008, p244) found that the ‘effects of the promotional instruments vary considerably across 
disease categories. For most disease categories, the average predicted DTP elasticities are 
substantially higher than the average predicted direct-to-consumer elasticity. However, the 
effectiveness of DTP instruments depends on the disease category’. A DTP advertising model 
is proposed by Lim and Kirikoshi (2008). 
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2.7.2. The Role of Promotional Marketing Instruments 
For both promotional marketing policies – direct-to-consumer (DTC) and direct-to-prescriber 
(DTP) – marketing instruments such as word-of-mouth, information, personal selling, 
advertising and sampling can be applied.  
The Role of Word-of-Mouth – The effectiveness of promotional actions can be improved by 
an actively supported distribution of positive messages via word-of-mouth. This approach is 
especially essential in pharmaceutical marketing, as the ‘impact of company marketing is 
significantly enhanced by the effect that occurs when physicians (costumers) first prescribing 
the product find it satisfactory and recommend it to their colleagues’ (Lilien et al., 1981, 
p494). In addition, it has been highlighted by Jaakkola and Renko (2007, p342) that 
‘marketers of new pharmaceuticals should also not underestimate the importance of gaining 
publicity and positive word-of-mouth among patients (consumers). New product acceptability 
in the pharmaceutical market may be strongly influenced by lay consumers, and that 
perceived complexity may overrule performance advantages even among professionals’. 
However, as by Cooley (2009, p46) stated, ‘consumers no longer depend on subjective 
sources such as word-of-mouth, but also look at objective internet sources’. Goetzinger et al. 
(2007, p128) also surmised that the ‘search for online health-related information has become 
increasingly popular’. Consequently, it is evident that the level of influence is influenced by 
word-of-mouth and information sources.  
The Role of Personal Selling – As previously stated, personal selling is a vital marketing 
instrument for promoting prescription drugs. This statement is supported by Mizik and 
Jacobson (2004, p1704), who found evidence that ‘personal selling has positive and 
statistically significant effects on the number of new prescriptions issued by a physician 
(costumer)’. For Kremer et al. (2008) and Manchanda (2005), personal selling is the most 
important promotional marketing instrument, too. Lurie et al. (1990, p240) also highlighted 
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that ‘changes in purchase practices were reported at least once by 25% of faculty and 32% of 
residents based on salesperson contacts’. The personal selling impact was also empirically 
explored by Narayanan et al. (2004), who revealed that personal selling can positively affect 
brand share. Consequently, according to Manchanda and Chintagunta (2004, p131), ‘personal 
selling has a positive and significant impact on the number of prescriptions written by a 
doctor (costumer)’, although on the other hand, as further stated by Manchanda and 
Chintagunta (2004, p143), ‘too much personal selling can dissuade a physician (costumer) 
from prescribing a drug’. This means that over-promotion (in this case personal selling) can 
influence sales (revenue) negatively. However, if an over-promotion (personal selling) does 
not take place, there is strong evidence of correlation between sales (revenue) and numbers of 
sales representatives, as determined by Rod et al. (2007). Furthermore, Gonul et al. (2001, 
p90) found evidence that the ‘informative value of personal selling makes physicians 
(costumers) aware of new drug alternatives and their specifics and prices, as well as 
supporting the idea that personal selling has a positive effect only up to a point, after which 
excessive personal selling becomes counteractive’. Consequently, based on a McKinsey 
report, Elling et al. (2002) questioned in general the effectiveness of the current salesperson 
system. For Mizik and Jacobson (2004, p1714), the ‘effect of salesforce activity on 
prescribing behaviour is also modest. Therefore, drug companies’ profits might be enhanced 
through a reduction in pharmaceutical sales representative numbers, combined with an 
increase in effectiveness of individual representatives’. This is supported by the fact that 
several drug companies have – though with only moderate success – attempted to increase 
their sales (revenue) by increasing the number of sales representatives, in spite of the number 
of medical practices having remained comparatively constant (Breuer et al., 2003). 
Consequently, we can ask the following question: Do prescription pharmaceutical sales 
people really sell anything, or do they just promote pills? According to an American Court of 
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Appeal ruling, their work is not “sales” in the traditional sense (they do not take orders) 
(Edwards, 2010). 
The Role of Personal Selling in Direct-to-Consumer (DTC) Advertising – According to 
Kremer et al. (2008, p239), there is ‘evidence that sales are most strongly affected by personal 
selling, followed by journal pages of advertising, and are least affected by direct-to consumer 
advertising’. Nevertheless, in addition to the evidence provided by common practice in the 
industry, earlier studies such as Narayanan et al. (2004) and Rod et al. (2007) suggested that 
there are synergies between the promotional interactions of DTC and personal selling. 
Furthermore, Chen (2007) pointed out that patients (consumers) are likely to visit physicians 
(costumers) in response to DTC. Therefore, it can be argued that it is beneficial to support the 
marketing activities of personal selling by direct-to-consumer advertising. As a result, for 
Vakratsas and Kolsarici (2008, p291), ‘less spending on physician (costumer) journal 
advertising may lead to less information communicated to physicians (costumers) and thus 
lower awareness of potential treatments. Therefore, underestimating physician (costumer) 
journal advertising may prompt a decision to underfund this marketing activity, resulting in 
fewer prescriptions’. Donohue and Berndt (2004) stated that direct-to-consumer advertising 
appears to affect whether or not someone receives medication of a given therapeutic benefit, 
whereas personal selling affects which particular medication they receive. This premise is 
supported by Narayanan et al. (2004), who stated that a feature of direct-to-consumer 
advertising shows that it is less ‘targeted’ than personal selling, whereas personal selling 
activity ensures that the target physician (costumer) is appropriately informed. Rosenthal et al. 
(2002) concluded that direct-to-consumer advertising is an important, but not the primary, 
driver of immediate growth. However, compared to the effects of DTP (direct-to-prescriber), 
the direct effect of direct-to-consumer advertising remains relatively small, at least for most 
disease categories. 
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Factors of Personal Selling Effectiveness – The results provided by Churchill et al. (1985, 
p113) indicated that the ‘strength of the relationship between the major determinants of sales 
effectiveness (as discussed above) and salespeople’s actual performance is influenced by the 
type of products salespeople sell’. The most important criteria that characterise a successful 
relationship between a salesperson and a customer were described by Saxe and Weitz (1982) 
in their 1982 study, in which they developed the 24-item SOCO (Sales Orientation-Customer 
Orientation) scale. In a later study, Gillis et al. (1998) described the six components that are 
measured by the SOCO scale. Looking at the individual salesperson in more detail, it is 
generally considered that there are specific personal attributes that are considered important. 
Parsons and Abeele (1981) measured the sales response of an established ethical drug to sales 
visits. They proposed twelve fundamental salesperson variables, in order for a salesperson to 
be considered “good”. Furthermore, Jaffe (2000) proposed seven (admittedly somewhat self-
evident) tactics to add power when dealing with physicians (costumers). He also advised 
building coalitions involving physicians (costumers); however, given that personal selling is 
by far the most expensive element of promotion, Gonul et al. (2001, p89) concluded that the 
‘scope of personal selling should be carefully scheduled in terms of frequency, length of 
visits, and number of free samples given away to optimize the company’s effectiveness of 
direct promotion efforts and expenses’.  
The Role of Personal Selling in Direct-to-Prescriber (DTP) Advertising – It is considered that 
the individual characteristics of the sales representatives and their relationship with the 
prescriber are key criteria. This statement is supported by Ambady and Krabbenhoft (2006), 
who investigated the relevance of a customer’s perception of a salesperson to their sales 
(revenue) success. This research has clearly shown that there is a strong relation between the 
customer perception of a salesperson and sales effectiveness. This is also supported by Hill 
(1999), who stated that the major determinant of the drug chosen by the physician (costumer) 
is the relationship between the salesperson and physician (costumer). The interaction between 
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salesperson and prescriber was also examined by Andaleeb and Tallman (1996, p79), who 
found that ‘physicians (costumers) viewed the field salesforce as a relevant source of 
information, but felt that they could also get the necessary information from other sources. 
Physicians (costumers) also had friendly relations with sales representatives and did not 
distrust them, but they did not view sales people as a vital part of their practice. Furthermore, 
the selling approach was not thought to be perceived negatively by the medical community, 
nor was the field salesforce considered as manipulative’. However, Gillis et al. (1998, p105) 
found that ‘general practitioners (costumers) perceived salespeople to be preoccupied with 
their own professional needs’.  
The Role of Sampling – The efficiency of personal selling can be enhanced through product 
sampling. Gonul et al. (2001) found evidence that sampling (provision of drugs at no costs) 
positively affects prescription probability. Hauser and Wernerfelt (1990) concluded that it has 
to be taken into account that money-off deals and hand samples make a brand easier to try, 
and therefore decreases the cost of evaluative search. However, samples and gifts were not 
viewed as essential for gaining access to physicians (costumers) (Andaleeb and Tallman, 
1996). Nevertheless, it can be posited that sales (revenue) are influenced by sampling. 
 
2.8. Summary of the Systematic Literature Review 
The relevant criteria and their sub-criteria (please refer to Paragraph 2.3.) were analysed, 
summarised and categorised according to Bain’s (1956) order-of-entry model and McCarthy’s 
and Perreault’s (1960) classical “4Ps” concept. For this purpose, a hierarchically structured 
framework containing three groups – marketing categories variables and attributes – was set 
up and the five main marketing categories of strategy, product, price, place and promotion 
were defined, each containing a group of variables. The inherent characteristics of variables 
are described by attributes. In a second step, the keywords of each statement were then 
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indicated and categorised according to the five marketing categories. In a third step, the 
previously indicated keywords were classified according to their categorical property as a 
variable or attribute. Within the two marketing category and variable classification schemes, 
the criteria were also ranked according to their importance in the literature. For this purpose, 
the numbers of criteria were counted within the 170 citations (see Table 2-1, step 10) 
highlighted as being relevant. These criteria were then ranked within each category (order-of-
entry, marketing mix [product, place (distribution)], promotion, price) according to the 
number of citations (n.) (see also Glitz, 1997). Table 2-4 presents an overview of the results 
of the systematic literature review.  
 
 Marketing Categories n.  Variables n.  Attributes
 Order of Market Entry 93  Market Share 37  Sales
 Physician
 Patient
 Market Leader
 Market Nichers
 Early Entry 30  Habit Formation
 Late Entry 26
 Product 16  Innovativeness 14
 Quality 13
 Branding 17
 Packaging 1
 Place (Distribution) 5
 Promotion 97  Personal Selling 34  Perception
 SOCO
 Advertising 26  DTC
 DTP
 Sampling 7
 Word-of-Mouth 4
 Price 25
n. shows number of times being mentioned
 
Table 2-4: Marketing relevance of marketing factors 
 
Marketing theory would suggest that all of the four Ps (Product, Promotion, Place and Price) 
are essential in marketing (Kotler, 2006). However, based on Table 2-4, the first major 
finding of the present study is that, in pharmaceutical marketing, promotion as a marketing 
instrument appears to be considerably more relevant than price, product or place. It was found 
that promotion policy is considerably more mentioned in literature (times being mentioned: 
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97), as it is followed by price (times being mentioned: 25), product (times being mentioned: 
16) and place (times being mentioned: 5). It should be noted that because of the partly 
multiple meanings of the initially 170 indicated citations, the total number in Table 6 appears 
to be higher. So far, an overview of marketing mix elements and instruments has been given. 
However, because of the apparent differences between the various markets (see Table 1-2), 
the adequate marketing mix proportion has to be defined.  
In total, 21 relevant marketing criteria and their sub-criteria (see Table 2-4) have been 
indicated by the systematic literature review as being important. In addition, some interesting 
insights into pharmaceutical marketing were revealed. These findings were structured on the 
basis of the order-of-market entry model (Bain, 1956) and the fundamental conceptual 
marketing model (see also Kotler, 2006), thus integrating existing knowledge from the 
pharmaceutical marketing and psychology genres, amongst others.  
 
2.8.1. Factors guiding Order-of-Entry 
As the previous section described (see 2.6.1.), order-of-market entry is a fundamental 
theoretical concept within pharmaceutical marketing. A company’s decision whether to enter 
a market as a first, early or late entrant is guided by three relevant parameters. First, the status 
and progress of a medical drug is driven basically by governmental authority approval and is 
dependent on the company’s medical drug research. Second, order-of-market entry is also 
dependent on competitors’ status and progress in research and their own strategic decisions 
regarding market entry (see also Subhash, 2009). Finally, for early entrants to enjoy success, 
innovativeness is an essential factor (Tellis and Golder, 1996) but has a ‘modest impact on 
success’ (Cooper and Kleinschmidt, 1993, p110).  
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2.8.2. Order-of-Entry defining Marketing Instruments 
‘Product differentiation is an essential discriminator between winning and losing new 
products’ (Cooper and Kleinschmidt, 1993, p108). This can be reached by adapting product 
mix attributes adequately (Kotler, 1998). A product policy is guided by the order-of-market 
entry decision (Vakratsas and Kolsaricis, 2008), as the product market standard is set by the 
first entrant (Lieberman and Montgomery, 1988). Furthermore, ‘the market response to 
quality is decreased by order-of-market entry’ (Bowman and Gatignon, 1996, p238).  
For Bowman and Gatignon (1996, p238), ‘later entrants are at a disadvantage in competing 
with price; they need to change price by a larger amount than earlier entrants to attain the 
same change in market share’. This is also in line with Daos’ (1984) conclusion that 
innovative new products lead to price pressure on existing products.  
Based on Kardes and Kalyanaram’s (1992) and Comanor and Wilson’s (1979) findings, there 
is a lack of marketing mix effectiveness (Vakratsas and Kolsaricis, 2008) as a decreasing 
function of order-of-market entry (Bond and Lean, 1979; Bowman and Gatignon, 1996). This 
results in the need for market formation (Vakratsas and Kolsaricis, 2008). Therefore, it is 
suggested that companies entering a market late have to employ intense marketing efforts and 
have to ‘shout louder to be heard’ (Robinson and Fornell, 1985, p316). On the other hand, 
only later entrants can benefit from the early entrants’ marketing efforts (Mitchell, 1989). 
Furthermore, Kardes and Kalyanaram (1992, p355) proposed that ‘promotional and channel-
related tactics which facilitate consumer learning (habit formation) should be implemented’. 
In summary it can be said that there are two trends apparent in this instance: (1) Early entrants 
have to invest in promotion in order to prepare the market and (2) late entrants have to invest 
in promotion ‘in order to be heard’.  
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2.8.3. Marketing Instruments leading to Sales 
As previously described (see Paragraph 2.9.2), product differentiation, as an essential 
discriminator, is considered key to successful marketing (see also Cooper and Kleinschmidt, 
1993; Kotler, 2006 and 1998; Sharp et al., 2001), resulting in higher product sales (revenue). 
Lexchin (2009, p145) revealed that ‘doctors (costumers) are generally ignorant both about the 
relative and absolute prices of medications’. However, this statement was questioned by Rice 
(2009, p184), who concluded that ‘HMO (Health Maintenance Organisation; a group of 
physicians (costumers) that has an agreement with health insurance(s) and provides care for a 
previously fixed fee) physicians (costumers) are more price-sensitive in prescribing brand 
name substitutes than non-HMO physicians (costumers)’. Furthermore, it is posited by several 
researchers (Bond and Lean, 1977; Kremer et al., 2008, p244) that ‘promotional expenditure 
have a significant and positive effect on sales (revenue) in pharmaceutical markets’. 
Furthermore, Gonul et al. (2001) and Hauser and Wernerfelt (1990) find evidence that 
personal selling and advertising (Kremer et al., 2008) positively affect prescription 
probability. It should be noted that place (distribution), as a marketing instrument, does not 
appear to play an essential important role in marketing success, according to some researchers 
(Cooper and Kleinschmidt, 1993; Ghosh et al., 1983; Smith, 1983).  
 
2.9. Conclusions of the Systematic Literature Review  
This chapter has provided an assessment of theory relevant to “physician-targeting” problem 
situations. A wide range of existing literature sources was tapped in order to develop insights 
into this issue. In other words, the literature was used to identify the underlying traits or styles 
of “physician-targeting”. An analysis of the “order-of-market entry” theory demonstrated that 
a) managers of pioneering brands should implement promotional and channel-related tactics 
that facilitate consumer learning (habit formation), b) late entrants have to shout louder to be 
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heard within the market and c) later entrants are at a disadvantage when competing on price, 
so they need to change the price by a larger amount than earlier entrants to attain the same 
change in market share. 
Many concepts and marketing instruments are described in the literature. Research is usually 
performed from a narrow perspective focusing on a few interactions and phenomena. 
However, not much work has been done so far (see Raisch, 1996, Singh, 2008) to combine all 
of these research efforts into an overall picture, to investigate the influence of these 
instruments on sales (revenue) or to provide a generally usable model for marketing 
managers.  
This systematic literature review faced a major obstacle, as most of the available studies 
investigated the variation of marketing mix variables in the less regulated US market (Berndt 
et al., 1997; Berndt et al., 2002; Berndt et al., 2003; Bowman and Gatignon, 1996; Bond and 
Lean, 1977; Golder and Tellis, 1993; Lieberman and Montgomery, 1988; Lilien and Eunsang, 
1990; Moore et al., 1991; Robinson and Fornell, 1985; Tellis and Golder, 1996; Urban et al., 
1986; Vernon, 1971). So far, no research has been found regarding this particular country. As 
a result, there is a need for research on “physician-targeting” models in specific market 
environments, which supports Steenkamp’s (2005) suggestion that targeted research is 
required within the marketing research area. Therefore, let us ‘move out of the US silo’ 
(Steenkamp, 2005, p6). 
 
The aim of this chapter was to delineate the dimensionality of pharmaceutical marketing 
instruments used when physicians (costumers) are targeted. This “physician-targeting” 
framework was derived from both marketing and psychology literature. Next, it is essential to 
gain more specific insights into “physician-targeting” and it needs to be examined in light of 
field data. The following chapter investigates the “physician-targeting” process from a 
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practical perspective, in order to validate this concept in the focus of the state-controlled 
market Swiss pharmaceutical market, to identify the most relevant marketing factors and to 
examine existing theories (please refer also to Paragraph 1.1.5). 
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3. The Relevance of Marketing Activities in the Swiss 
Prescription Drugs Market: A Qualitative Focus Group 
Study  
 
3.1. Situation of Swiss Pharmaceutical Market and its Impact on actual 
Research 
It has been in the first chapter highlighted that the Swiss prescription pharmaceutical market, 
as a state controlled market, has several pelicularities different to other pharmaceutical 
markets making it relevant for the present research. These pelicularities are briefly 
summarised below.  
First of all, pharmaceutical companies benefit from a protected market that indicates the 
presence of a market failure. Prescription medical drugs have to be approved by a 
governmental body (Swissmedic) in a first place. Furthermore, it can be assumed that not a 
big differentiation regarding to the product property issues such as quality takes place. 
Consequently, there is only room for a product differentiation in terms of ‘packaging’ and 
‘branding’. The approval of pharmaceutical substances is a long and time consuming process, 
inhibiting parallel imports of other alternative and/or cheaper medical drugs, reducing the 
competitive pressure. This is similar to the US market where the medical drug approval is 
given by the US Food and Drug Administration (FDA). In contrast to the US market, a ban on 
parallel imports is implemented in Switzerland. 
Furthermore, pricing plays an important role as well. In Switzerland, the prices are set by the 
Swiss Agency for Therapeutic Products (Swissmedic). Despite of this, pharmaceutical 
companies may actively influence the price level via lobbying by attempting to influence 
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decisions made by officials in the government. Nevertheless, the market does not appear to be 
very price sensitive as the patients (consumers) as well as the prescribers (costumers) are not 
those that have to pay for it (it is normally the health insurances). Furthermore, there is a 
motivation to prescribe more expensive drugs, as self dispensing physician have a financial 
benefit and the patients have the perception of receiving a medical drug with higher quality 
(efficacy and less side effects). This fact leads to the conclusion that the prescribers 
(costumers) are the final decision makers and consequently the most important ‘factor’ of the 
market system. This is different to the US market and indicates a market failure too. 
There are also differences regarding to the promotional marketing activities that can be 
employed in Switzerland in comparison to the US market. There is a ban for direct-to-
consumer (DTC) promotional activities in Switzerland. However, some companies have 
found ways to conduct indirect, legally accepted, direct-to-consumer (DTC) promotion such 
as ‘news articles publication’ and/or ‘health television programs sponsorship’. On the other 
hand, the practice of direct-to-physicians (DTP) promotion is legally accepted and conducted 
by employing ‘sales personal’, ‘mailings’ and ‘advertising’ measures (ads and articles in 
specific medical doctors directed outlets/publications, brochures, etc.). 
Regarding the distributional (place) marketing activities, there is a limitation of distributional 
channels present and therefore no differentiations in the distributional policy can be made by 
pharmaceutical companies. The internet as a sales channel (online pharmacies) does not play 
a role in Switzerland. 
In conclusion it can be said that the Swiss prescription pharmaceutical market is a highly 
interesting market to be investigated from a practical (managerial) as well as theoretical 
perspective. This is especially the case because of the fact that the relevance and relationship 
of marketing factors can be separately investigated using marketing factors that are not 
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applied or altered in the Swiss prescription pharmaceuticals market as control variables. This 
fact differentiates the present research to the research conducted in US market. 
 
3.2. Introduction  
Although the conclusions drawn by the systematic literature review (Chapter 2) have been 
evidenced and supported by the United States of America’s scientific literature, they mainly 
analyse the free (unregulated) US prescription pharmaceutical market. Most of this research 
has not addressed the different aspects of regulated markets. For instance, the regulated Swiss 
prescription pharmaceutical market is unlike the unregulated US prescription pharmaceutical 
market and some other countries that are operating similarly to the non-US approach. 
Therefore, in order to gather additional scientific knowledge that will enable the development 
of theories applicable to non-US markets, a qualitative research was conducted. 
For this purpose, a two-stage empirical qualitative approach was employed. The first stage 
was a focus group study and the second stage a Delphi group study. In this chapter, the focus 
group study is presented. The Delphi group study is presented in the next chapter. These two 
studies aimed to generate some insights into the importance and impact of marketing 
instruments for the following main reasons. First of all, it was necessary to utilise qualitative 
fieldwork in order to determine whether or not the constructs suggested by previous research 
(see Chapter 2) were actually relevant within a regulated prescription pharmaceutical 
environment. Secondly, qualitative fieldwork (Chapters 3 and 4) was required in order to 
more fully explicate the constructs which were suggested by the literature, to thus add depth 
and richness. The analysed data gathered from the qualitative focus and Delphi group studies 
(see Chapters 3 and 4) and the tentative constructs emerging from the literature-based 
explication approach described in Chapter 2 were analysed in light of qualitative data (see 
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Chapter 4) in order to provide a robust delineation of the constructs of interest regarding 
“physician-targeting”. 
Thus, the present chapter begins with a discussion of the overall methodology utilised to 
collect and analyse the qualitative data. Following that, the methodology of the focus group 
study is described, the results are presented, a summary is offered, a prescription decision 
process model is proposed and the most relevant marketing factors are derived.  
 
3.3. Focus Group Study 
3.3.1. Introduction 
The focus group element of the present study attempts to assess marketing tools in 
Switzerland, highlighted by a group of participants working in the field of pharmaceuticals. In 
this paragraph, the previously derived propositions of the systematic literature review are 
evaluated and advanced. The provided interpretations are based on the focus group results 
(see Table 3-1) and the systematic literature review findings (see Table 2-4).  
In social and behavioural sciences, qualitative research methods deal with understanding 
things rather than quantitatively measuring them (Gordon and Langmaid, 1988), and they 
usually involve some type of interview with people (Bortz and Doering, 2006). Furthermore, 
as emphasised by Glitz (1997, p387), ‘they can offer additional clues about beliefs and 
attitudes. Quantitative study methods are normally based on retrospective data material (e.g. 
collected market data) and structured questionnaires’. Quantitative methods are therefore less 
likely to yield any new findings or different views. On the other hand, these research methods 
have a larger sample size and are therefore statistically more robust. In addition, study 
participants are normally not ready to invest more than 10 to 30 minutes of their time for 
study participation. As a result, the informational content will be limited. In contrast, 
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qualitative methods in general have longer interview times and therefore gather more in-depth 
information. This methodology has been described by several authors (see also Lee and 
Lings, 2008; Morgan, 1988). 
In health services research, qualitative research methods, especially focus groups, are 
becoming increasingly prominent and their value has been more widely acknowledged (for 
methodology see also Krueger, 1994; Merton et al., 1956; Smith, 1998; Wilkinson, 1998). In 
addition, Smith (1998, p229) stated that ‘there has been increasing interest in the application 
of focus groups in pharmacy practice and health services research’. Furthermore, ‘even when 
the reliability and validity of the data cannot be measured in the same way as for quantitative 
findings, qualitative data are credible, if careful procedures are applied’ (Glitz, 1997, p387).  
 
3.3.2. Research Procedures and Settings 
For the focus group discussion, a set of research questions was developed, ensuring that the 
stated research objectives in Chapter 1 were covered. For this purpose, a brainstorming 
session was performed by the focus group facilitator and the monitor team. This 
brainstorming resulted in a set of questions, which enabled the conceptualisation of the 
dimensionality of pharmaceutical marketing instruments and clarified the influence of 
pharmaceutical marketing instruments on “physician-targeting” leading to an increase in sales 
(revenue). Furthermore, it was ensured that the aspect of order-of-market entry (Bond and 
Lean, 1977) and all 4Ps were covered (Kotler, 2006). In addition, the clear wording of the 
questions was ensured and words were selected that avoided biasing the respondents (Schmidt 
and Hollensen, 2006). As a result, a set of nine open-ended, non-standardised questions was 
developed. The questions were ordered regarding their topic, starting with general marketing, 
product, price and promotion, and then they were piloted on a small sample of three 
marketing academic experts at the Zurich University of Applied Sciences in Winterthur, 
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Switzerland. Based on the outcome of the pilot study, which did not require any further 
modifications to the questions for the main focus group study, the following set of questions 
was agreed to address the research objectives:   
• Question [Q1]: What is the procedure when purchasing prescription drugs? 
• Question [Q2]: What are the most efficient sales methods for prescription drugs? 
• Question [Q3]: What are the criteria when appointments are given to sales reps? 
• Question [Q4]: What methods are applied in prescription drug sales? 
• Question [Q5]: Which criteria are applied when choosing a pharmaceutical product? 
• Question [Q6]: Which product would you choose if you had a choice between two 
similar products from a well-known and an unknown producer? 
• Question [Q7]: What is the influence of price on the purchase decision? 
• Question [Q8]: What is the salesperson’s influence on the physician (costumer)’s 
decision? 
• Question [Q9]: How do you gather product information? What are the most important 
sources? 
 
In the next step, a requirement profile for the focus group participants was set up. As 
described in Chapter 2, different interest groups are involved in the prescription drugs market 
(see also Kocher, 2007). According to Kuehn and Patric’s (2003) market system model (see 
Figure 1-5 and Appendix 1), the relevant interest groups are producers, opinion leaders, 
pharmacists (sellers), wholesalers, physicians (costumers), insurers and patients (consumers). 
As already shown in Chapter 2, the most important group relevant for physician-targeted sales 
are producers, physicians (costumers) and pharmacists. Because of this, it was envisaged to 
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set up a focus group with the parties involved on the sales and purchase sides. Furthermore, 
another criterion was seniority (years of experience, level of involvement, level of position, 
educational background) in order to ensure the participants’ depth of knowledge.  
It is the nature of focus group discussions that a small sample size of participants (experts) is 
employed in order to gather more in-depth information. Consequently, there is a natural upper 
size limit when doing a group interview. This typically can include ‘up to ten experts who 
have some knowledge of/or experience with the topic under discussion’ (Glitz, 1997, p386). 
In order to limit the total length of the interview time, to ensure that sufficient in-depth 
information can be gathered and because of the complexity of the topic (e.g. Morgan, 1998), 
the focus group size was limited to a maximum of five participants. 
The facilitator and monitor team indicated via personal contacts the potential candidates 
fulfilling the requirement profile. These potential candidates were then contacted via mail, 
providing general information about the study’s aim, procedure, location, the assurance of 
anonymity and required time (two hours) in the first instance, and if no  answer was received 
within a week, via telephone. All approached candidates agreed to participate, but a suitable 
date and time had to be found. All participants also agreed to the recording of the focus group 
through email confirmation. No financial compensation was offered. According to the 
requirement profile, a well-balanced mix of highly experienced individuals could be 
appointed. 
• SA – This candidate, involved on the pharmaceutical sales side, is a former head of 
marketing and sales for a leading Swiss global pharmaceutical company, management 
board member and chief executive officer of two Swiss OTC companies in the Basel 
area today. Based on the long experience in high level positions, SA will provide 
interesting information from a producer’s perspective, as well as marketing and sales 
approaches. 
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• BB – This candidate, involved on the pharmaceutical purchase side, holding a PhD, is a 
specialist for internal medicine FMH based in Zurich. BB will contribute to the focus 
group regarding his long practical experience in dealing with pharmaceutical sales 
people and marketing campaigns, and BB can provide information about existing needs 
and concerns from the prescriber (costumer)’s perspective. 
• SC – This candidate, involved in the sales side, holds a position as an independent 
consultant for a supply chain and commercial service management company, mainly 
involved in projects for a leading American global pharmaceutical company based in 
Switzerland. Not being directly involved in the sales process, but in charge of process 
design and management, SC will contribute to the focus group from a distant and 
professional perspective. 
• BD – This candidate, involved in the purchase side, holding a PhD, is a psychiatrist, a 
lecturer at Zurich University, author and board member of the Swiss agency for the 
authorisation and supervision of therapeutic products (Swissmedic). BD will contribute 
to the focus group regarding their long practical experience in dealing with 
pharmaceutical sales people and marketing campaigns, and he can provide information 
about existing needs and concerns from the prescriber (costumer)’s perspective. As a 
psychiatrist and an academic, it is likely that might have a different view than his 
colleague BB.  
• BE – This candidate, involved on the pharmaceutical purchase side, is a pharmacist and 
owner of a pharmacy located in Zurich. BE will contribute to the focus group regarding 
the long practical experience in dealing with pharmaceutical sales people and 
marketing campaigns, and can provide information about existing needs and concerns 
from the pharmacist’s perspective. 
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The focus group discussion took place in a meeting room, centrally located near the Enge 
train station in Zurich, Switzerland, which was provided without charge by an advocacy firm. 
These facilities were prepared before hand, and a video projector and tape recorder with a 
microphone were installed and tested. In order to accommodate the participants’ full-time job 
commitments, the start was set for four o’clock in the afternoon and took place for two hours. 
The participants were personally welcomed by the facilitator on their arrival and guided to the 
meeting room. No seating order was given, drinking water was provided and a brief 
introduction of the participants took place. 
The focus group was then briefed by the facilitator, a presentation was made about conducting 
the research and to explain the research objectives and the procedure of the discussion was 
given. An agreement on confidentiality, impartiality and that all opinions within the group 
were welcomed was made. The facilitator led the group through a discussion of the series of 
nine prepared questions, making sure everyone responded and was probed for detail when 
necessary, and encouraged group interaction, while keeping discussions focused on the topic. 
These questions were open in format in order to give the participants as much freedom as 
possible when answering. Each participant was also asked to engage in individual 
brainstorming, so as to generate as many ideas as possible for dealing with the issue. These 
questions were presented to the participants on the video projector. A short break of five 
minutes was given in the middle of the interview, following the end of the discussion on the 
third question. The discussion was tape-recorded and the main statements were noted by the 
study assistant. After the focus group discussion, a small chocolate box was given to the 
participants and information was given about the further process of this study. The 
participants were also informed that the results would be submitted to them within a few 
months’ time. In addition, each participant answered a few questions about their professional 
and personal characteristics. 
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After the focus group session, all the notes were compiled and the tapes were transcribed 
verbatim by the facilitator, including the starting time shown on the counter of the tape 
recorder, on word processing software. Because of the clear differences between the 
participants’ voices, they could be easily distinguished. This manuscript was then proofread 
for typing mistakes and translated from German into English. However, although the 
translation was performed as carefully as possible and proofread by a professional in order to 
minimise possible misinterpretations, it had to be taken into account that the meaning could 
have been slightly altered. In particular, the translated comments could appear more formal 
than the meaning of the statements, due to language characteristics. The adequacy of 
translations in cross-cultural research has been discussed by several authors (Lee and Lings, 
2008; Craig and Douglas, 2005). As stated by Lee and Lings (2008), there are at least some 
common attitudinal or behavioural factors across cultures. In the present study, most of the 
participants, because of their professional international activities, are familiar with the English 
cultural background. Nonetheless, the translated statements may appear to a native English 
speaker to be quite formal (the complete transcript can be viewed in Appendix 3). 
 
3.3.3. Focus Group Findings and Analysis  
In the first step, the content of the transcript was coded regarding “pharmaceutical marketing 
strategy”, “product”, “price” and “promotion”. In a second step, the indicated text fragments 
were analysed for content regarding frequency, the statement given (content, agreement, and 
person), transferred and sorted regarding similar content in a meta-matrix (see Appendix 4). 
Within the matrix, sellers versus buyers and the group opinion were used as units of analysis. 
Finally, the statements of the focus group members and literatures were compared, analysed 
and conclusions derived (Glitz, 1997).  
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3.3.3.1. Pharmaceutical Marketing Strategy  
In summary, the order-of-market entry effect guides companies’ strategic marketing 
decisions. This approach considers the physician (costumer)’s prescription habit formation. 
Furthermore, it is emphasised that the decision-maker (physician (costumer)) plays a central 
role. Two fundamental strategic marketing communication strategies, the marketing push and 
the marketing pull, the physician (costumer), and the choice of the marketing communication 
strategy is guided by the medical drug class. The pharmaceutical company that applies the 
marketing push strategy will influence the physician (costumer) indirectly through opinion 
leaders, or directly by employing promotional measures. However, the marketing pull strategy 
is becoming increasingly important. In order to be able to set up a physician (costumer)-
specific marketing strategy, the physicians (costumers)’ scientific or economic orientation has 
to be taken into account. The following criteria were stated by the group members, as shown 
in Table 3-1. 
Seller Buyer Group Literature
Marketing Pull (3, +) Marketing Pull (4, +) Dogramatzis, 2002
Marketing Push (3, +) Marketing Push (1, +) Marketing Push (1, +) Dogramatzis, 2002
Opinion Leader (1, +) Opinion Leader (2, +) Opinion Leader (2, +) Lilien et al., 1981
Physicians' Preference (2,+) Physicians' Preference (4,+) Physicians' Preference (1,+) Zhang et al., 2007
Physicians' Orientation (5,+) Physicians' Orientation (1,+) Avorn et al., 1982; Azoulay, 2002
The number within the brackets indicate the number of participant quoting this statement
The plus or minus symbol indicates if a positive or negative statement was given
 
Table 3-1: Marketing strategy factors 
 
It should be added that, regarding marketing strategy, there was an overall high level of 
agreement within the focus group. However, marketing pull was only raised by participants 
involved on the buying side. The reason for this behaviour could be that direct promotion to 
consumers is an illegal practice5. On the other hand, physicians (costumers)’ orientation was 
only raised by the participants involved on the seller side. This can be explained by the fact 
                                                 
5
 It has to be noted, as previously mentioned, that in Switzerland direct-to-consumer (DTC) promotion is an 
illegal promotion practice (Kocher and Oggier, 2007). However, patients (consumers) can be influenced by 
employing TV, radio and the internet as indirect promotional channels. 
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that these participants deal with different physicians (costumers) on a daily basis and 
therefore have a broader market knowledge. When the participants were prompted to any 
negative aspects regarding their statements on pharmaceutical marketing, no comments were 
proffered. Furthermore, despite the confirmation of non-state-regulated, market-related, 
scientific and general marketing, as well as pharmaceutical marketing literature, some new 
aspects were mentioned, specifically that it is important to be first into a hospital as 
physicians (costumers) seldom change prescriptions. Furthermore, the physicians 
(costumers)’ prescription might also be influenced by patients (consumers) who ask for a 
specific medical drug they have heard of or read about from an alternative source. 
General marketing literature (see Brassington and Pettitt, 2005), as well as pharmaceutical 
marketing literature (Jaakkola and Renko, 2007), describes that decision-makers play a central 
role when it comes to purchasing decisions. This statement was confirmed by participant SA, 
who specified that in pharmaceutical marketing, “physicians (costumers) are the decision-
makers, when purchasing prescription drugs” (transcription line 103-104).  
The classically applied strategy within pharmaceutical marketing, as pointed out by 
participant SA, is the marketing push, which is discussed in the general marketing literature 
(Oliver and Farris, 1989). According to participant SA, this “classical sales approach includes 
the following steps: influencing the physician (costumer) by showing the benefit and making 
sure that the drug is being distributed at the pharmacy” (transcription line 104-106). As a 
result, pharmaceutical companies have to ensure their access to physicians (costumers). This 
was summarised by participant SA, who pointed out that “prescription drugs can only be 
prescribed by a doctor. Therefore, personal acquaintanceship with a physician (costumer) is a 
major criterion for success” (transcription line 26-27). Thus, as a non-state-regulated, market-
related pharmaceutical marketing study has shown, the marketing strategic consequence is 
that “product information and sales strategy have to go via the doctor” (participant BE, 
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transcription line 48). Access to a physician (costumer) in order to derive marketing 
communication is viewed as a major challenge in pharmaceutical marketing practice 
(Physicians Weekly, 2010). In order to overcome this hurdle, a practical approach was 
proposed by the entire focus group whereby pharmaceutical companies should “organise 
events covering a non-pharmaceutical topic once per year. This enables them to reach doctors 
(costumers) who normally would not take part” (transcription line 50-52).  
In contrast, the non-state-regulated, market-related pharmaceutical marketing scientific 
literature has shown that there is an apparent trend of more informed patients (consumers) 
within the field (Findlay, 2002; National Consumers League, 2006; Shaw, 2008). These 
findings were also confirmed by the entire focus group, which stated “patients (consumers) 
are increasingly gathering the relevant information and asking doctors (costumers) for a 
specific medication” (transcription line 54-55). Furthermore, it was stated by the entire focus 
group that “customers do ask in the pharmacy for additional information about a product they 
have already heard about” (transcription line 55-56). Consequently, it can be concluded that 
both physicians (costumers) and pharmacists are faced with this trend. Therefore, it was 
pointed out by the entire focus group that the marketing strategy of “information pulling” is 
also applied in Swiss pharmaceutical marketing (transcription line 53). In general marketing, 
this marketing strategy has been described by Oliver and Farris (1989). The practical 
implication of this strategy in pharmaceutical marketing is, as stated by participant BB, “the 
patient (consumer) asks the doctor for a prescription of a drug that has been recommended by 
the pharmacists” (transcription line 10-11). In general marketing it is evident that different 
information channels influence the consumer (see Brassington and Pettitt, 2005). For 
pharmaceutical marketing, the Internet was mentioned, besides the physician (costumer), as 
another information channel by participant BE: “Consumers often go to the pharmacy and ask 
for a drug they have encountered on the Internet” (transcription line 24).  
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The decision as to whether to apply a marketing push or pull strategy is influenced by the 
medical drug class, as shown by the general marketing literature (see also Dogramatzis, 
2002). This conclusion is supported by participant BE’s statement that “life style drugs are 
better advertised via patients (consumers) who ask the doctor for the preparation” 
(transcription line 48-49). In order to confirm this statement, it was pointed out by the entire 
focus group that “the market introduction on Viagra would have been very difficult without 
laymen’s involvement and an enormous marketing effort” (transcription line 154-155). 
Non-state-regulated, market-related scientific literature clearly establishes that opinion leaders 
play a central role in pharmaceutical marketing (Lilien et al., 1981). The relevance of opinion 
leaders in Swiss prescription pharmaceutical marketing was confirmed by participant SA, 
who stated that “opinion leaders are the main target group” (transcription line 29-30). 
Consequently, as added by participant SC, “information on opinion leaders” (transcription 
line 39-41) is essential. In order to employ an opinion leader marketing communication 
strategy, it is necessary for pharmaceutical companies to gain sufficient market knowledge in 
the first instance. It was pointed out by participant BB that this could involve, for example, 
gaining knowledge about “a regional relation network that endorses the medication” 
(transcription line 32), which will provide positive word-of-mouth communication. This 
element has not been covered by scientific research, although the importance of word-of-
mouth communication in general marketing that is applicable in pharmaceutical marketing 
has been discussed in the non-state-regulated, market-related scientific literature (Stern and 
Gould, 1988; Pruden and Vavra, 2004). In the second step, potential individuals have to be 
identified, approached and convinced. In order to provide a practical example of an opinion 
leader, the entire focus group proposed that “an opinion leader can be a head doctor or a 
specialist in a regional hospital providing regular seminars” (transcription line 255), and the 
opinion leader is usually “a person that has shown exceptional vocational competence” and is 
already recognised as an opinion leader within the relation network (transcription line 257). In 
 103 
addition, participant BB recommended that “the relevant opinion leaders have to be 
convinced one or two years before a new product will be launched” (transcription line 42-43).  
Furthermore, the personal preference of the decision-maker is another aspect to be considered, 
as shown by a non-state-regulated, market-related study (Zhang et al., 2007). Regarding this 
point, participant SA stated that the “doctor’s specialisation is of relevance” (transcription line 
63). It was further pointed out by participant SC that it should kept in mind that “physicians 
(costumers) do have preferences” (transcription line 15) regarding their prescription choice.  
The physician (costumer)’s preference is guided by several criteria. The scientific 
pharmaceutical marketing literature has shown that there are two groups of physicians 
(costumers): scientifically- and economically-oriented physicians (see also Avorn et al., 1982; 
Azoulay, 2002). Participant SA pointed out that “scientifically-oriented physicians 
(costumers) decide on the basis of the medical scientific documentation, clinical study results 
and independent studies” (transcription line 5-6). On the other hand, “economically-orientated 
doctors (costumers) decide on the basis of a price to performance ratio, the best customer 
service and best margins” (participant SA, transcription line 42-43). In summary, sales 
success “depends on the product’s features, the application area and target group orientation” 
(participant SC, transcription line 110). This statement is also supported by the literature (see 
also Cooper and Kleinschmidt, 1993; Kotler, 2006 and 1998; Sharp et al., 2001). 
Furthermore, it was emphasised by participant SC that “marketing performed after the market 
introduction phase has to be extremely target group-orientated” (transcription line 112-113). 
The entire focus group highlighted the negative example of Serotonin inhibitors as a failed 
market introduction: “Serotonin inhibitors were unsuccessfully introduced because of poor 
marketing performance. Consequently, their potential has not been recognised” (transcription 
line 155-157). 
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In order to summarise the discussion, the group members derived a specific strategic 
marketing recommendation. Taking the personal prescription preference into consideration, it 
was agreed that, as shown by non-state-regulated, market-related pharmaceutical marketing 
studies, “a prescription habit seldom changes” (transcription line 153) (see also Jaakkola and 
Renko, 2007; Zhang et al., 2007). It was also pointed out that “general practitioners 
(costumers) usually have little reason to change their patients (consumers)’ hospital 
prescriptions” (transcription line 35-36). Consequently, as participant BB stated, it is 
important for the pharmaceutical company “to be in a hospital first” (transcription line 34-35). 
Participant BD therefore concluded that it is important that a “medication has been introduced 
first”, because “good previous experience will cause hesitation in changing the drug” 
(transcription line 17-18). As a result, it is relevant for the pharmaceutical company that the 
“substance has been presented at a scientific congress previous to market introduction” 
(participant BD, transcription line 115-116). In summary, participant SC emphasised that the 
“marketing strategy and especially pre-launch activities have to be set-up accordingly” 
(transcription line 110-111). This strategic marketing recommendation provided by the entire 
focus group is based on the order-of-market entry effect and is strongly supported by non-
state-regulated, market-related scientific research conducted on order-of-market entry in the 
pharmaceutical marketing field (see also Castro and Chrisman, 1995; Rodriquez-Pinto et al., 
2008). Consequently, there is a need for further research on order-of-market entry that takes 
place in the specific environment of a state-regulated prescription pharmaceutical market. 
 
3.3.3.2. Product  
In summary, it was stated that the prescribing decision is made on the basis of the physician 
(costumer)’s personal experience, which is guided by his or her judgment on the product’s 
features and confidence in the product. The factor ‘product features’ can be defined as a set of 
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attributes containing indications, effectiveness, safety, side-effect profiles, compliance, drug 
delivery, product description and packaging. Factor confidence in the product can be defined 
as a set of attributes containing brand, company size, place of origin (production) and the 
number of prescriptions. There is an ongoing trend away from branded products and towards 
generics. The following criteria were stated by the group members, as shown in Table 3-2. 
Seller Buyer Group Literature
Habit Formation (1,+) Habit Formation (1,+) Jaakkola and Renko, 2007
Product Properties
Application Area (1,+) Dogramatzis, 2002
Effectiveness (1,+) Effectiveness (2,+) Smith, 1990
Safety (2,+) Dogramatzis, 2002
Side Effects (2,+) Side Effects (1,+) Dogramatzis, 2002
Compliance (1,+) Compliance (1,+) Dogramatzis, 2002
Drug Delivery (1,+) Dogramatzis, 2002
Medical Documentation (1,+) Dogramatzis, 2002
Product Presentation (1,+) Dogramatzis, 2002
Confidence
Confidence (1,+) Confidence (3,+) Flechter, 1989
Brand (2,+/-) Brand (1,+) Flechter, 1989
Company Size (1,+) Company Size (1,+) Flechter, 1989
Place of Production (1,+) Maheswaran, 1994
The number within the brackets indicate the number of participant quoting this statement
The plus or minus symbol indicates if a positive or negative statement was given
 
Table 3-2: Product design-related marketing factors 
 
It should be added that, regarding marketing strategy, there was an overall high level of 
agreement within the group. When participants were prompted to mention any negative 
aspects regarding their statements on pharmaceutical marketing, no comments were given. 
Despite confirmation in the non-state-regulated, market-related, scientific and general 
marketing literature, as well as the pharmaceutical marketing literature, some new aspects 
were cited, especially that the effectiveness of a medical drug is normally exaggerated by the 
pharmaceutical company. Furthermore, one interesting statement is that, according to the 
focus group, there seems not to be a big difference between the effectiveness of different 
prescription pharmaceutical brands (products, medical drugs) within the same medical drug 
class. In other words, prescribers (costumers) do not recognise a difference between brands 
within the same medical class. For example, this would mean that there is no difference 
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recognised between Panadol Children, Panadol 500mg, Max Strength, Night-time, etc., 
containing Paracetamol (pain killer). This statement is in contrast to the literature (Smith, 
1983; Flechter, 1989; Dogramatzis, 2002).  
In general marketing, consumer behaviour research has shown that a purchase decision is 
made on the basis of previous product experience, leading to habit formation and resulting in 
personal preference. This process can be described as a learning process that influences the 
likelihood that the same choice will be made the next time (Zhang et al., 2007). The process 
of consumer habit formation is present in pharmaceutical marketing as well (Jaakkola and 
Renko, 2007). This statement was confirmed by participant BB, who pointed out that “the 
physician (costumer)’s prescription decision is made on the basis of his or her personal 
experience” (transcription line 11-12 and 129). This view was also supported by the entire 
focus group: “the sum of the experience you have of a firm also gives a certain impression 
about the product” (transcription line 159).  
Previous non-state-regulated, market-related pharmaceutical marketing research has indicated 
that a product’s features represent a major decisive factor when it comes to product choice 
(Cooper and Kleinschmidt, 1993; Sharp et al., 2001). It was shown by Cooper and 
Kleinschmidt (1993) that product features can be defined as a set of different attributes. One 
relevant decisive attribute is “product indication (application area)” (participant SA, 
transcription line 125-126) as indicated by the general marketing literature. It has to be noted 
that a medical drug will not be chosen if it is not applicable to a specific need (Dogramatzis, 
2002). However, some medical drugs are more suitable for a specific problem than others. 
Another important attribute of product features is “product effectiveness” (participant BB, 
transcription line 129). This statement was supported by the group discussion, which 
concluded that “medication has to show good effectiveness at first and will then be prescribed 
afterwards” (transcription line 152-153). The relevance of effectiveness as an attribute for 
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product features has been shown by the general marketing literature (Dogramatzis, 2002; 
Smith, 1990). Nevertheless, the entire focus group critically stated that “the difference” 
between the medical drug and its effectiveness “is usually exaggerated by competitors” 
(transcription line 148). Furthermore, “safety” was viewed by two participants (SA, SC; 
transcription line 125-126, 131) as being essential. The “side-effect profile” for the 
prescribing decision was stated by three participants (SA, SC, BB, transcription line 125-126, 
131, and 129) as being relevant. The importance of safety and the side-effect profile as 
attributes for product features has been shown by the general marketing literature 
(Dogramatzis, 2002; Smith, 1990). In addition, according to the comments of two 
participants, “compliance” (SA, BE, transcription line 137-138, and 134) as well as “drug 
delivery” (transcription line 132-133) are relevant to the prescribing decision as shown by the 
general marketing literature (Dogramatzis, 2002). Furthermore, it was highlighted that “good 
medical documentation” (participant BD, transcription line 129-130), meaning the product 
description, and “good product presentation” (participant SC, transcription line 41), meaning 
packaging, are important, as shown by the general marketing literature (Dogramatzis, 2002).  
Another decisive factor in product choice is confidence in the producer and product. This has 
also been shown by non-state-regulated, market-related scientific pharmaceutical marketing 
research (Flechter, 1989). One relevant attribute of product confidence is brand. The majority 
of the participants (two sellers, one buyer) agreed that branding plays a central role for the 
prescriber (costumer). It was stated that if there are “two similar products, the branded 
product will be chosen” (transcription line 141). In addition, “I would definitely choose a 
product from a well-known firm” (transcription line 142). This is also supported by the 
general marketing literature (Dogramatzis, 2002; Flechter, 1989).  
On the other hand, there is an apparent trend towards a switch to generic products 
(transcription line 176), as stated by participant SA: “pharmacists often give a generic 
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substitute” (transcription line 3). Despite consumers showing more confidence in branded 
products (see also Smith, 1983; Flechter, 1989; Dogramatzis, 2002), price sensitivity has 
increased and has forced consumers (payers) to take into consideration non-branded products 
(generics) that are usually cheaper and normally contain the same substance. This has also 
been shown by non-state-regulated, market-related scientific pharmaceutical marketing 
research (Kremer et al., 2008). Company size is another decisive attribute regarding product 
confidence, as stated by two participants: “In the case of an unknown producer, the larger one 
will be chosen” (participant SA, transcription line 138) and “in the case of problems, the 
larger company will more likely be able to pay” (participant BB, transcription line 139-140). 
As pointed out by participant SA, “the producer’s reputation is a relevant issue – large 
companies have an advantage over small companies” (transcription line 126-127). In addition, 
participant BB stated “I choose the company I [physician (costumer)] and the patients 
(consumers) have more confidence in” (transcription line 139). This is also supported by non-
state-regulated, market-related scientific pharmaceutical marketing research conducted by 
(Flechter, 1989). In addition, according to the participant BE, “a frequent query is whether the 
drug has been produced in Switzerland” (transcription line 146). The relevance of the country 
of origin for the consumer’s purchase decision is shown by non-state-regulated, market-
related scientific research (Maheswaran, 1994; Martin and Eroglu, 1993; Ettenson et al., 
1988; Han and Terpstra, 1988; Morganosky and Lazarde, 1987). Furthermore, “it is a 
disadvantage when a drug is seldom prescribed” (participant BD, transcription line 19).  
The focus group highlighted the relevance of a physician (costumer)’s confidence in a 
medical drug when it comes to the prescription decision. Furthermore, factors influencing 
quality perceptions such as safety, especially the side-effect profile, are of relevance. In 
addition, packaging plays a role, as stated by the participants. However, in order to be able to 
justify the statements above, further research is required. 
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3.3.3.3. Promotion 
It was concluded that two fundamental promotional approaches are apparent: the marketing 
push, applying direct-to-physician (costumer) (DTP) promotional measures, and the 
marketing pull, applying direct-to-consumer (DTC) promotional measures. The most relevant 
promotional instruments are advertising and personal selling. 
The most essential communication channels are discussed in the general marketing 
pharmaceutical literature (Dogramatzis, 2002). Kremer et al. (2008, p239) classified three of 
the most relevant promotion channels in pharmaceutical marketing: advertising, personal 
selling and others [including physician (costumer) meetings and events, direct mailing and 
sampling]. It was stated earlier by the focus group that two types of promotion strategies are 
present, namely the push strategy, aiming to target prescribers (costumers) in order to increase 
their product awareness and predilection, applying direct-to-prescriber (costumer) promotion 
(DTP), and the pull strategy, targeting the consumer (patients) audience (DTC) directly by 
employing a set of promotional activities (see also Dogramatzis, 2002). 
Personal selling ensures direct personal contact between company representatives and 
physicians (costumers). In general, physicians (costumers) appreciate the sales representatives 
as information suppliers, but view them as being biased. However, the willingness to 
welcome a salesperson depends on the doctor’s specialisation and the size and image of the 
pharmaceutical company. Personal sales contact with physicians (costumers) is important in 
order to maintain a long-term relationship, which, according to Hill (1999), is essential for 
sales success. Consequently, the personal attributes of a salesperson are relevant. 
Furthermore, the frequency and length of sales visits is important as well. The following 
criteria were stated by the group members, as shown in Table 3-3. 
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Seller Buyer Group Literature
Physicians' Acceptance (1,+) Physicians' Acceptance (4, +) Physicians' Acceptance (4,+) Andaleeb et al. 1996
Physician Access (1,+) Physician Access (1,+) Kremer et al. 2008
SR Information Provider (2,+)SR Information Provider (1,+) Andaleeb et al. 1996
SR Personality (4,+) SR Personality (1,+) SR Personality (2,+) Gillis et al. 1998
SR Reliability (6, +) SR Reliability (1, +) Gillis et al. 1998
SR Relevance (1, +) SR Relevance (1, +) Mizik et al. 2004
The number within the brackets indicate the number of participant quoting this statement
The plus or minus symbol indicates if a positive or negative statement was given
 
Table 3-3: Personal sales-related marketing factors 
 
It has to be noted that, in general, there was quite high agreement within the focus group. 
However, the acceptance of sales visits and the reliability of sales representatives were 
discussed by the buyer side participants. It can be concluded that there is a critical attitude 
present when dealing with sales representatives. In other words, in general, physicians 
(costumers) do not fully trust the information that is given to them by a pharmaceutical 
salesperson. On the other hand, the salesperson’s personality was mainly mentioned by the 
seller side participants. The conclusion could be made that personal influence regarding the 
sales success of the salesperson is overestimated. Despite confirmation in the non-state-
regulated, market-related scientific, general marketing and pharmaceutical marketing 
literature, some new aspects, not yet covered by scientific research, were mentioned. The 
relevance of personal sales representatives was questioned. The statements indicate that some 
doctors (costumers) welcome sales representatives and appreciate printing material. 
Therefore, the assumption might be that the effectiveness of personal sales is dependent on 
the medical drug class. Consequently, the relative importance of salespeople versus others 
marketing activities is of interest. 
According to Fill (2002, p70), in general marketing ‘personal selling is defined as an 
interpersonal communication tool which involves face to face activities undertaken by 
individuals, often representing an organisation, in order to inform, persuade or remind an 
individual or group to take appropriate action, as required by the sponsor’s representative’. 
This definition was supported by participant SA, who stated that “the salesperson has an 
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influence on the doctor ... as an information supplier” (transcription line 193-194). However, 
this is not covered by research. In addition, the relevance of personal selling in 
pharmaceutical marketing has also been examined by Mizik and Jacobson (2004, p1704), who 
found evidence that ‘personal selling has positive and statistically significant effects on the 
number of new prescriptions issued by a physician (costumer)’. 
Non-state-regulated, market-related research conducted by Kremer et al. (2008, p244) 
revealed that the ‘effects of the promotional instruments vary considerably across disease 
categories’. This can be underlined by the entire focus group, which agreed that “certain 
groups of specialised doctors (costumers) are more likely to welcome sales representatives 
than others” (transcription line 90-91). Furthermore, it was added by participant SA that 
“many physicians (costumers) do not accept any sales visits, especially from small firms” 
(transcription line 27-28). There was agreement with this statement within the entire focus 
group: “Some doctors (costumers) do not welcome sales reps at all” (transcription line 94). 
This phenomenon has not been investigated so far. On the other hand, some “doctors 
(costumers) advise their medical practice assistant only to welcome representatives from 
certain companies or areas of interest” (entire focus group, transcription line 95-96). In 
contrast, this is not applicable to everybody, as participant BB stated: “I do not have any 
preferences when arranging sales appointments. This gives me the chance to get acquainted 
with a new medicine. There are also chances for meetings at a congress. It works by 
coincidence” (transcription line 72-74). It was added by participant SA that, in order to make 
an appointment with certain doctors (costumers), it is “relevant to meet them primarily at a 
congress” (transcription line 28-29). For participant BD, personal contacts with sales 
executives are essential in the case of similar products (transcription line 20-21).  
In general, physicians (costumers) appreciate personal sales visits. As revealed by the study of 
Andaleeb and Tallman (1996, p79), ‘physicians (costumers) had friendly relations with sales 
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representatives and did not distrust them, but they did not view sales people as a vital part of 
their practice’. Therefore, participant BD stated that “the salesperson is in general quite well 
informed, also gives information about possible side-effects, but is a little bit biased. If you 
listen to them on a regular basis, it is an easy way to gain further education” (transcription line 
81-84). This statement was supported by participant BE, who stated that “the sales reps only 
give me some inspiration, but I will seek additional information in cases of interesting 
information” (transcription line 211-212), and by participant BE, who added “the 
conversation might give me some initial information. If necessary, I might seek more 
substantial information” (transcription line 86-88).  
Miller and Heinmans (1991) highlighted that personal selling is a crucial element in ensuring 
customers’ post-purchase satisfaction and in building profitable, long-term buyer seller 
relationships built on trust and understanding. This was underlined by the entire focus group, 
which emphasised “it should always be the same salesperson you are in charge with” 
(transcription line 228-229). In addition, participant SC stated that “as more products for a 
certain treatment are on the market, the sympathy for and/or antipathy of a sales rep become 
even more important” (transcription line 202-203). This is supported by Hills’ (1999) non-
state-regulated, market-related research, in which it was suggested that the major determinant 
of the drug chosen by the physician (costumer) is the relationship between the salesperson and 
physician (costumer). In contrast, participant SA pointed out that “if the salesperson … is 
being tripped up all the time, the physician (costumer) will be influenced, but negatively” 
(transcription line 194-196). 
The interaction between salesperson and prescriber (costumer) was also examined by non-
state-regulated, market-related scientific pharmaceutical marketing research conducted by 
Andaleeb and Tallman (1996, p79), who found that ‘physicians (costumers) viewed the field 
salesforce as a relevant source of information, but felt that they could also get the necessary 
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information from other sources’. This finding is supported by participant BD, who stated 
“almost every piece of information provided by sales reps is biased. A sales visit is only 
useful for me when some helpful information is given. I do not look at the accompanying 
documents” (transcription line 208-210). This view was supported by the focus group 
discussion: “It is very difficult to access objective information. Therefore, pharmaceutical 
representatives still remain an acceptable information source. Information from the relevant 
specialised literature is usually too critical and deters from trying new medical approaches” 
(transcription line 97-100). This statement is supported by Gillis et al.’s (1998, p105) non-
state-regulated, market-related research, in that ‘general practitioners (costumers) perceived 
salespeople to be preoccupied with their own professional needs’. Furthermore, for participant 
BD, the pharmaceutical representative cannot provide him with any “new vocational, subject-
orientated information” (transcription line 204-205).  
Looking at the individual salesperson in more detail, it is generally considered that certain 
specific personal attributes are important (see also Gillis et al., 1998). Participant BB gave a 
set of criteria: “I do expect reliable information and a convincing personal appearance” 
(transcription line 197). For participant SC, “frequent sales visits” are important (participant 
SC, transcription line 39-41). These statements are supported by Gonul et al.’s (2001, p89) 
non-state-regulated, market-related research, in that ‘the scope of personal selling should be 
carefully scheduled in terms of frequency and length of visits in order to optimize the 
company’s effectiveness of direct promotion efforts and expenses’.  
A pharmaceutical company has to ensure that promotional activities cover all areas used by 
the physician (costumer) when gathering product information, but it also has to deal with 
critical concerns raised by the physicians (costumers) regarding the reliability of the 
information provided. The most important channels are the internet, Compendium6, 
information materials provided by the company, expert opinions and colleagues. On the other 
                                                 
6
 Compendium is a Swiss medical drug data base (www.compendium.ch). 
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hand, alternative channels, providing unbiased information such as sales figures, are also 
consulted. Furthermore, the company has to ensure that information channels used by patients 
(consumers) are covered by their promotional activities as well. The most relevant channels 
are the internet and layman’s press. However, the practice of direct-to-consumer (DTC) 
marketing is illegal in Switzerland. The following criteria were stated by the group members, 
as shown in Table 3-4. 
Seller Buyer Group Literature
Internet (2, +) Internet (1, +) Goetzinger et al. 2007
Medical Documentation (6,+)
Independent Information (3, +)
Laymen Press (1, +) Laymen Press (1, +)
Over Promotion (1, -) Manachanda et al. 2004
The number within the brackets indicate the number of participant quoting this statement
The plus or minus symbol indicates if a positive or negative statement was given
 
Table 3-4: Advertising-related marketing factors 
 
The issues of medical documentation and independent information were mainly raised by the 
buyer side participants, which demonstrates the importance of these aspects for prescribers 
(costumers). 
The most relevant direct-to-prescriber (costumer) promotional channels (DTP) were discussed 
by the focus group. It was pointed out by participant SA that he usually searches for 
information about a competitor’s product on the internet (transcription line 215). This 
statement is supported by Goetzinger et al.’s (2007, p128) non-state-regulated, market-related 
research, which concluded that ‘the search for online health-related information has become 
increasingly popular’. Participant BE added that he uses “Compendium and the company’s 
information” as a source (transcription line 226). In addition, participant BB stated that he 
reads “the critical pharmaceutical information from Etzel Gisling7 and also asks colleagues at 
congresses” (transcription line 219-221). The significant relevance of word-of-mouth was 
shown by Lilien et al. (1981). For participant BB, the most relevant information sources are 
                                                 
7
 Etzel Gisling is a Swiss specialist in internal medicine, clinical pharmacology and toxicology based in Wil, 
Switzerland, regularly writing critical articles covering pharmaceutical issues. 
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“printing materials and presentations at scientific congresses” (transcription line 108-109); 
furthermore, “scientific medical documentation is relevant” (participant BD, transcription line 
18-19) because it shows the company’s standards (participant BE, transcription line 121-122). 
It can therefore be summarised that “convincing documentation is essential” (participant BB, 
transcription line 32). In addition, for participant BD, “a good slogan mentioning the key 
therapeutic problem is also essential” (transcription line 115). 
Furthermore, it was emphasised by participant BD that “layman’s press”, as a direct-to-
consumer (DTC) promotional channel, “should be applied” as well. Nevertheless, “despite the 
circumstance that direct-to-customer advertising is illegal in Switzerland, this is becoming 
more and more popular” (transcription line 56-57) (Kocher and Oggier, 2007). As such, 
ethical concerns regarding the influence of advertising on the prescription behaviour of 
prescribers (costumers) in the Swiss market were raised by Strebel and Michaud (2009). 
Concerns regarding the reliability of informational content provided by the producers were 
also raised (transcription line 218-219). These concerns were also made by Roth et al. (2004). 
Alternative information sources have also been mentioned (see also Solomon et al., 2010). 
According to participant SC, interesting product and company information can also be found 
on online stock-trading platforms (transcription line 222). In addition, for participant BD, 
“sales (revenue) figures for a substance are very important indicators as well” (transcription 
line 223) and “a rise in share prices is usually related to the product. This is official, unbiased 
information” (transcription line 223-224). These purchase decision criteria have not been 
covered by research. In summary, as agreed by the group, “a good salesperson is competent in 
vocational matters, knows the medicine’s documentation, has a good appearance and 
demonstrates appropriate communication skills” (transcription line 232-233). 
However, it should be kept in mind, as stated by participant BD, that “there can also be too 
much promotion” (transcription line 46). This statement is confirmed by Manchanda and 
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Chintagunta’s (2004, p143) non-state-regulated, market-related research. They revealed that 
‘too much personal selling can dissuade a physician (costumer) from prescribing a drug’. 
Consequently, it should also be taken into account that there can be too much promotion. 
Therefore, a good promotional balance has to be achieved in order to avoid over- or under-
promotion. As a result, there is a need for further research into the role and relevance of 
promotion measures regarding sales that take place in the specific context of a state-regulated 
prescription pharmaceutical market which restricts promotional activities (an overview of 
promotional practice rules can be viewed at www.sgci.ch.; Refer to Pharmakodex-Praxis). 
 
3.3.3.4. Price 
It was concluded that the buyer’s financial incentive is the key criteria for a successful price 
policy. This is supported by Muehlemanns’ (2005) ethical concerns regarding the influence of 
pricing conditions on the prescription behaviour of self-dispensing prescribers (costumers) 
(see also Paragraph 1.1.3) in the Swiss market. It was stated that a recently implemented 
governmental regulation introduced incentive schemes for buyers and led to a rise in price 
sensitivity. However, this statement is not supported by Swiss-related scientific research. As a 
result, patients (consumers) are increasingly asking their physicians (costumers) and/or 
pharmacists for the most economical version of a prescribed drug, normally a generic version. 
There was a high level of agreement within the group. In total, five statements were given by 
the selling side and seven by the buying side. The focus group statements confirmed non-
state-regulated, market-related scientific, general marketing and as pharmaceutical marketing 
literature, as discussed below. 
The implementation of a new governmental regulation has led to an increase in the payer’s 
financial incentive when purchasing a medical drug, and therefore to an increase in price 
sensitivity. As a result, there is an increasing demand for generic products as a substitute for 
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the original (branded) medical drug. Regarding pricing, two main drivers come into play: the 
number of competitors and the perceived product value.  
It was shown by Sutherland et al.’s (2008) non-state-regulated, market-related research that 
financial profit is one of the key drivers when doing business. Consequently, it can be 
concluded, as corroborated by participant SA, that “financial incentives” (transcription line 
104) increase personal benefit and are therefore an important motivator for sellers and buyers. 
This conclusion is supported by Marteau et al.’s (2009, p983) non-state-regulated, market-
related scientific research, in that ‘personal financial incentives are increasingly being used to 
motivate patients (consumers) and general populations to change their behaviour’. 
Consequently, the “pricing conditions of a purchase are relevant” (participant BB, 
transcription line 13-14). This statement is supported by participant BB, who stated that 
“price plays an important role for me” (transcription line 178).  
Regarding patients (consumers)’ price sensitivity (see also general marketing literature: 
Brassington and Pettitt, 2007), it was pointed out by participant SA that “until recently, the 
price did not have any relevance. However, since the government implemented a new 
regulation in 2006, whereby 20% of the price of the original (branded) and 10% for the 
generic medical drug has to be paid directly by the patient (consumer), the price is more 
relevant” (transcription line 168-170). As a result, this new regulation (Art. 38a KLV, see also 
www.bag.admin.ch) has resulted in an increase in users (consumer)’ financial incentives and 
therefore price elasticity. Consequently, “the patient (consumer)’s price sensitivity has 
increased” (transcription line 173), as stated by participant BD. This leads to the situation 
where “the patient (consumer) considers the price when he has to pay out of his own pocket” 
(participant BE, transcription line 185-186). As a result, “physicians (costumers) are also 
confronted more frequently with this issue” (participant BD, transcription line 173-174). This 
was confirmed by participant BD, who pointed out that he would recommend a generic 
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product to his patients (consumers) because of the lower price (transcription line 143). It has 
to be noted that generic drugs are copies of brand name drugs that have exactly the same 
medical substance, dosage, intended use, effects, side-effects, route of administration, risks, 
safety, and strength as the original drug (www.fda.org). Consequently, it can be said that the 
quality is similar between the original (branded) and generic medical drug containing the 
same substance. Furthermore, participant BE mentioned that “patients (consumers) … are 
increasingly asking for generic drugs when purchasing medication” (transcription line 186-
187). This statement is supported by sales (revenue) figures, indicating a higher increase in 
generic drug use versus the original preparation (Swissinfo, 2007). Furthermore, the price 
level is influenced by competition, as stated by participant BE: “A medical drug without a 
generic substitute still has a high price” (transcription line 184-185). This is supported by 
Lambkins’ (1993) non-state-regulated, market-related finding that pricing is influenced by 
two aspects. The first is the number of competitors and the second is the product’s perceived 
value. This finding is also supported by non-state-regulated, market-related research 
conducted by Erickson and Johansson (1985), who concluded that, according to the general 
marketing literature, the customer may expect a price to reflect the quality of the product. 
Furthermore, Zeithaml (1988) specified that the customer weights up the promises given by 
the producer against the price. Consequently, it is likely that ‘consumers pay higher prices as 
a result of the advertising that occurs in the industry’ (Rizzo, 1999, p89). Regarding pricing, 
further research is also needed in order to clarify the role of pricing that takes place in a state-
regulated market, thus restricting companies’ pricing policies. 
 
3.3.4. Summary of the Focus Group Discussion  
The analysis of the focus group discussion has derived five fundamental motivational factors 
leading to prescribing decisions. The analysis has revealed that early market entry is relevant 
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in order to form a long-term prescription habit (see also Kardes and Kalyanaram, 1992). 
Furthermore, - habit formation can also be influenced by a company’s product policy (see 
also Cooper and Kleinschmidt, 1993). It was discussed that the prescriber (costumer)’s 
financial reward is important when prescribing a drug (see also Sutherland et al., 2008). In 
addition, the physician (costumer)’s product confidence is decisive. The prescriber 
(costumer)’s product confidence is influenced by the pharmaceutical company, along with 
product policy (see also Kardes and Kalyanaram, 1992) and product quality. Another 
important factor is the product knowledge level. Physicians (costumers) gain knowledge 
directly through a company’s promotional activities or indirectly through independent 
information sources (see Dogramatzis, 2002). As a result, the following process model can be 
presented (Figure 3-1). 
 
Prescription
Decision
(Sales)
Marketing Instrument Factors
Prescription Habit
Product Confidence
Financial Reward
Dependent Source
Independent Source
Prescribers’ 
Knowledge
Order of 
Market Entry
Product Policy 
(Features, e.q. Quality)
Pricing Policy
Direct to Prescriber 
Promotion (DTP)
 
Figure 3-1: Prescription decision process model 
 
In addition, a content analysis of the focus group transcript was performed (see also 
Krippendorff, 2003, Martin and Bateson, 2007). In a first step, as already described in the 
systematic literature review chapter, a hierarchical structured framework containing three 
groups – “marketing categories”, “variables” and “attributes” – was set up, and the five main 
marketing categories “strategy”, “product”, “price”, “place (distribution)” and “promotion” 
were defined, each containing the group of variables. The inherent characteristics of variables 
are described by attributes. In a second step, the keywords of each statement were then 
indicated and categorised according to the five marketing categories. However, no statements 
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relating to place (i.e. distribution) were found. In a third step, the previously indicated 
keywords were classified according to their categorical property as a variable or attribute. In 
total, the content analysis derived 11 relevant marketing variables and their 24 attributes (see 
Table 3-5). 
Marketing 
Categories 
Variables Attributes 
Product 
 
Properties 
Safety; Side-effects; 
Efficacy; Indication 
(Applicability); 
Innovativeness 
Few prescriptions as a signal of increased risk 
Packaging Drug delivery 
Price Price Level No attributes 
Promotion Personal Selling Number of visits; Experience; Acts as an 
information provider; Communication of USP’s; 
Competence; Contacts at congresses; Continuity 
of sales relation; Physician’s contact anxiety; 
Personality of salesperson; Style of selling; 
Sympathy to salesperson 
Advertising Informational content of documentation 
(Objectivity, Scientific, Style of brochures); 
Physician-oriented advertisement; Experience 
exchange with colleagues; Providing speciality 
literature; Health television programs; Further 
education; Providing of information (via 
Databases, Internet, Journals);Involvement of 
layman press; Clinical studies 
Word-of-Mouth (OL) Head doctors; Specialists and Professors 
[according to their local or regional relevance] 
Table 3-5: Marketing factors 
 
In the next chapter, a three-step Delphi group study is conducted. The Delphi study was set-
up based on the findings derived from the systematic literature review (Chapter 2) and the 
focus group study in the present chapter. The Delphi group study leads to a ranking of the 
most important variables in pharmaceutical marketing and enables the proposition of 
hypotheses, as well as a “physician-targeting” conceptual model. 
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4. The Relevance of Marketing Activities in the Swiss 
Prescription Drugs Market: A Qualitative Delphi Group 
Study  
 
4.1. Introduction  
This chapter presents the proposed conceptual model, including hypotheses, and additional 
findings derived from the perspective of Swiss healthcare practitioners (costumers). This 
chapter also provides advanced discussions on the findings derived in Chapters 2 and 3.  
As already explained, a two-stage empirical qualitative approach is employed for this 
purpose. The first stage is a focus group study (see Chapter 3) and the second stage, as 
presented in the present chapter, is a Delphi group study. Thus, this chapter begins with a 
discussion of the methodology used for a Delphi group study. Based on the findings from the 
focus group study (see Chapter 3), a Delphi group study is set up. In the second part of this 
chapter, the methodology employed for the Delphi group study is then described, following 
which the results are presented, summarised, a set of hypotheses is posited and a conceptual 
model is provided. 
 
4.2. Delphi Group Study 
4.2.1. Introduction 
The aim of the second qualitative study is to assess the previously derived results from the 
focus group study and to draw additional outcomes from the Swiss healthcare professionals’ 
experience. Therefore, an adapted three-step Delphi group survey was performed (Haeder and 
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Haeder, 2000; Linstone and Turoff, 1975). In the Delphi study set-up, the previously derived 
findings from the focus group were included. 
The concept of the Delphi group procedure was developed by the RAND Corporation during 
the 1950s as a forecasting methodology (Helmer, 1967). For Dalkey and Helmer (1963, 
p458), ‘the aim of this technique is to obtain the reliable consensus of opinions of experts 
with a series of questionnaires interspersed with controlled opinion feedback’. This statement 
is supported by Rowe and Wright (1999, p353), who emphasised that the ‘Delphi technique is 
intended for use in judgment and forecasting situations in which pure model-based statistical 
methods are not practical because of the lack of appropriate data’ (see also Wright et al., 
1996). However, its relevance is finally defined by the members involved. So far, the Delphi 
technique has been described and reviewed by several researchers (Haeder and Haeder, 2000; 
Hill and Fowles, 1975; Linstone and Turoff 1975; Lock, 1987; Parenté and Anderson, 1987; 
Stewart, 1987; Rowe et al., 1991). In order to reach a consensus within the Delphi group, an 
adapted three-step interactive questioning procedure was applied, involving senior healthcare 
marketing professionals, to gather their opinions and professional insights.  
 
4.2.2. Research Procedures and Settings 
In the first round, the Delphi group study aimed to identify issues and solicit ideas, in order to 
determine the most relevant marketing mix criteria and to assess and provide expanded 
knowledge of the process model derived from the focus group study. In a first step, general 
questions were developed by the monitor team8 to enable the conceptualisation of the Delphi 
group study, aiming to explore the dimensionality of pharmaceutical marketing and clarifying 
the influence of pharmaceutical marketing instruments on “physician-targeting” leading to an 
increase of sales (revenue). For this purpose a brainstorming session was employed to create 
                                                 
8
 Members of the monitor team were: Michael Stros, Aston University; Prof John Marriott, Aston University; 
Prof. Juerg Hari, Zurich University of Applied Sciences. 
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three open-ended, non-standardised general questions, ensuring that clear words were selected 
(Schmidt and Hollensen, 2006), covering order-of-market entry (Bond and Lean, 1977) and 
all four marketing mix instruments (Kotler, 2006). Furthermore, it was ensured that the results 
derived from the focus group were considered as well.  
These questions were piloted on a small sample of three marketing academic experts at the 
Zurich University of Applied Sciences in Winterthur, Switzerland. Based on the outcome of 
the pilot study, only a few minor changes were required. Consequently, the following three 
questions were developed: 
• Question [Q1]: What are the most important key factors leading  
to high product turnover?  
• Question [Q2]: What are the greatest challenges for you in the “product” area? 
• Question [Q3]: Why do many products struggle to reach their financial expectations? 
 
In a next step, a requirement profile for the participants was created. The study aimed to set 
up a Delphi group with only Swiss healthcare professionals involved in the buying or selling 
side of pharmaceutical marketing and in a relevant management position. Consequently, the 
following participant criteria were defined: (1) level of involvement in pharmaceutical 
marketing processes, (2) position of responsibility, (3) number of years’ experience and (4) 
educational background. 
A Delphi group study consists of a small sample size of participants (experts), usually 
between ten and twenty (see also Haeder and Haeder, 2000). A nomination process was 
performed by the monitor team. Potential candidates matching the previously defined 
participant criteria were directly contacted via telephone call (applying a judgement sampling 
strategy), during which they were provided with general information about the study’s aims, 
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the procedure and the assurance of anonymity, in order to gain their readiness for study 
participation. No financial compensation was offered. As a result, a well-balanced mix of 
eleven healthcare professionals from academic institutions and different pharmaceutical 
companies based in Switzerland could be nominated (see Table 4-1).  
(1) Level of 
involvement in 
pharmaceutical 
marketing processes 
High  
(directly involved) 
(8) 
Low 
(not directly involved) 
(3) 
Conclusion: Input from daily 
managerial practice can be expected 
(2) Position of 
responsibility 
Marketing Director 
(5) 
CEO 
(4) 
Professor 
(2) 
Conclusion: Because of the high 
level management positions, a broad 
professional insight will be provided 
(3) Number of years 
of experience 
< 20 years 
(5) 
> 20 years 
(6) 
Conclusion: The given statements 
will be based on long term marketing 
experience 
(4) Educational 
background 
Graduate 
(university) 
(5) 
Academic (PhD) 
(6) 
Conclusion: Due to the high 
educational profile, profound 
statements will be given 
Table 4-1: Profile of the participating Delphi group experts 
 
It should be noted that the difference between the focus group participants and the Delphi 
group participants is their expertise in the marketing of the latter group. The focus group was 
composed of a mix of experts with academic background, In order to gather an overall view, 
it was the intention to cover the major interest groups within the pharmaceutical market 
[company, prescriber (costumer and opinion leader), seller (pharmacists) and consultant]. On 
the other hand, the experts of the Delphi group were prescription pharmaceuticals marketers. 
Next, a cover letter was created and a questionnaire containing these three questions was 
devised (see Appendix 5), asking each participant to engage in individual brainstorming, so as 
to generate as many ideas as possible for dealing with the issue, in order to receive an 
unbiased and wide set of answers. The postal reply questionnaires were sent out to the experts 
concerned. The anonymous responses that arrived from ten out of eleven participants within a 
fortnight were collected and collated. The answers were then elaborated by the coordinator 
and analysed against those issues they saw as important. 
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In the second round of the Delphi group study, marketing variables derived from the 
systematic literature review and the focus group study were further investigated. 
Consequently, a slightly altered Delphi technique procedure, considered ideal according to the 
literature (see also Haeder and Haeder, 2000; Hill and Fowles, 1975; Linstone and Turoff 
1975; Lock, 1987; Parenté and Anderson, 1987; Stewart, 1987; Rowe et al., 1991), was 
applied. Criteria such as efficacy, safety and side-effects, tolerability, packaging, pharmacy, 
internet, wholesalers, hospitals, price level, reimbursement by insurance, results phase of III 
and IV clinical studies, publications in journals, word-of-mouth, advertisement, personal 
selling and sampling were employed. These variables were included in the structured round 
two questionnaire (see Figure 4-1). This questionnaire was then piloted on a small sample of 
three marketing academic experts at the Zurich University of Applied Sciences in Winterthur, 
Switzerland. Only a few minor alterations had to be made. The developed second 
questionnaire was mailed to the participants together with a summary of the answers derived 
from the first Delphi group round, a cover letter (see Appendix 6) and a reply postal envelope. 
The Delphi group members were asked to review the presented results and to rank the 
proposed marketing variables taken from the round one study with regard to their relevance to 
the sales process. To avoid a non-neutral specification, an eight-point Likert-type scale 
(Likert, 1993) with extremes from “strongly disagree” to “strongly agree” was applied.  
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Marketing Variables Strong Agree – Strong Disagree 
Categories   
Product   
 Efficacy □    □    □    □    □    □    □    □ 
 Safety and Side Effects □    □    □    □    □    □    □    □ 
 Tolerability □    □    □    □    □    □    □    □ 
 Packaging □    □    □    □    □    □    □    □ 
 Results Phase III Study □    □    □    □    □    □    □    □ 
 Results Phase IV Study □    □    □    □    □    □    □    □ 
 
  
Place (distribution)   
 Pharmacy □    □    □    □    □    □    □    □ 
 Internet □    □    □    □    □    □    □    □ 
 Wholesalers □    □    □    □    □    □    □    □ 
 Hospitals □    □    □    □    □    □    □    □ 
   
Price   
 Price Level □    □    □    □    □    □    □    □ 
 Reimbursement from Insurance □    □    □    □    □    □    □    □ 
 
  
Promotion   
 Publications in Journals □    □    □    □    □    □    □    □ 
 Word-of-Mouth □    □    □    □    □    □    □    □ 
 Advertisement □    □    □    □    □    □    □    □ 
 Personal Selling □    □    □    □    □    □    □    □ 
 Sampling □    □    □    □    □    □    □    □ 
   
 
 
Figure 4-1: Delphi group round two study questionnaire 
 
Participants anonymously recorded their responses and returned them to the coordinator 
within a fortnight. Ten out of eleven experts replied (91%). The answers were then elaborated 
and analysed by the coordinator. Responses to questions were grouped and categorised by 
frequency. This analysis tallied the votes for each of the responses, determined the standard 
deviation and mean value and finally summarised the responses for the next round. 
In the third round of the Delphi group study, the results from the second round were further 
investigated in order to reach a consensus within the Delphi group. Consequently, the results 
of the second distribution were summarised and evaluated. High standard deviation associated 
with certain answers from round two indicated a high level of disagreement within the group. 
The contradicting questions and answers sets were taken for further investigation. In order to 
develop the third round questionnaire, a cut-off sampling method was applied for the selection 
of the questions (Royall, 1970; Bailar et al., 1983). The selection criterion was set at the upper 
third part of the standard deviation’s normal distribution (65th percentile). Furthermore, in 
order to ensure reliability and validity, similar questions that were answered in a contradictory 
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manner were considered invalid and thus were discarded (Burton, 2000). Such opposing test 
statements were therefore scattered throughout the questionnaire. A random selection 
procedure was applied. This questionnaire was piloted on internal staff at the Zurich 
University of Applied Sciences in Winterthur, Switzerland. No changes were required. 
The questionnaire was sent to the group members for comment and to clarify any points 
which had been unsatisfactorily answered in the previous round. The Delphi group members 
were asked to indicate their agreement or disagreement with the statements given by using the 
provided boxes (see Figure 4-2). The participants of this survey were given a fortnight to 
respond to this third questionnaire (see Appendix 7). Nine out of the ten remaining 
participants replied (90%). The answers were then collected, analysed and summarised by the 
coordinator. 
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 Statement Agree Disagree 
1 One of the major decision criteria regarding prescription drugs is their 
price level  
  
2 The product distribution in the pharmacy does not have a major impact 
on their sales (revenue) figures 
  
3 Product advertising is a consumer need    
4 An actively performed product promotion by the wholesaler is not 
relevant for the product success 
  
5 The design of the packaging and its ease of use is important when 
buying the product 
  
6 The salesperson will sell better when incentives are given   
7 The personal interaction between the salesperson and the customer has 
an important effect on the sales success 
  
8 It is not essential whether or not the pharmaceutical product is included 
in the wholesaler’s product range 
  
9 Publications in well-respected journals are essential for the consumers’ 
confidence and therefore for the sales process 
  
10 The price level is an unimportant decision factor when choosing a 
prescription drug 
  
11 The functionality is the only requirement made to packaging   
12 Favorable publications in well-respected journals are generally not 
noticed by the consumer 
  
13 The consumer (end-user) will only marginally be influenced by a 
marketing campaign 
  
14 It is essential to ensure a broad product distribution in pharmacies, well 
displayed locations within the pharmacy and advice given by 
pharmacist 
  
Figure 4-2: Delphi group round three study questionnaire  
 
4.2.3. Round One Delphi Group Findings and Analysis 
In this section, the findings of the first round Delphi group study are presented and a content 
analysis is performed. The same methodology used for the evaluation of the focus group 
transcript is applied.  
In a first step, the collected answers (see Appendix 8) were coded regarding “pharmaceutical 
marketing strategy”, “product”, “price” and “promotion” (see also McCarthy and Perreault, 
1960). In the second step, the indicated text fragments were analysed for content regarding 
frequency, the statement given (content, agreement and person), transferred and sorted 
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regarding similar content in a meta-matrix (see Appendix 9). Finally, the statements of the 
focus group members and from the literature were compared, analysed and conclusions 
derived (Glitz, 1997). In order to ensure that no relevant information had been missed out, the 
analysis was repeated. It has to be noted that the collected answers are anonymous and cannot 
be assigned to a specific participant. 
 
4.2.3.1. Pharmaceutical Marketing Strategy 
In summary it can be concluded that it is important to know the market environment, in order 
to enable product differentiation against competitors and to gain knowledge about potentially 
accessible physicians (costumers) in order to set-up a targeting strategy, while questioning the 
efficacy of me-too preparations. However, producers might be challenged by upcoming new 
product categories and regulatory issues. Furthermore, it was highlighted that order-of-market 
entry plays a central role. For long-term sales success, the prescription habit is important. 
Consequently, it was stated that the first drug on the market with even lower efficacy can 
create more sales (revenue) than one that enters later. Despite confirmation in the non-state-
regulated, market-related scientific, general marketing and pharmaceutical marketing 
literature, some new aspects, not covered by scientific research, were mentioned. 
Interestingly, as the focus group had already stated, differences in the effectiveness of 
different drugs was questioned. 
Target orientation is a core success criterion in marketing, as highlighted in the general 
marketing literature (see also Brassington and Pettitt, 2007; Dogramatzis, 2002) and discussed 
by the focus group. It was also highlighted by the Delphi group that positioning plays an 
important role. This was underlined by one of the participants’ statement that “the products do 
not struggle, but they are wrongly positioned” (P9, line 123-124). Furthermore, it was 
emphasised that it is essential for sales success “to define a clear-cut positioning statement 
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and market segmentation amongst direct competitors” (P7, line 72-73). As a result, as 
mentioned by one participant, it is important to “know the competitors well” (P9, line 53). In 
addition, besides good positioning, a clear differentiation is relevant. Consequently, the 
product has to “be perceived as different and unique” (P7, line 71) and the “differentiation 
against competitors has to be based on really relevant parameters” (P5, line 66). It was stated 
by the focus group, and also concluded in the non-state-regulated, market-related scientific 
literature, that product differentiation is a key success factor (see also Cooper and 
Kleinschmidt, 1993; Kotler, 2006 and 1998; Sharp et al., 2001). Furthermore, according to 
Vakratsas and Kolsaricis (2008), the disadvantage of being late can be overcome with a 
differentiated product strategy. However, “most pharmaceutical drugs are ‘me-too’ 
preparations with no advantage over well known, accepted drugs” (P8, line 121) with a “lack 
of differentiation to competitors” (P4, line 101). This statement cannot be supported by the 
scientific literature. 
The efficacy of a me-too strategy was questioned by Schmalensees’ (1982) non-state-
regulated, market-related research. This is in line with the strategic marketing 
recommendation given by the focus group. Consequently, it was pointed out that it is 
important that the product has clear and unique selling propositions (USP’s) (P1, line 56).  
Furthermore, it was emphasised by a respondent that “the product, marketing and sales have 
to fit fully to the target market segment” (P1, line 4-5). This is supported by several non-state-
regulated, market-related researchers (Cooper and Kleinschmidt, 1993; Kotler, 2006 and 
1998; Sharp et al., 2001) and by the focus group. Consequently, it was agreed that a targeting 
strategy is essential in order to “know who the accessible potential physicians (costumers) 
are” (P4, line 24; P2, line 8). As a result, one answer summarised that awareness of “medical 
doctors (costumers), pharmacies and patients (consumers)” (P1, line 2) is important.  
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Therefore, the market environment has to be understood (political, economic, legal, etc. 
constraints) (P9, line 124-125) and continuously monitored. Prescription pharmaceutical drug 
producers face several challenging factors. On the one hand, “alternative medicine substitutes 
are increasingly competing with the classical pharmaceutical market (no prescription is 
required)” (P6, line 114-115, this statement cannot be supported by the scientific literature), 
while on the other hand, “legal regulations” have to be taken into account when marketing a 
pharmaceutical drug (P9, line 84-85), and “there is the appearance of new product categories” 
(P6, line 114) that has to be kept in focus. Consequently, pharmaceutical firms need 
“continuous management of current and future competitors” (P8, line 81-82).  
Early market entry plays a central role regarding a product’s success. It was shown by several 
non-state-regulated, market-related researchers (Jaakkola and Renko, 2007; Zhang et al., 
2007) and agreed by the focus group that prescription habits are a central reason behind a 
purchase decision. Therefore, habit formation is an important task in marketing. Furthermore, 
scientific non-state-regulated, market-related research has shown that order-of-market entry 
plays an important role regarding habit formation (see also Lean and Bond, 1977; Castro and 
Chrisman, 1995; Kardes and Kalyanaram, 1992; Rodgriuez-Pinot et al., 2008). These findings 
are supported by the Delphi group as well. One participant stated that “the first drug on the 
market, even with lower efficacy, can collect more sales (revenue) and is more present in the 
minds of the customers” (P3, line 15-17). Consequently, as emphasised by one Delphi group 
respondent, pharmaceutical companies have to “shorten the product development process 
from the idea-finding stage to the marketable product phase” (P7, line 73-74). This statement 
is supported by other participants, who concluded that pharmaceutical drugs are less 
successful because an underestimation of time parameters (P5, line 105) leads to a “late 
market entry” (P3, line 98), resulting in a “sub-optimal launch” and the inability “to regain 
momentum” (P7, line 117). As a result, it is essential, as highlighted by one Delphi group 
respondent, to “focus on the launched product” (P5, line 106) and to “know the customers’ 
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needs” (P9, line 52), as highlighted by non-state-regulated, market-related scientific 
pharmaceutical marketing research.  
As a result, it was stated by the respondents that, in order to ensure market success, a 
“strategic long-term clinical development plan, a strategic positioning and messaging plan 
building on a clinical plan, strong pre-launch activities in line with the strategy, a stable and 
dedicated marketing, sales, medical and regulatory teams, an efficient marketing mix and a 
good story that is easy to tell are required” (P5, line 28-30; P6, line 111-113; P7, line 44-49). 
Consequently, it can be concluded that strong pre-launch activities seem to have an impact on 
sales (revenue) increases during the launch phase. However, the question remains as to which 
marketing activities (marketing mix and its marketing instruments) should be applied. As a 
result, more research is required in order to investigate these activities in the context of a 
state-regulated market.  
 
4.2.3.2. Product 
In summary, regarding promotion policy, the applicability of a pharmaceutical drug for a 
specific need is the most important criterion. In order to gain a differentiated product against 
competitors, innovativeness is required. Furthermore, it was highlighted that product 
properties such as therapeutic efficacy, a low or tolerable side-effect profile, packaging and 
labelling are of relevance. Additionally, because a producer’s reputation is associated with 
confidence, product brand is of importance. Despite confirmation by the non-state-regulated, 
market-related scientific, general marketing and pharmaceutical marketing literature, the 
relevance of packaging, not covered by scientific research, was mentioned. 
It was discussed by the focus group, and is shown in the non-state-regulated, market-related 
scientific pharmaceutical marketing literature (see also Brassington and Pettitt, 2007; 
Dogramatzis, 2002), that applicability for a specific need is the most important criterion when 
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a product choice is made. This was also supported by the Delphi group, in that a 
pharmaceutical drug has to solve a biological problem. This is underlined by the answer of 
one Delphi group respondent, who stated that “if the drug reduces or heals the issue faster or 
more comfortably than a comparable drug, then preference is given to the first drug” (P3, line 
11-14). Therefore, it is relevant for a pharmaceutical company “to have the ‘right’ drug at the 
right time” (P4, 61-62), in order to “cover the needs of and to provide clear advantages for 
patients (consumers) and doctors (costumers)” (P6, line 68; P9, line 52) by “developing a 
highly innovative and differentiated product” (P7, line 43-44). This is in line with Tellis and 
Golder’s (1996) non-state-regulated, market-related findings, which determined that product 
innovativeness is essential to gain unique attributes for a high market share (Berndt et al., 
1997) and important for early market entrants. However, according to Cooper and 
Kleinschmidt’s (1993, p110) non-state-regulated, market-related research, ‘innovativeness has 
a modest impact on success’. 
Consistent with the non-state-regulated, market-related literature (Cooper and Kleinschmidt, 
1993; Sharp et al., 2001), as well as the focus group, product properties are of high relevance 
when a purchase decision is made. This is also supported by the Delphi group. Consequently, 
it was mentioned by seven participants that a good drug should show high therapeutic efficacy 
and a low or tolerable side-effect profile (P5, line 28; P8, line 83; P4, line 62-63; P1, line 55; 
P3, line 95; P2, line 6; P6, line 31-32). This statement was supported by the focus group, as 
well as by Gonul et al. (2001) in their non-state-regulated, market-related research. They 
concluded that product properties come first when choosing a product. In addition, good 
packaging and labelling is important. This is relevant especially because these are the “causes 
of 30 to 40% of drug recalls” (P4, line 64; P7, line 74). This statement cannot be supported by 
the scientific literature; however, “over-packaging should be avoided” (P7, line 75). 
 134 
Regarding branding in general pharmaceutical marketing, there are two fundamental strategic 
approaches present: branding and the me-too strategy (see also Brassington and Pettitt, 2007; 
Dogramatzis, 2002). The importance of branding was pointed out by one Delphi group 
participant. Furthermore, it was stated that “the producing company with its company name 
and culture is responsible for the product and thus creates general public trust” (P6, line 40-
41). This is supported by Flechter’s (1989) non-state-regulated, market-related findings and 
the statements made by the focus group, who pointed out that a producer’s reputation and the 
resulting confidence play an important role for the purchaser. Therefore, it is important “to 
achieve quickly a high product brand awareness and image” (P6, line 41-42). However, the 
Delphi group respondent stated that a me-too strategy is not effective. This has already been 
questioned by Schmalensee (1982).  
In summary it can be concluded that product confidence that might be gained by quality 
criteria, as well by product awareness, seems to be of high relevance according to the focus 
group. This is also partly in support of the Delphi group statements. However, additional 
research is required in order to provide more clarification in the context of a state-regulated 
market. 
 
4.2.3.3. Place (Distribution) 
It was mentioned by one Delphi group respondent that “product accessibility” is of high 
importance (P3, line 19-21). It is therefore imperative to ensure a “fast and complete 
distribution and a good availability and visibility at the sales channels”, leading to a “fast and 
high penetration among the target audience” (P6, line 38-39). However, according to the non-
state-regulated, market-related literature, distribution does not play an essential role in 
pharmaceutical sales (revenue) success (Cooper and Kleinschmidt, 1993; Ghosh et al., 1983; 
Smith, 1983) and was not discussed by the focus group, although different distributional mix 
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strategies are discussed in the general marketing literature (see also Brassington and Pettitt, 
2007; Dogramatzis, 2002). The Delphi group statements supported non-state-regulated, 
market-related, scientific, general marketing and pharmaceutical marketing literature. It has to 
be added that there is no room for distributional variations in the state-controlled Swiss 
market. Prescription pharmaceuticals are distributed via wholesalers to pharmacies, hospitals 
and self-dispensing physicians (costumers), and no alternative channels can be used. 
Therefore, distribution will not be investigated further in this research.  
 
4.2.3.4. Promotion 
Regarding promotion policy, it can be concluded that it is essential to make “as much noise as 
possible” (P6, line 42) and to have a “simple and logical sales story” (P6, line 68). Three main 
promotional instruments were mentioned by the Delphi group members: personal selling and 
advertising such as scientific documentation, patient (consumer) information and public 
relations. It was highlighted that, for personal selling, the professionalism of the salesforce 
following a marketing strategy containing an integrated call plan is important. However, it 
was pointed out that the appointment of sales visits is a challenge. Despite confirmation in the 
non-state-regulated, market-related, scientific, general marketing and pharmaceutical 
marketing literature, some new aspects, not covered by scientific research, were mentioned. It 
was stated that the success of marketing lasts only for a certain period and is therefore time-
related. 
The importance of promotional activities in pharmaceutical marketing has been shown by 
non-state-regulated, market-related, pharmaceutical marketing research (Bond and Lean, 
1977; Kremer et al., 2008). In support of these findings, it was pointed out by one Delphi 
group respondent that one of the main aims of pharmaceutical drug promotion is to make as 
much “noise as possible” in order to become “top of the mind” (P6, line 42; P3, line 17-18) 
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and to generate more prescriptions (P2, line 93). It was concluded by Robinson and Fornell 
(1985, p316) that late market entrants especially have to ‘shout louder to be heard’. Therefore, 
it is essential to have a “simple and logical sales story” (P6, line 68) and “convincing 
arguments” (P9, line 52).  
The relevance of personal selling was discussed by the focus group and in the non-state-
regulated, market-related, scientific literature (see also Kremer et al., 2008; Manchanda, 2005; 
Mizik and Jacobson, 2004). This issue was also raised by one Delphi group respondent, who 
stated that, regarding personal sales, one important sales (revenue) success factor is the 
“professionalism of the salesforce, being enthusiastic, highly motivated and having a good 
level of product knowledge” (P2, line 7-8). This statement is supported by non-state-
regulated, market-related, scientific research (Gillis et al., 1998; Saxe and Weitz, 1982; 
Parsons and Adeele, 1981). Furthermore, according to one Delphi group respondent, it is 
important that “sales follow a marketing strategy” (P4, line 24-25). Consequently, it is 
necessary to “implement an integrated call plan considering the number of sales calls, 
frequency of visits and accompanying supporting activities such as direct mailings, etc.” (P2, 
line 8-9, P4, line 26-27). This is in line with Gonul et al.’s findings (2001). Nevertheless, it is 
a challenge for the sales representative, as pointed out by three participants, to get “sales 
appointments” (P2, line 58-59; P9, line 84; P5, line 66-67). This statement supports the 
conclusion derived from the focus group, but it is not covered by research. 
Another critical aspect to be considered is human resources. According to one participant’s 
statement, there is a current unsatisfactory situation within the pharmaceutical business 
regarding the “high turnover of staff (every 1.5 - 2 years), leading to a young, inexperienced 
team and a non-dedicated salesforce and management” (P5, line 105), thus “having a negative 
impact on customer interface and knowledge transfer” (P8, line 80-81). This statement cannot 
be supported by the scientific literature. 
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Only the Delphi group mentioned direct-to-prescriber (costumer) (DTP) promotional 
measures. It was highlighted that an appropriate “promotion mix has to be set up containing 
mailings, journal advertisements and conference activities” (P2, line 9). Pharmaceutical 
marketing mix strategies are discussed in the general marketing literature (see also 
Brassington and Pettitt, 2007; Dogramatzis, 2002). Additionally, the relevance of scientific 
documentation, as shown by a non-state-regulated, market-related, pharmaceutical marketing 
study, was highlighted by one participant: “The producer has to document the scientific 
outcomes and proven evidence of seriously conducted medical trials, particularly for the 
medical environment” (P6, line 32-34). The importance of scientific-oriented documentation 
has already been pointed out by Avorn et al. (1982) and Azoulays’ (2002) in their non-state-
regulated, market-related research, as well as by the focus group. It has to be ensured that 
“transparent, understandable and complete patient (consumer) information is given” (P6, line 
37-38).  
In summary we can refer to one participant’s statement that “success by marketing has a short 
life time” (P8, line 121-122) (see also the general marketing literature: Brassington and 
Pettitt, 2007). Furthermore, it should be ensured that “no over or under-spending” in 
marketing takes place (P5, line 65). The relevance of this aspect has already been discussed 
by the focus group and the non-state-regulated, market-related, scientific pharmaceutical 
marketing literature (Manchanda and Chintagunta, 2004). As already suggested earlier by the 
focus and Delphi groups, promotional marketing activities seem to have a high relevance for 
launch activities and product confidence building. Therefore, additional research will be 
conducted in this respect.  
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4.2.3.5. Price 
For pricing policy, it can be summarised that a customer’s buying power plays a central role. 
Consequently, the affordability of a medical drug has to be considered. On the other hand, 
high margins are financial incentives and can motivate doctors (costumers) to prescribe a 
specific medication. As a result, it can be expected that pricing will become more important. 
The Delphi group statements are supported by the non-state-regulated, market-related, 
scientific, general marketing and pharmaceutical marketing literature. 
The controversial role of pricing is discussed in the literature. According to Lexchin (2009, 
p145), ‘doctors (costumers) are generally ignorant regarding the price level of pharmaceutical 
drugs’. However, as pointed out by Muehlemann (2005) and the focus group, the doctor and 
the patient (consumer)’s (see Brassington and Pettitt, 2007) price awareness will rise when 
financial incentives are given. Furthermore, the price affordability of a pharmaceutical drug 
for the payer is an important aspect when the price level is set, as described in the general 
marketing literature (see Brassington and Pettitt, 2007). This was also highlighted by some of 
the Delphi group members, who stated that, regarding pricing, the customer’s buying power is 
of relevance: “The customer must be able to pay for the drug (either through healthcare 
insurance or by personal assets)” (P3, line 14-15). Nevertheless, it was revealed by Copper 
and Kleinschmidt’s (1993) non-state-regulated, market-related, scientific pharmaceutical 
marketing research that a low-price strategy is generally not effective. In addition, it was 
emphasised by one Delphi group respondent that it is important to provide a high margin as a 
financial incentive to sellers. The relevance of financial incentives is shown by Sutherland et 
al. (2008) in their non-state-regulated, market-related research and was discussed by the focus 
group. However, these margins are “under pressure due to increased price control from 
governments, consumer protection organisations, parallel imports and generic (competitive) 
products” (P7, line 76-79; P2, line 6; P6, 108-109). Consequently, as stated by one 
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participant, Swiss pharmaceutical drug “prices will become the most important issue in the 
future” (P1, line 55-56).  
In conclusion it can be said that pricing plays a special role in the state-controlled Swiss 
market. On the one hand, the price level is defined by a governmental body (Swissmedic) but 
is usually negotiated in the first place by the pharmaceutical companies. Medical drug prices 
remain fixed and are seldom altered after a review that takes place within three years by the 
Swiss Federal Office of Public Health (www.bag.adim.ch). This is despite the fact that the 
medical drug is sometimes sold at a remarkably lower price in other markets. In addition, 
pharmaceuticals cannot be imported (prohibition of parallel imports). Consequently, as an 
example, Swiss medical drug prices are on average 50% higher than in Germany 
(Tagesanzeiger, 2012). Furthermore, self-dispensing physicians (costumers) as well as 
pharmacists are motivated to prescribe the more expensive drug to bolster their income, which 
is generated by their own medical drug sales business. As a result, there is a need for further 
research on the role of pricing in this specific restricted market. 
 
4.2.4. Round One Summary of the Delphi Group Study 
The analysis of the Delphi round one study answers revealed seven factors related to 
prescription decisions. It was highlighted by the Delphi group respondents that early market 
entry is important for the doctor’s prescription information (see also Lean and Bond, 1977; 
Castro and Chrisman, 1995; Kardes and Kalyanaram, 1992; Jaakkola and Renko, 2007; 
Rodgriuez-Pinot et al., 2008). In addition to this it was mentioned that product confidence 
building (see also Flechter 1989) is of relevance. Furthermore, it was pointed out that the 
product applicability for a specific need, given by the product’s properties, is an essential 
criterion (see also Brassington and Pettitt, 2007; Dogramatzis, 2002). Another decisive factor 
is product knowledge level. It was stated that by employing promotional measures and 
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making “as much noise as possible”, through channels such as personal selling and 
advertising, the product would be present in the prescriber (costumer)’s mind. The Delphi 
group members also emphasised the relevance of affordability for the buyer (see Brassington 
and Pettitt, 2007), as well as a good margin for maximising the personal financial benefit of 
making the purchase decision (see also Sutherland et al., 2008). Consequently, the following 
process model can be presented (Figure 4-3). 
.
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Figure 4-3: Prescription Delphi group round one decision process model 
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In addition, the Delphi group round one study participants’ answers were analysed for content 
(see also Krippendorff, 2003; Martin and Bateson, 2007) and frequency, then summarised and 
categorised in line with the marketing mix instruments “product”, “promotion” and “price” 
[according to McCarthy and Perreault’s (1960) 4Ps concept]. An overview of all of the results 
derived from the Delphi group study is presented in Table 4-2. The number of responses is 
also provided.  
Product Safety and Side Effects
Tolerability
Packaging
Clinical Study Results III (Applicability)
Clinical Study Results IV (Applicability)
Promotion Personal Selling
Word-of-Mouth
Price Price Level
Reimbursement from Insurance
2
1
1
10
Marketing 
Categories Variables
Round 1 Study
number of responses
4
5
1
11 participants
1
2
 
Table 4-2: Relative importance, response rate and standard deviation of pharmaceutical marketing variables in 
      round one 
 
4.2.5. Rounds Two and Three: Delphi Group Findings and Analysis 
In the second round of the Delphi group study, marketing variables derived from the 
systematic literature review and the focus group study were further investigated. Therefore, a 
differentiation analysis, comparing the outcomes from the systematic literature review, focus 
group and Delphi group round one study, was performed. There was generally a quite high 
similarity between the results derived from the studies. However, the Delphi group round one 
study finding (see Table 4-2) was expanded by the additional variables derived from the focus 
group. These are promotion as well as distributional and product policies, as indicated in 
Table 4-3. 
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The answers from the completed questionnaires (see Figure 4-1) were collated, and the 
number of responses (n.), relative importance (r.i.; lowest equals 0, highest equals 1), 
response rate (r.r.) and standard deviation (s.d.) of every single variable as shown in Table 4-
3, were calculated. In general, there was high agreement within the group for most of the 
variables, as shown by the standard deviation. However, there was also disagreement (applied 
cut-off criteria: 65th percentile) within the group for some variables. This prompted further 
investigation in order to clarify this disagreement. 
r.i. r.r. s.d
Product Efficacy (Quality) 0.93 90% 0.88 No
Packaging 0.50 90% 2.05 No
Safety and Side Effects (Quality) 0.90 90% 0.83 No
Tolerability (Quality) 0.79 90% 1.00 No
Clinical Study Results IV (Innovativeness, Applicability) 0.75 70% 1.48 No
Clinical Study Results III (Innovativeness, Applicability) 0.72 100% 1.24 No
Place Hospitals 0.97 90% 0.44 Yes
(Distribution) Internet 0.24 90% 0.64 Yes
Pharmacy 0.71 70% 2.00 Yes
Wholesalers 0.56 70% 1.88 Yes
Promotion Word-of-Mouth 0.84 100% 1.42 No
Personal Selling 0.79 70% 1.94 No
Advertising 0.56 40% 1.73 Yes
Publications in Journals (Information) 0.73 70% 1.62 Yes
Sampling 0.71 40% 1.50 Yes
Price Reimbursement from Insurance 0.93 70% 0.73 No
Price Level 0.60 80% 2.10 No
n. shows number of responses - r.i. row shows relative importance (lowest 0 - highest 1)
r.r. row shows response rate - s.d. row shows standard deviation
Marketing 
Categories Variables
Round 2 Study
10 participants Added in Round 2 Study
 
Table 4-3: Relative importance, response rate and standard deviation of pharmaceutical marketing variables in 
      round two 
 
In the third round of the Delphi group study, the results from the second round were further 
investigated, in order to reach a consensus within the Delphi group. Therefore, the outcome 
from the second round was reassessed, employing a questionnaire investigating those 
variables showing a high disagreement. Those variables that were further investigated (8 out 
of 18) are indicated in Table 4-5 (last column). Again, the number of responses, relative 
importance, response rate and standard deviation of every single variable were calculated. The 
importance of pharmaceutical marketing variables is illustrated by means of standardisation 
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(lowest equals 0, highest equals 1) in Table 4-4. Answer sets showing contradictory opinions 
were discarded (34 out of 334).  
r.i. r.r. s.d.
Product Efficacy (Quality) 0.93 90% 0.88 No
Safety and Side Effects (Quality) 0.90 90% 0.83 No
Tolerability (Quality) 0.79 90% 1.00 No
Clinical Study Results IV (Innovativeness, Applicability) 0.75 70% 1.48 No
Clinical Study Results III (Innovativeness, Applicability) 0.72 100% 1.24 No
Packaging 0.49 100% 2.15 Yes
Place Hospitals 0.97 90% 0.44 No
(Distribution) Internet 0.24 90% 0.64 No
Pharmacy 0.73 78% 1.95 Yes
Wholesalers 0.56 67% 2.17 Yes
Promotion Word-of-Mouth 0.84 100% 1.42 No
Sampling 0.71 40% 1.50 No
Advertising 0.56 44% 1.73 Yes
Personal Selling 0.80 78% 1.90 Yes
Publications in Journals (Information) 0.74 89% 1.69 Yes
Price Reimbursement from Insurance 0.93 70% 0.73 No
Price Level 0.61 78% 2.19 Yes
n. shows number of responses - r.i. row shows relative importance (lowest 0 - highest 1)
r.r. row shows response rate - s.d. row shows standard deviation
9 participants
Variables further 
investigated in Round 3 Marketing Categories Variables
Round 3 Study
 
Table 4-4: Relative importance, response rate and standard deviation of pharmaceutical marketing variables in  
      round three 
 
4.2.6. Summary of Rounds Two and Three of the Delphi Group Results  
The analysis of the results of the third round of the Delphi group study indicates that a 
successful marketing strategy for pharmaceuticals has to consider appropriate product 
properties including issues such as efficacy, safety and side-effects, tolerability and 
packaging. Furthermore, it is vital that the product is distributed via sales channels such as 
hospitals, pharmacies, self-dispensing physicians (costumers) and wholesalers. In addition, 
the promotion policy has to contain word-of-mouth, personal selling, product applicability 
(indication), information, sampling and advertising. It is also essential that the drug will be 
reimbursed by health insurance and that a reasonable pricing level is set. A ranking of the 
marketing variables according to their relative importance within their marketing category is 
shown in Table 4-5. 
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Product Efficacy (Quality) 1 0.93 0.88
Safety and Side Effects (Quality) 2 0.90 0.83
Tolerability (Quality) 3 0.79 1.00
Clinical Study Results IV (Innovativeness, Applicability) 4 0.75 1.48
Clinical Study Results III (Innovativeness, Applicability) 5 0.72 1.24
Packaging 6 0.49 2.15
Place Hospitals 1 0.97 0.44
(Distribution) Pharmacy 2 0.73 1.95
Wholesalers 3 0.56 2.17
Internet 4 0.24 0.64
Promotion Word-of-Mouth 1 0.84 1.42
Personal Selling 2 0.80 1.90
Publications in Journals (Information) 3 0.74 1.69
Sampling 4 0.71 1.50
Advertising 5 0.56 1.73
Price Reimbursement from Insurance 1 0.93 0.73
Price Level 2 0.61 2.19
r.i. row shows relative importance (lowest 0 - highest 1)
s.d. row shows standard deviation
Rank r.i. s.d.Marketing Categories Variables
 
Table 4-5: Ranking of the most important variables in pharmaceutical marketing 
 
4.3. Summary of the Qualitative Studies  
The analysis of the focus group discussion and Delphi group round one study has revealed a 
couple of prevalent gaps in scientific pharmaceutical marketing research.  
First, the question of the applicability of research performed in a different market 
environment can be raised. Most pharmaceutical marketing theories and concepts highlighted 
by the focus and Delphi groups are described in the literature. However, most of this research 
was conducted in non-state-regulated, market-related markets, usually the US market. Earlier 
works and reviews have tended to have a limited perspective on a single aspect of marketing 
or sales in the sector (see also Paragraph 1.3). Thus, they do not cover adequately all aspects 
of the conceptual framework of “physician-targeting”. There is a need for further research in 
order to clarify the applicability of this research for a state-regulated (Swiss) market, which 
would enable the development of a market-specific ‘“physician-targeting” model (see also 
Stremersch and Van Dyck, 2009).  
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Second, most of these theories and concepts have been investigated in single, independent 
studies and under isolated circumstances and different market environments, but they have 
not been investigated from a broader perspective.  
Third, some of the mentioned theories and concepts are only vaguely or not actually described 
in marketing research. Regarding marketing strategy, there were a couple of new and 
interesting issues raised. For “product policy”, product features are relevant, but their relative 
importance is uncertain. Another aspect to be investigated is the fact that there does not seem 
to be a big difference regarding efficacy between medical drugs, resulting in a lack of 
differentiation between products. However, the relative importance between these variables is 
uncertain. Furthermore, the importance of packaging and the risk of over-packaging were 
emphasised. The influence of packaging on sales (revenue) is another criterion that should be 
investigated. Moreover, the Delphi group concluded that the applicability of a pharmaceutical 
drug for a specific need is the most important criterion (see also Cooper and Kleinschmidt, 
1993; Sharp et al., 2001). In order to differentiate a product from its competitors’, 
innovativeness is required. Furthermore, it was concluded that product confidence is of 
significant importance. Consequently, the variables (1) quality (efficacy, safety and side-
effects, tolerability) (2) indication (product applicability) and (3) packaging were regarded as 
being relevant. These results are supported by several researchers (Smith, 1983; Flechter, 
1989; Dogramatzis, 2002).  
As stated by the Delphi group members, product accessibility within a particular territory is 
an important factor. Therefore, product distribution should include sales channels such as (1) 
hospitals, (2) physicians (costumers) and (3) pharmacies as an important factor. The internet 
(4), as an additional (unofficial) sales channel for prescription drugs, was of less relevance 
(see also Brassington and Pettitt, 2007; Dogramatzis, 2002). However, it has to be emphasised 
that there is no room for distributional variations in the state-controlled Swiss market. 
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Prescription pharmaceuticals are distributed via wholesalers to pharmacies, hospitals and self-
dispensing physicians (costumers), so no alternative channels can be applied. Therefore, 
distribution policy will not be investigated further in this research. 
Regarding “promotion policy”, there were controversial statements regarding the 
effectiveness and the likelihood that sales representatives are welcomed by physicians 
(costumers). In addition, additional promotional activities such as direct mailing and 
advertisements seem to have an effect on personal sales effectiveness. Furthermore, it was 
stated that promotional activities have a lifespan and over-promotion should be avoided. 
Additionally, the Delphi group highlighted that, for personal selling, the professionalism of 
the salesforce following a marketing strategy containing an integrated call plan is important. 
However, it was pointed out that arranging sales visit appointments is a challenge. It should 
be understood that the salesperson has a certain level of influence over the doctor in terms of 
fulfilling their mission as an information supplier. These results are in line with the study 
from Pitt and Nel (1988), which produced similar results. Pitt and Nel studied factors 
influencing the prescription behaviour of 210 general practitioners (costumers) in Australia. 
They suggested that, of the marketing tools available to the pharmaceutical firm, personal 
selling is the most powerful. Furthermore, the relevance of personal selling is also supported 
by Black (2005, p119), who states that in ‘order to influence prescription choice by multi-
faceted education-based strategies, personal selling is the most effective one’. Consequently, 
the following additional promotional marketing variables were indicated as being essential: 
(1) word-of-mouth, (2) personal selling, (3) communication of phase IV/III clinical study 
results, (4) journal publications, (5) sampling and (6) advertising (see also Brassington and 
Pettitt, 2007; Dogramatzis, 2002). It has to be added that the expenses for opinion leader 
directed promotion as well as word-of-mouth directed promotion are not separated and 
therefore cannot be tested separately. Furthermore, sampling will be viewed as a part of 
personal selling activity and also will not be separately tested. 
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For “pricing policy”, it can be summarised that the customer’s buying power plays a central 
role. Consequently, the affordability of medical drugs has to be considered. However, medical 
drugs in Switzerland are usually covered by health insurance. Furthermore, high margins are a 
financial incentive and can motivate doctors (costumers) to prescribe a specific medication. 
Nevertheless, the price level seems, even when considering continuously rising healthcare 
costs (Henry, 2004; Kaech, 2004), to be viewed as less important. This phenomenon can also 
be explained by the fact that ‘the ones who make the decisions are not identical with those 
who receive the service and/or pay for it’ (Harms et al., 2002, p147).  
Furthermore, the influence on the study outcome caused by the participants’ involvement in 
pharmaceutical marketing process was evaluated (please see also Figure 4-1). The statements 
contributed by the participants ‘being more directly involved’ were based on their practical 
experience. In contrast, the statements given by the participants ‘not being directly involved’ 
and therefore being less biased/influenced by the pharmaceutical industry were more 
independent/unbiased. In addition to this, the ‘position of responsibility’ as well as the 
participants ‘educational background’ had an influence on the group members’ contribution 
too. The participants being involved in more ‘managerial position’ could contribute in terms 
of strategic issues, whereas those involved in more operational positions could contribute with 
practical statements. The Delphi group members with practical experience have provided 
direct from the field insights whereas a more academic perspective was given by the other 
participants. Furthermore, participants with a higher ‘number of years of experience’ have 
also given an input that was based on their long term pharmaceutical marketing experience. In 
summary it can be concluded that the Delphi group was a well-balanced mix of healthcare 
professionals with different managerial, operational, practical and academic perspectives 
providing interesting insights to the Swiss prescription pharmaceutical market.  
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Because this empirical qualitative study has focused on the Swiss pharmaceutical market, it is 
not surprising that the resulting pharmaceutical marketing mix instruments differ from those 
derived from the systematic literature review. This discrepancy can be explained by the 
different market environments, as discussed in Paragraph 1.1.3.  
 
4.4. Deriving Hypotheses 
In this paragraph, the conclusions that have been derived from the systematic literature review 
(see Chapter 2) will be re-examined in the light of the additional qualitative data gathered. 
Hypotheses will be proposed and a conceptual model delivered. This will enable the 
conceptualisation of the dimensionality of pharmaceutical marketing instruments to clarify the 
influence of pharmaceutical marketing instruments on “physician-targeting”, leading to an 
increase in sales (revenue), as given by the research objectives. 
In general, as well as in the pharmaceutical marketing literature covering mainly the U.S. 
market, it is described that the prescription decision [sales (revenue)] (dependent variable) is 
guided by order-of-market entry (independent variable) (Urban et al., 1986; Berndt et al., 
1997; Kalyanaram and Urban, 1992; Lean and Bond, 1977; Golder and Tellis, 1993). These 
authors established a positive relation between these variables. Furthermore, it is shown in the 
scientific literature (Kardes and Kalyanaram, 1992), and was confirmed by the focus and 
Delphi groups, that this is caused by habit formation (prescription habit). So far, no research 
has been published investigating the effect of order-of-market entry in state-regulated 
pharmaceutical markets. Because of the importance of order-of-market entry, there is a need 
for research, in order to clarify whether the same effect takes place in this specific market 
environment. Consequently, the following hypothesis can be derived, hypothesising a similar 
relation that takes place in non-state-regulated markets: 
H1:  The earlier a market entrant enters the market, the higher the sales (revenue) will be. 
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It was stated by the focus and Delphi groups, and is described in the general marketing and 
pharmaceutical marketing literature, that product features (defined as a set of marketing 
measures) (see also Cooper and Kleinschmidt, 1993; Kotler, 2006 and 1998; Sharp et al., 
2001; Dogramatzis, 2002) play a central role in a physician (costumer)’s prescription decision 
(dependent variable), thus suggesting a positive relation. Furthermore, it was stated by the 
focus group that product confidence is relevant for the physician (costumer)’s prescription 
decision (sales (revenue)) (see also Flechter, 1989). Therefore, it can be hypothesised that: 
H2:  Medical drugs with fewer drug interactions with other drugs are more  
likely to be prescribed by practitioners (costumers). 
H3:  Medical drugs with lower side-effects are more  
likely to be prescribed by practitioners (costumers). 
H4:  The better the medical drug’s perceived product quality, the more likely  
 the medical drug will be prescribed. 
H5:  Medical drugs with more feasible packaging are more likely to be  
prescribed by practitioners (costumers). 
 
Furthermore, it was stated by the focus and Delphi groups that the patient (consumer)’s price 
sensitivity is of relevance (see also Brassington and Pettit, 2007; Dogramatzis, 2002). As a 
result, physicians (costumers) are also confronted with this issue and its influence on their 
prescription decision (sales (revenue)). Therefore, the “price level” (the affordability of a 
medical drug) is an important variable in any pricing policy. Furthermore, the focus group 
concluded that financial reward (seller’s margin) is relevant when it comes to the prescription 
decision. However, Lexchin (2009, p145) noted that ‘doctors (costumers) are generally 
ignorant of both relative and absolute prices of medications’. Based on the existing research 
and actual findings, the interaction between these variables is quite unclear, so further 
investigation is required. Nevertheless, a negative relation between the “price level” and the 
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“prescription decision [sales (revenue)]” variable is suggested, which is in line with market 
theory suggesting (see also Arnold, 2008) a negative relation between volume and price 
within a non-regulated (ideal) market. 
H6:  Medical drugs with a lower price (price level) are more likely to be prescribed by 
practitioners (costumers). 
 
The general marketing literature (Brassington and Pettit, 2007) and scientific literature (Bond 
and Lean, 1977; Kremer et al., 2008) describe that promotional expenditure have a significant 
and positive effect on sales (revenue) in pharmaceutical markets. This was also confirmed by 
the focus and Delphi groups. It was emphasised that it is important to make a lot of noise in 
the market, in order to ensure that the product is present and prescriptions are made. It has to 
be added that sampling is viewed as a part of the personal selling activity and will therefore 
also not be separately tested. Furthermore, available market data, as discussed in the next 
chapter, do not distinguish between direct-to-physician (costumer) (DTP) directed 
expenditure and direct-to-opinion leader- as well as word-of-mouth-directed marketing 
expenditure. Therefore, the following hypotheses, suggesting a positive relationship between 
the independent and the dependent variable, are proposed: 
H7:  Better promoted medical drugs are more likely to be prescribed by physicians 
(costumers). 
H7a:  An increase in personal selling activities will positively influence the number of 
prescriptions. 
H7b: An increase in medical drug mailings will positively influence the number of 
prescriptions.  
H7c:  More advertising has a positive influence on the number of prescriptions. 
 
It has previously been revealed by the Systematic Literature Review (see Chapter 2.8.3) as 
well as by the focus (see Chapter 3.2.4) and the Delphi group study (see Chapter 4.2.3.3) that 
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there is no room for variations in distributional (place) marketing measures in the state-
controlled Swiss market. Prescription pharmaceuticals are normally distributed via 
wholesalers to pharmacies, hospitals and self-dispensing physicians (costumers), and no 
alternative channels are used. Therefore, the influence of the marketing mix element of 
distribution (place) on the prescription decision will not be further investigated in this 
research. Consequently, this instrument has not been included in the conceptual model and no 
hypotheses have been derived. 
Since the sales (revenue) of the leading therapy categories (medical drug class) within the 
total pharmaceutical market sales (revenue) predominate, most pharmaceutical companies 
conduct research in closely related therapeutic areas, often employing similar technological 
approaches, which inevitably leads to strong competition in those market segments and to 
different peculiarities of the specific drug class.  
 
4.5. Deriving a Conceptual Physician-targeting Model 
Taking this into consideration, the following conceptual “physician-targeting” model is 
presented (Figure 4-4). 
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Product Policy (Features)
Quality
Prescription
Decision
(Sales)
Marketing Categories
Pricing Policy
Promotion Policy (DTP)
Average Price (AP)
Drug Interaction (IA)
Drug Side Effects (SE)
Marketing Expenditures (MA)
H1 (-)
H7c (+)
H6 (-)
H7a (+)
H7b (+)
Personal Selling Expenditures (DE)
Advertising Expenditures (AE)
Order of
Market Entry
H3 (-)
Perceived Quality (PQ)
H5 (+)
Mailing Expenditures (ME)
(Information)
Packaging Alternatives (PA)
H2 (-)
H4 (+)
 
Figure 4-4: Conceptual physician-targeting model 
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4.6. Limitations 
The main limitation of the focus and Delphi group studies lies in the fact that these methods 
can never guarantee a distortion-free picture. Although the methods used strive to produce 
consensus among experts, even an expert judgement may not always be objective (see also 
Haeder and Haeder, 2000; Hill and Fowles, 1975; Linstone and Turoff 1975; Lock, 1987; 
Parenté and Anderson- Parenté, 1987; Stewart, 1987; Rowe et al., 1991). However, because 
of their broad professional and academic experience, valid and reliable responses can be 
assumed from the participants. Furthermore, it is the nature of the Delphi group and focus 
group techniques that the sample size is relatively small and therefore not broadly 
representative (focus group n = 5, Delphi group n = 11). As such, the results cannot be 
interpreted as definitive or as representative of the industry due to the limitations of the size of 
the panel of acknowledged Swiss experts providing prescriptive advice.  
 
4.7. Conclusions of the Qualitative Study 
In this chapter, a conceptual “physician-targeting” model was created, based on the 
conclusions derived from the systematic literature review and the focus and Delphi group 
findings. The qualitative data provided evidence of the relevant marketing factors and 
substantive aspects in the Swiss prescription pharmaceutical market, as previously found in 
the scientific literature. A serial research study was undertaken, examining essential 
marketing success factors by means of two qualitative studies and by applying focus group 
and Delphi survey techniques. Swiss healthcare professionals in middle and senior 
management positions (focus group n = 5, Delphi group n = 11) were asked to voice their 
personal opinions regarding the importance of various factors that might influence the 
turnover of prescription drugs. The fundamental findings garnered from the systematic 
literature review were used for the Delphi group survey set-up. To reach a consensus within 
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the Delphi group, a three-step interactive procedure was applied. For the evaluation of the 
focus group results and Delphi group round one study, a content analysis was performed. The 
results of the Delphi study were investigated, using descriptive statistics. The present study 
ultimately yielded a ranking of marketing instruments perceived to be important in the 
marketing of pharmaceuticals in Switzerland, and then derived hypotheses to provide a robust 
basis for further research. 
In the next chapter, this model will be validated by applying statistical methods employing 
Swiss prescription pharmaceutical market data and focusing on specific markets. 
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5. Statistical Market Data Analysis 
 
5.1. Introduction 
In this chapter, the secondary market data provided by a Swiss market research company are 
prepared for analysis, using Excel and statistical analysis software (SPSS). For this purpose, 
the data delivered on twelve spreadsheets were combined and cleaned. Some of the missing 
(product property-related) variables were acquired from different sources. In total, a dataset 
containing thirteen relevant variables was derived. In the next step, the data were tested for 
their quality. For this purpose they were checked for outliers, missing values, arithmetic 
mean, variance, standard deviation and normal distribution. The analysis of the data revealed 
a multi-level structure. As such, appropriate analysis methods were designed and employed.  
 
5.2. Analysis of Secondary Data 
In the literature, secondary data analysis is defined as any further analysis of an existing 
dataset, which presents interpretations, conclusions or knowledge in addition to, or different 
from, those produced in the first report on the inquiry as a whole and its main results (Hakim, 
1982). Moreover, it involves the analysis of someone else’s data: a collection of data obtained 
by another researcher which is available for re-analysis (Sobal, 1981). Furthermore, as stated 
by Smith (2008, p324), ‘this involves using the original, or novel, research questions, 
statistical approaches and theoretical frameworks and may be undertaken by the original 
researcher or by someone new’. Despite a number of methodological concerns, as highlighted 
by Smith (2008), ‘a relatively large proportion of numeric papers in the “Sociology” as well 
as in “Life Science” have applied secondary data analysis’ (Smith, 2008, p327). A review of 
the published output of eight mainstream and well-regarded journals was undertaken by Smith 
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(2008). This research revealed that about one-quarter of all papers reviewed adopted some 
form of quantitative method (492 out of 2016), and of these around 41 per cent (202 out of 
492) used secondary data analysis (Smith, 2008).  
The use of secondary data has outstanding advantages over using primary data. According to 
Smith (2008, p328), ‘it allows researchers to access data on a scale they could not hope to 
replicate first hand and enables the researcher to access data that is usually of highest quality’. 
The usage of secondary data for scientific research has also been justified by Booth et al. 
(2008), especially in the case where these data are not easily available from a primary source. 
For the present work, it would not have been feasible, because of a lack of access to the 
required information channels, to collect the sort of information provided by the market data. 
Therefore, it is suggested that, before undertaking any primary research, study marketers 
should complete an exhaustive search of secondary data sources (Cross, 2000). In order to 
support this statement we can refer to Castleberry (2001, p195), who asks ‘Why create 
knowledge using primary data collection, if that knowledge already exists and can be found 
using secondary data?’  
However, as by Young and Ryu (2000, p303) emphasised, ‘there are many limitations that 
have to be managed when a secondary analysis is performed’. Furthermore it was highlighted 
by Young and Ryu (2000, p303) that researchers must be thoroughly familiar with the dataset, 
in order to select appropriate proxy measures for their study’s concepts and to avoid the 
temptation to measure concepts not well-represented in the data.  
In summary, despite existing methodological concerns regarding the usage of secondary data 
in scientific research, and because of the need for market data in the present work, this 
research can only be conducted by using secondary data. This can be justified by the 
requirement given by the research, in that market data should provide as complete as possible 
a body of marketing-related information for a certain period (in this case, ten years). 
  
158 
Furthermore, it is not easy to collect market data for a non-market involved institution such as 
a university. Therefore, these data had to be gathered from a specialised market research 
institute. 
 
5.3. Data Collection Method 
In order to test the previously derived hypotheses (see Chapter 4), secondary and primary data 
were applied. In this section, the methodology behind the data collection is presented.  
 
5.3.1. Secondary Data Collection 
The data were collected by the Swiss market research company via an associated network of 
associated doctors (costumers), pharmacists and wholesalers. Medical drugs sales (revenue) 
transactions were gathered on a monthly basis from pharmaceutical companies, wholesalers, 
hospitals, pharmacies and dispensing physicians (costumers). For this purpose, a 
questionnaire inquiring about the required market data was mailed on a regular basis to 
participants, who were compensated financially for their efforts. Several restraints regarding 
usage, publication and confidentiality had to be made, as will be discussed later. The market 
research company in Switzerland is a leading market data provider and business consultant in 
the pharmaceutical and healthcare industry, with over 100 subsidiaries world- wide (for 
further information, please see also www.imshealth.ch). These data cover five prescription 
pharmaceutical drug classes, containing sales (revenue) information on 37 substances from 
108 medical drug products for the period 1995 to 2005. However, because the provided 
dataset was incomplete, additional data such as “drug side-effects (SE)”, “drug interaction 
(IA)” and “defined daily drug dose (DDD)” had to be taken from alternative sources. They are 
freely available and were gathered from the Swiss agency for the authorisation and 
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supervision of therapeutic products (www.kompendium.ch) and the WHO Collaborating 
Centre for Drug Statistics Methodology (www.whocc.no).  
 
5.3.2. Primary Data Collection 
No data regarding “perceived drug quality (PQ)” by doctors (costumers) were available. 
Therefore, primary data for this measure had to be collected. In a first step, a questionnaire 
was designed (see Appendix 9). In the first section of this questionnaire, a brief introduction 
to the research and survey was made. Furthermore, a confidentiality statement and the 
approximate time of participation were given. This questionnaire was previously pre-tested 
within Aston University. In the second section of the survey, the participants were asked to 
rank the medical substance on a semantic scale (1-9, not efficient to highly efficient, or no 
answer) as perceived by the participants. A comment section was also included. Because 
market data are not restricted to a specific application, no restriction was given. Finally, the 
opportunity was given to add comments, as well as an email address, to participate in a prize 
draw to win an Ipod Shuffle and, if interested, to receive the study results.  
In a second step, these questions were implemented using the online survey tool “Bristol 
Online Surveys” (www.survey.bris.ac.uk), in order to enable an email-directed survey 
approach. As already previously discussed, two parties are involved within the prescription 
process – the doctor, as the prescribing decision-maker, and the pharmacist, as the involved 
party that usually provides the medical drug to the patient (consumer), but also might change 
the prescription (substituting by another brand). Doctors (costumers) were segmented 
according to their vocational specialisation (general practitioner; internal medicine; 
cardiology; diabetology; endocrinology).  
In the third step, the survey was prepared for distribution among pharmacists and doctors 
(costumers). For this purpose the Swiss Professional Society of Doctors (costumers) 
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(www.fmh.ch) and the Swiss Pharmacist Association (www.pharmasuisse.org) were 
contacted in order to provide support for the distribution. However, the medical association 
refused participation, but the pharmacist association agreed to distribute the survey (80 
potential participants). Consequently, an alternative distribution channel had to be found. The 
online questionnaire was then distributed via the Swiss market research agency “Pharma 
Agentur” (www.pharmaagentur.ch), located in Baar (Zug), Switzerland, and reaching 6,000 
medical doctors (costumers). The mail that was distributed is shown in Appendix 10. In order 
to motivate the participants to return the questionnaire, a prize draw was arranged. The data 
collection was done over a two-week period. This resulted in a total of 165 completed 
questionnaires (15 pharmacists, response rate 19%; 150 doctors (costumers), response rate 
2.5%) and 77 incomplete questionnaires. According to a market researcher from “Pharma 
Agentur”, a low response rate is quite common among medical doctors (costumers). This can 
also be supported by the literature (Asch et al., 1997; Amerimedconsulting, 2010). However, 
the response rate is also highly dependent on institutional reputation, as described by Sloan et 
al. (1997). Within the sample of participants, 29% were female, 71% male, 45% of the 
answering doctors (costumers) were general practitioners (costumers) and 44% internal 
medicine. A total of 22% of the participants were from the Zurich region, 16% from the Berne 
region and 10% from St. Gallen as well as Aargau. Furthermore, most of the answering 
participants had lengthy vocational experience (more than 20 years for 41%; 16-20 and 11-15 
of 18%). Within one week, 71% of the responses were given.  
 
5.4. Organisation and Development of the Dataset 
These market data were delivered in 12 Excel files and presented in different organisational 
structures, as well as numeric and time formats. An overview of the delivered data files is 
shown in Appendix 10. This information had to be transformed and merged into a SPSS-
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readable format. One challenge was that sales (revenue) data were provided on a weekly 
basis, whereas marketing expenses were on a quarterly basis. Consequently, marketing 
expenses had to be recalculated for a weekly basis. For this purpose the weekly average was 
taken. The merging and transformation of a vast amount of data, organised in rows containing 
partly incomplete information into columns, had to be performed in a cautious manner to 
ensure that no information was missed out or mixed up. For this purpose, the data had to be 
cleaned and checked for missing details and outliers. Specific Excel program routines 
(macros, small programmable software routines) were created and the finalised dataset was 
double checked. Missing data were left blank and outliers indicated. However, because the 
market data only covered sales (revenue), marketing and packaging information, not product 
features, additional data had to be gathered from alternative sources. Data on product features 
such as daily drug dosage were acquired from the WHO Centre for Drug Statistic 
Methodology (www.whocc.no). These data are freely available and can be easily downloaded 
from the website. In addition, data about drug interactions and the side-effects profile were 
taken from a database provided by Swiss prescription drugs approval authorities 
(www.kompendium.ch). For this purpose, the freely available information leaflet for every 
medical drug was downloaded and the numbers of described drug interactions, as well as 
side-effects, were counted. As already previously indicated, strict confidentiality was a 
requirement for the usage of these data provided by IMS. As a result, no actual figures can be 
published (i.e. as raw spreadsheet data), so substance, product name and medical drug class 
data have been coded accordingly (please see Appendix 11). However, the actual research is 
not affected by this restriction, because these data are only used for model testing and 
therefore do not need to be presented as raw data. 
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5.5. Descriptive Analysis of Individual Scales  
The market dataset contains five medical drug classes in total: (1) Beta Blockers, (2) ACE 
Inhibitors, (3) Angiotensin II Antagonists, (4) PDE5-Inhibitors and (5) Statins. A short 
description of these medication classes is now given: 
Beta Blockers: The market dataset of Beta Blockers [ATC Code (Anatomical Therapeutic 
Chemical Classification System): C07A, Beta Blocking Agents] contains eight 
pharmaceutical substances and 25 medical products in total. 
ACE Inhibitors: The market dataset of ACE inhibitors (ATC code: C09A plain; C09B 
combinations) contains eight pharmaceutical substances and 30 medical products in total. 
Angiotensin II Antagonists: The market dataset of Angiotensin II Antagonists (ATC code: 
C09C, plain) contains six pharmaceutical substances and 10 medical products in total. 
PDE5 Inhibitors: The market dataset of the therapeutic category phosphodiesterase type 5 
inhibitors (PDE5 inhibitors) (ATC code: GO4B3) contains six pharmaceutical substances and 
60 medical products in total.  
Statins: The market dataset of Statins (ATC code: C10A, plain) contains five pharmaceutical 
substances and 20 medical products in total. It has to be noted that the therapeutic category of 
Statins (members of the lipid lowering class) has been available since the late 1980s. 
Therefore, no order-of-entry data are available for this medical drug category. 
In order to prepare these data for statistical analysis, it was necessary to perform a test for 
normality and to examine the characteristics of the variables, in order to determine if these 
measures were appropriate for further use in hypothesis testing applications. The examination 
focused on the distributional characteristics of the measures, including a search for significant 
outliers, and the statistical testing of distributions (including frequency, interval, mean, 
variance, median, and standard deviation). For this purpose, graphical techniques were used to 
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gain a basic picture of each measure’s distribution. According to Rovezzi (2002), a normal 
distribution on a 99% confidence level is not present if the z-score is larger than +/- 2.58. For 
skewness, the z-score is derived from “skewness / SQRT (6/n)”, and for kurtosis by “kurtosis 
/ SQRT (24/n)” (see also Fields, 2005). 
 
5.5.1. General Model Variables 
5.5.1.1. Order-of-Entry  
This measure indicates the order-of-market entry of a specific product within a specific 
medical drug class. However, the order-of-market entry is not available for Statins because 
none was introduced between 1995 and 2005, i.e. all drugs were already on the market by 
1995. It has to be noted that the ordinal order-of-market entry variable has been treated as an 
interval variable in the literature (see Kalyanaram et al., 1995, 1992). This is an acceptable 
practice, as stated by Winship and Mare (1984, p517), and ‘one solution to this problem is to 
assume that the ordered categories constitute a continuous scale’ (see also Stevens, 1946; 
Knapp, 1990). Furthermore, it has been highlighted by Knapp (1990, p121) that there are ‘no 
agreed-upon rules for determining whether a particular scale is ordinal, less than ordinal, or 
more than ordinal resulting in a controversial discussion taking place in scientific literature, 
the so-called Stevens controversy’ (see also Stevens, 1946). The following statistical 
characteristics were calculated, despite the controversial views of researchers about their 
relevance (see also Knapp, 1990): arithmetic mean = 9.663; median = 9.0; mode = 5; standard 
deviation = 5.982; variance = 35.779; range = 22. Furthermore, no missing values were found. 
Figure 5-1 (see Appendix 14) shows the frequency distribution. As evident, a skew towards 
the higher values is present. A skewness (0.521; zS = 1.972) and kurtosis (-.602; zK = -1.140) 
were calculated, which revealed that normal distribution is, according to this criterion, 
present. This is in support of Harwell and Gatti (2001, p112), who stated that ‘ordinal data are 
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not continuous and cannot be normally distributed, creating problems for many statistical 
procedures’. Consequently, as will be discussed later, a transformation procedure will be 
applied (see Paragraph 5.6.5). 
 
5.5.1.2. Sales from Factory 
This measure indicates, in Swiss francs per month, the stated real sales (revenue) for a 
specific medical drug manufacturer. These data were provided by IMS, showing the following 
statistical characteristics: arithmetic mean = 354565; median = 51068; mode = 0; standard 
deviation = 946356 with range = 7815434. Furthermore, no missing values were found. 
Figure 5-2 (see Appendix 14) shows the frequency distribution. As seen, a skew towards the 
higher values is present. A skewness (6.142; zS = 23.253) and kurtosis (46.089; zK = 87.245) 
were calculated, which revealed that no normal distribution is present. In addition, there also 
appeared to be some negative values within these data. This can be reasoned by the fact that 
some goods would have been returned to the producer on the indicated date. Consequently, as 
we shall discuss later, a transformation procedure in order to deal with the non-normal 
distributed data will be applied (see Paragraph 5.6.5).  
 
5.5.2. Product Policy Variables 
5.5.2.1. Interaction with other Drugs  
This variable indicates interactions with other drugs within the same medical drug class. The 
information was taken from medical information provided by Swissmedic 
(www.swissmedic.ch), the Swiss agency for the authorisation and supervision of therapeutic 
products (see www.kompendium.ch). The total numbers of interactions were counted and 
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listed for each medical drug. The terminology “interaction with other drugs” is described in a 
medical dictionary as follows:  
‘A drug interaction can be defined as an interaction between a drug and another substance that 
prevents the drug from performing as expected. The interaction may increase or decrease the 
effectiveness of the drugs’ (Day, 2007, p53).  
Consequently, it can be concluded that “fewer interactions” with other drugs are more 
beneficial for the therapeutic success. The following statistical characteristics were indicated: 
arithmetic mean = 14.374; median = 14; mode = 14; standard deviation = 5.261 with  
variance = 27.676; range = 30; skewness = 1.233 (zS = 4.668); kurtosis = 2.875 (zK = 5.442).  
Figure 5-3 (see Appendix 14) shows the frequency distribution. It has to be concluded that no 
normal distribution is present. Consequently, as discussed later in Paragraph 5.6.5., a 
transformation procedure in order to deal with the non-normal distributed data will be applied. 
 
5.5.2.2. Number of Side-effects 
This variable indicates the side-effects of the given medical drug in regard to other drugs 
within the same medical drug class. Again, this information is taken from medical 
information provided by Swissmedic. The total numbers of side-effects were counted and 
listed for each medical drug. The terminology “side-effects” is described in a medical 
dictionary as follows:  
‘An adverse effect may be termed a “side-effect“ when judged to be secondary to a main or 
therapeutic effect. Adverse effects may cause complications of a disease or procedure and 
negatively affect its prognosis. They may also lead to non-compliance with a treatment 
regimen’ (Day, 2007, p196). 
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Consequently, it can be stated that fewer “side-effects” are more beneficial for therapeutic 
success. The following statistical characteristics were indicated: arithmetic mean = 68.639; 
median = 553; mode = 107; standard deviation = 34.925 with variance = 1220;  
skewness = 0.434 (zS = 1.643); kurtosis = -.961 (zK = -1.819). Figure 5-4 (see Appendix 14) 
shows frequency distribution. Taking the descriptive analysis into account, it has to be 
concluded that no normal distribution is present. Consequently, a transformation procedure in 
order to deal with the non-normal distributed data will be applied (see Paragraph 5.6.5). 
 
5.5.2.3. Perceived Quality 
This variable (range 1 to 9) indicates the efficacy of a specific medical drug as perceived by 
prescribers (costumers) in relation to other medical drugs within a specific drug class. At this 
point it should emphasised, as stated by Jamieson (2004, p1217), that ‘it has become common 
practice to assume that Likert-type categories (Likert, 1993) constitute interval-level 
measurement’ (see also Stevens, 1946 and Knapp, 1990). This information was gathered via a 
survey that was designed especially for this purpose. All rankings given for each substance by 
the participants were then added and mean average calculated, leading to the perceived 
quality figure. The following statistical characteristics were indicated: arithmetic mean = 
4.379; median = 4.537; mode = 4.537; standard deviation = 0.544; variance = 0.296; range = 
3.596; skewness = -2.429 (zS = -4.598); kurtosis = 9.989 (zK = 37.818). Figure 5-5 (see 
Appendix 14) shows the frequency of distribution. Taking the descriptive analysis into 
account, it has to be concluded that no normal distribution is present. As a result, a 
transformation procedure in order to deal with the non-normal distributed data will be applied 
(see Paragraph 5.6.5). 
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5.5.2.4. Packaging Alternatives 
The variable package size was derived from the number of available package sizes. This 
information on the number of portions and dosage was provided by IMS. The following 
statistical characteristics were indicated: frequency = 109 (number of products); arithmetic 
mean = 4.12; median = 4.0; mode = 4; standard deviation = 1.418; variance = 2.010;  
range = 6; skewness = -.058 (zS = -0.220); kurtosis = 0.514 (zK = 0.973). Figure 5-6 (see 
Appendix 14) shows the frequency distribution. Taking the descriptive analysis into account, 
it has to be concluded that normal distribution is present. 
 
5.5.3. Pricing Policy Variables 
As previously discussed, sales price is not driven by the market, as in other pharmaceutical 
arenas such as the American market, but is based on a cost calculation taking into account 
distribution and production costs. The official sales price is set by the governmental authority 
(Swissmedic) based on the product’s efficacy. Furthermore, a comparison with foreign 
markets is made and therapeutic properties are considered. Consequently, pharmaceutical 
companies have limited options for implementing their own price policy.  
 
5.5.3.1. Average Price 
When analysing price, it is important to perform a price standardisation test in order to enable 
a comparison between the different substances within a medical drug class. This is because 
the absolute amount of medication may vary depending on efficacy and the medications are 
available in different dosages and packaging units, for which price neither decreases nor 
increases linearly. Consequently it is not obvious which dosing measure should be compared 
with what. In order to derive a standardised price, the actual price, provided by IMS, for one 
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day’s therapy was calculated by applying the “defined daily drug dose (DDD)” taken from the 
patient (consumer) information leaflet. The “defined daily dose (DDD)” is described by the 
“WHO Collaborating Centre for Drug Statistics Methodology (WHOCC)” as follows:  
‘A common problem when comparing drugs is that different medication can be of different 
strengths and different potency. DDD aims to solve this by relating all drug use to a 
standardized unit which is analogous to one day's worth. It is the assumed average 
maintenance dose per day for a drug used for its main indication in adults’ 
(www.whocc.no/ddd/definition_and_general_considera/). 
The formula for calculating DDDs is as follows: 
_ _ _ _ _
_ ( )
_ _
Items issued Amount of Drug per itemDrug Usage DDDs
WHO DDD Measure
 ×
=  
 
 
It appeared that price variation over the whole period (1995 to 2005) was low. An average 
price was calculated, and the following statistical characteristics were indicated: arithmetic 
mean = 42.756; median = 1.125; mode = 1.63; standard deviation = 254.343; variance = 
64690.482; range = 1762.52; skewness = 6.422 (zS = 24.313); kurtosis = 40.487  
(zK = 76.641). Figure 5-7 (see Appendix 14) shows frequency distribution. Taking the 
descriptive analysis into account, it has to be concluded that no normal distribution is present. 
Consequently, as we shall discuss later, a transformation procedure in order to deal with the 
non-normal distributed data will be applied (see Paragraph 5.6.5). 
 
5.5.4. Promotion Policy Variables 
The dataset contains marketing promotion index (MPI) data (see also www.imshealth.ch), 
thus enabling the analysis of marketing efficacy. The MPI contains data on three promotional 
marketing instruments: (1) personal selling expenditure, (2) expenditure for a physician 
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(costumer)’s targeted direct mailings and (3) professional advertising expenditure for 
magazines ads. It should be noted that sampling expenses and personal selling expenses are 
included, and therefore they cannot be tested separately. Furthermore, the market data do not 
distinguish between direct-to-physician (costumer) (DTP) directed expenditure and direct-to-
opinion leaders as well as word-of-mouth directed marketing expenditure. In addition, the 
MPI enables the evaluation of promotional activities regarding a specific product, as well as 
the market and the producer, and shows standardised expenses. The data, provided by IMS, 
cover the sales channels ‘pharmacy’ and ‘self-dispensing physicians (costumers) of 
prescription medicines’ for the period 1995 to 2005.  
 
5.5.4.1. Personal Selling Expenditure 
This variable shows monthly personal selling (detailing) expenditure in Swiss francs. The 
following statistical characteristics were indicated: arithmetic mean = 994954; median = 
60231; mode = 0; standard deviation = 2416250; variance = 5.838E12; range = 12276116; 
skewness = 2.994 (zS = 11.335); kurtosis = 8.887 (zK = 16.823). Figure 5-8 (see Appendix 14) 
shows the frequency distribution. Taking the descriptive analysis into account, it has to be 
concluded that no normal distribution is present. As a result, a transformation procedure in 
order to deal with the non-normal distributed data will be applied (see Paragraph 5.6.5). 
 
5.5.4.2. Mailing Expenditure 
This variable shows monthly mailing expenditure in Swiss francs. The following statistical 
characteristics were indicated: arithmetic mean = 58816; median = 7007; mode = 0; standard 
deviation = 138984; variance =1.932E10; range = 665920; skewness = 3.055 (zS = 11.566); 
kurtosis = 8.930 (zK = 16.904). Figure 5-9 (see Appendix 14) shows the frequency 
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distribution. Taking the descriptive analysis into account, it has to be concluded that no 
normal distribution is present. 
 
5.5.4.3. Advertising Expenditure 
This variable shows monthly advertising expenditure in Swiss francs. The following statistical 
characteristics were indicated: arithmetic mean = 289239; median = 9306; mode = 0; standard 
deviation = 7.93933E5; variance = 6.303E11; range = 4939089; skewness = 4.104  
(zS = 15.537); kurtosis = 18.435 (zK = 34.897). Figure 5-10 (see Appendix 14) shows the 
frequency distribution. Taking the descriptive analysis into account, it has to be concluded 
that no normal distribution is present. Consequently, a transformation procedure will be 
applied (see Paragraph 5.6.5). 
In summary it can be said that none of the data show a normal distribution that is acceptable 
according to the requirement set by the skewness and kurtosis test. A non-normal distribution 
can be a quite critical issue regarding the robustness of statistical results. Consequently, this 
has to be taken into consideration when analysing the data. Some specific methodological 
approaches will have to be applied in order to be able to deal with these skewed data. Within 
the next sections, an in-depth description and justification of the applied methodology will be 
given.  
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5.6. Data Analysis  
In this section, a descriptive analysis exploring the data will be performed. A structure 
analysis will then be conducted, leading to actual statistical analysis using multiple regression.  
 
5.6.1. Data Exploration 
In the first step, a sales-time diagram of two markets was produced in order to investigate 
patterns within the given data. This provided a first impression of the data and facilitated the 
planning of further analysis. As will be shown later, a relevant conclusion was derived that 
fundamentally guided the design of the analysis. In addition, practical aspects such as data 
handling could be explored as well. For this purpose, data from two markets (drug classes), 
ATIIR Antagonists and Statins, were explored further. The selection criteria for choosing 
these categories were: general practitioner’s wide usage of these prescription drugs, a 
minimum of five drugs within the class and the availability of market share data. Data points 
containing missing values were removed completely from the dataset. The skewness of the 
data is irrelevant for the descriptive analysis.  
First, a descriptive analysis of the effect of order-of-market entry on sales (revenue) for the 
ATIIR antagonists market was performed. The data are limited to distribution channels for 
pharmacies and endocrinologists from 1995 to 2005. The data of the most applied 
medications within two therapeutic classes were applied. As illustrated in Figure 5-11, the 
ATIIR antagonists market demonstrated growth up to 2005.  
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Figure 5-11: Sales of ATIIR-antagonists 
 
For sales (revenue) volume, the curves show that, for each drug, good performance during the 
launch phase (see Figure 5-11) is decisive. After that, there is, for gamma and epsilon, usually 
not a very high increase in sales (revenue) volume. However, two medical drugs (ATTIR-
alpha, delta) show especially different behaviour. The market pioneer (ATIIR-gamma) was 
absolutely outperformed by ATIIR-alpha. In 2004, ATIIR-alpha reached a high share and was 
the clearly market leader. In the same year, ATIIR-delta enjoyed higher sales (revenue) 
volume than ATIIR-gamma as well. In a second step, the Swiss Statins market for 1995 to 
2005 will be explored (see Figure 5-12).  
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Figure 5-12: Sales of Statins 
 
The Statins market reached its height in 2004 and collapsed for some of the drugs thereafter, 
which can be linked to the patent expiration of statin-gamma and statin-beta. Statin-gamma 
continually shows rising sales (revenue) volume and was seen as the absolute (2002) market 
leader. While statin-gamma had a high market share in 1995, it declined in 2005 (see Figure 
5-12). 
These descriptive statistics demonstrate that the order-of-market entry effect, as suggested by 
theory (see also Chapter 2), does not appear here, as illustrated in Figures 5-11; 5-12. In both 
cases, a later entrant managed to overtake the first entrant, which raises the need to ask what 
caused this observed behaviour. Furthermore, there are different slopes of sales (revenue) 
curves and different sales increases/decreases within the same time period. The observation of 
different slopes is not present in the marketing scientific literature. However, in economics, 
the idea of beta (slope) as a decisive factor is widely used. The slope is a relevant factor in the 
theory of price elasticity of demand (see also Arnold, 2008). Elasticity can be defined as the 
inversion of beta (Elasticity = 1 / Beta). Consequently, the implementation of an additional 
variable as an indicator for the slope (Beta value), in addition to the existing dependent 
“average sales (AS)” variable, is suggested.  
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5.6.2. Analysis of the Data Structure  
Previously, a conceptual model was developed, a dataset presented and a descriptive analysis 
performed. In the following section, an analysis strategy will be designed and the formal 
hypotheses tested.  
The data analysis revealed a hierarchical data structure. Within a medical drug class (in our 
case, five), multiple substances are applied (37). Some of the brands (in total 108) use the 
same substance (multiple brands can use the same substance, e.g. Paracetamol). Therefore, a 
two-level structure, containing a brand (first) and a substance (second) level, is suggested. 
The substance level includes “perceived quality (PQ)”, “drug interaction (IA)”, and “drug 
side-effects (SE)”. These data only refer to a specific substance, and there is no dependency 
on a specific brand (multiple brands can use the same substance, e.g. Paracetamol). The brand 
level, on the other hand, contains the “order-of-market entry (OE)”, “number of package 
alternatives (PA)”, “average price (AP)” and “marketing expenditure (MA)” as independent 
variables, whereas “sales” results in a dependent variable, as shown in the following 
illustration (see Figure 5-13): 
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Figure 5-13: Visualisation of the data structure 
 
5.6.3. Preparation of Data 
In order to proceed with the analysis, the data were transformed into a specific format. For 
this purpose, relevant information on every medical product, indicating the “drug class code 
(DC)”, “substance code (SC)”, “brand name code (BN)”, “perceived quality (PQ)”, “order-of-
market entry (OE)”, “number of packaging alternatives (PA)”, “application range (AR)”, 
“number of drug interactions (IA)”, “number of side-effects (SE)” was collated on an Excel 
spreadsheet. In addition, the “total detailing expenditure (DE)” in Swiss francs, “total mailing 
expenditure (ME)”, “total advertising expenditure (AE)”, the “average daily drug dose (DDD) 
price (AP)”, the “average of product sales (AS)” (total sales (revenue) divided by time period 
(time)), “beta of sales (BS)” (slope of quarterly sales expenditure (derived with SPSS, using 
linear regression function)) were calculated. This resulted in a dataset containing 86 data 
points on the brand level (first level). 
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5.6.4. The Analysis Strategy 
There is no single best way to analyse a multi-level structure. As stated by Harrell (2001), the 
individual steps that a researcher should take in building a model are based on the 
investigator’s research questions, whether the analysis is explanatory or confirmatory and 
whether the analytic emphasis is on parameter estimation, model fit or prediction.  
In order to test the presented model (see Figure 5-13), a hierarchical linear model (HLM), also 
called a random coefficient model (see also Leeuw and Kreft, 1986; Longford, 1993), was 
considered. This methodology seemed especially suitable because, as indicated by Kozlowski 
and Klein (2000), the nesting of micro- and macro-level phenomena is taken into account, as 
well as macro-level effects that occur through interactions with micro-level elements 
(Kozlowski and Klein, 2000). Consequently, according to Goldstein (1995), the major 
advantage of the HLM is the possibility to link multiple levels simultaneously in a single 
regression equation. However, according to most researchers (Hox and Maas, 2002; Wieseke 
et al., 2008), there is a minimum sample size per level and group in order to run an HLM. A 
rule of thumb recommends a minimum of 30 samples per group (Bell et al., 2008; Hox and 
Maas, 2002; Moineddin et al., 2007). Unfortunately, the present data do not fulfil this 
requirement. It also has to be stated that, because of the nature of these data (secondary data 
for the entire market), the sample size cannot be expanded (additional data added), as there 
are no additional data available. Furthermore, an HLM test run confirmed the instability of the 
results when using this dataset. Taking structural reasons into account, these data cannot be 
altered and they do not fulfil the requirement of a minimum sample size. However, the 
advantage of using a secondary dataset containing an amount of marketing-relevant 
information is that it can only be collected by a professional marketer, which outweighs the 
disadvantages of using a more appropriate method for the analysis of multi-level structures 
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such as HLM. As a result, an HLM analysis cannot be applied. Consequently, a multiple 
regression analysis will be conducted. 
A multiple regression analysis is defined by Hair et al. (1998, p20) as ‘a general statistical 
technique used to analyse the relationship between a single dependent variable and several 
independent variables’. In other words, it can be said that multiple regression is only able to 
test hypotheses regarding a single dependent variable. This means that the complete 
conceptual model hypothesised in Chapter 4 cannot be tested all at once, so multiple models 
must be examined instead. In this case, the application of regression analysis is viewed as the 
best strategy for testing the given conceptual model. In the next sections, this analysis strategy 
is developed and then performed.  
 
5.6.4.1. Assumption of Multiple Regression 
In order to be able to use multiple regression, a couple of requirements for the data are given. 
It is especially relevant that the statistical independence of observations, normality and linear 
relationships between the dependent and independent variables, and the equality of variance 
(homoscedasticity), is present (see also Hair et al., 1998; Kleinbaum et al., 1998). Several 
diagnostic statistics and diagrams were produced to identify outliers and to analyse the 
violation of assumptions, multicollinearity and the power of the test (see also Hair et al., 
1998; Kleinbaum et al., 1998; Kaplan, 1995). The assumptions of normality, linearity and 
homoscedasticity where examined using graphical techniques (see also Hair et al., 1998; 
Kleinbaum et al., 1998). Nevertheless, for the data collection process, as previously described, 
the statistical independence of the observations can be assumed.  
According to Osborne (2002), a serious violation of the assumption of normality can affect a 
result. Furthermore, it has to be pointed out that, according to Micceri (1989), it is not unusual 
that data are not distributed normally within the fields of psychology and education. For this 
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case, the literature suggests a data transformation procedure (see also Backhaus et al., 2003; 
Hair et al., 1998; Hartwig and Dearing, 1979; Osborne, 2002). However, Kleinbaum et al. 
(1998, p117) stated that ‘only extreme departures from normality lead to spurious results’. 
Furthermore, in addition to individual univariate normality, multivariate normality should be 
assessed. Even when all individual univariate distributions are normal, it is not necessary true 
that multivariate distribution is going to be normal (Hair et al., 1998; Sharma 1996). 
However, as stated by Kleinbaum et al. (1998), multiple regression is quite robust against 
departures from the assumption of homoscedasticity. This statement is also supported by Hair 
et al. (1998), who concluded that it is not very critical for the reliability of multiple regression 
analysis results when the assumption of normal distribution does not take place.  
Within marketing management, the assumption of a linear relation between dependent and 
independent variables is commonly made (see also Kotler and Keller, 2006). Consequently, 
because of lack of contrary evidence, all relationships are hypothesised as being linear. 
Finally, because of the way this research is designed, taking into consideration the design of 
the data collection method, independence can be assumed. 
According to Kleinbaum et al. (1998), outliers might have a negative influence on the 
multiple regression analysis outcome, which can be reasoned by the fact that outliers may 
negatively influence normal distribution. The deletion of outliers is controversial in the 
literature (see also Barnett and Lewis, 1994), since it might influence the results of the 
statistical analysis. However, based on the reason for outliers such as errors in answering 
questions, as well as data imputation errors, deletion might be justified. Unfortunately, there 
is no generally applicable strategy on how to deal with outliers (see also West et al., 1995). A 
range of statistical methods available on SPSS can be applied in order to identify possible 
outliers. The indicated outliers can be justified. They have not been caused by a measurement 
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or data handling error. However, the fact that outliers have been removed needs to be 
considered when statistical results are interpreted. 
Another issue that has to be taken into account is multicollinearity. As stated by Kleinbaum et 
al. (1998), multicollinearity takes place when there is a significant correlation between 
independent variables in a regression model. Consequently, it is difficult to separate the 
effects of each independent variable, which results in unstable statistical results (see also 
Cohen and Cohen, 1975; Kleinbaum et al., 1998). One approach employed to tackle this 
problem is the deletion of one of the collinear variables or transforming collinear variables 
(see also Cohen and Cohen, 1975).  
 
5.6.5. Operationalisation of the Multiple Regression Analysis 
In this section, an analysis of the multi-level structure will be performed, using multiple linear 
regression. In order to test the previously presented hypotheses, a set of multiple regression 
equations is produced. Every equation is then examined for violation of the assumption, as 
already discussed in Paragraph 5.6.  
 
5.6.5.1. Data Preparation and Assumption Test 
A test for multicollinearity was performed, during which tolerance values and their variance 
inflation factors were examined. According to Kleinbaum et al. (1998), problematic 
multicollinearity can be indicated by tolerance values below 0.1 and variance inflation factors 
above 30. Based on the above, multicollinearity between “advertising expenditure (AE)” 
(tolerance = 0.138; variation inflation = 7.261); “detailing expenditure (DE)”  
(tolerance = 0.064; variation inflation = 15.591) and “mailing expenditure (ME)”  
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(tolerance = 0.1; variation inflation = 10.018) was detected. There is also a quite high 
correlation between these factors, as illustrated in the following table (see Table 5-1). 
   DE ME AE 
DE Pearson Correlation 1.000 .943 .921 
  
Sig. (2-tailed)   .000 .000 
ME Pearson Correlation .943 1.000 .883 
  
Sig. (2-tailed) .000   .000 
AE Pearson Correlation .921 .883 1.000 
  
Sig. (2-tailed) .000 .000   
Table 5-1: Marketing variable correlations 
 
Therefore, these variables were combined by adding up the values and then calculating the 
monthly average. This resulted in the single marketing variable “average marketing 
expenditure (AM)”. Consequently, the hypotheses H7a, H7b and H7c cannot be tested and 
will therefore be removed from the proposed model. In a next step, the data were checked for 
outliers and missing data. Five outliers from the “average price (AP)” variable, and one 
outlier from the “average sales (AS)” (total sales (revenue) divided by time period (time)) and 
“perceived quality (PQ)” were removed. Furthermore, because the sales (revenue) data of five 
products had only one data point, “beta sales” (slope of quarterly sales expenditure (derived 
with SPSS, using the linear regression function) could not be calculated, which led to five 
missing values (5.8%). The “application range (AR)”, “drug interaction (IA)” and “side-
effects (SE)” variables contained three missing values (3.4%). In addition, five missing values 
(5.8%) for “average marketing expenditure (AM)” were found. The indicated outliers can be 
justified. They were not caused by a measurement or data handling error; instead, they were 
missing due to th unavailability of data. These data can therefore be characterised as MAR 
(missing at random) values. This means that whatever caused the data to be missing does not 
depend upon the missing data itself (Little and Rubin, 2002). Consequently, there are no 
restrictions given when replacing these data with an estimated value, as described in the 
following section. 
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The handling of missing values is quite challenging. SPSS has single imputation approaches 
such as mean value and regression substitution. However, several authors such as Graham 
(2009), Howell (2007) and Schafer (1997) do not recommend the use of these methods 
because of their weaknesses (altering of the correlation coefficient). Instead, the EM 
algorithm (multiple imputation) is recommended (Graham, 2009; Little and Rubin, 2002; 
Schafer, 1997). These researchers highlight that multiple imputations are suitable because it 
has been shown that they produce unbiased parameter estimates and they are robust to 
departures from normality assumptions and provide adequate results in the case of a small 
sample size. For this purpose, the freely available software for multiple imputation NORM 
(see also Pennsylvania State University homepage: sites.stat.psu.edu) was applied (see also 
Schafer, 1997). The missing values were replaced by estimates derived from the NORM 
routine. It has to be added that the low number of missing values (below 5%) can be viewed 
as statistically insignificant (see also Howell, 2007; Little and Rubin, 2002).  
In a second step, a transformation, in order to reach normality, was performed. In the 
literature (Backhaus et al., 2003; Hair et al., 1998; Hartwig and Dearing, 1979; Osborne, 
2002), three different transformation procedures are suggested: (1) square root transformation, 
(2) logarithmic transformation and (3) inverse transformation. It is suggested that a minimum 
amount of transformation, beginning with the square root transformation, should be applied, 
in order to improve normality (Osborne, 2002). In this case, the logarithmic transformation 
using e as the base was viewed as being appropriate because this function has shown the best 
results regarding improvement towards normal distribution. It should be added that a higher 
base tends to pull extreme values more drastically than a lower base (Cleveland, 1984). 
Transformation improves normality by reducing the distances between data points. However, 
Osborne (2002) states that all data points remain in the same relative order as they were prior 
to transformation, which allows researchers to continue to interpret results in terms of 
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increasing scores. The transformation resulted in a significant improvement of normality, as 
illustrated in the following table (see Table 5-2): 
Variable Skewness z-Score Kurtosis z-Score Comments 
PQ -1.076 -4.074 1.297 2.455 improvement was reached 
OE 0.521 1.973 -0.602 -1.139 normally distributed 
PA -0.058 -0.220 -0.644 -1.220 normally distributed 
IA 0.363 1.374 1.072 2.029 normally distributed 
SE 0.344 1.302 -0.802 -1.518 normally distributed 
AM -0.146 -0.553 -0.659 -1.247 normally distributed 
AP 0.493 1.866 2.427 4.594 improvement was reached 
AS 0.251 0.950 -0.205 -0.388 normally distributed 
BS -1.536 -5.815 0.893 1.690 improvement was reached 
Table 5-2: Normality test results 
 
Since, with a multi-level data structure, an analysis using multiple regression needs to be 
conducted for every single level separately, the data have to be aggregated for the second 
level, as suggested by Hox (2010). For the data aggregation of the second level (substance), 
first-level (brand) data were taken and their average value for every single substance was 
calculated. This resulted in a reduced dataset (initially 86 data points) containing 26 data 
points on the second level. The data were then standardised on SPSS, which resulted in an 
overall average of zero and a standard deviation and variance of one.  
Regarding sample size, the market data can be considered as being complete for the 
previously (see Paragraph 5.5) described five drug classes. Consequently, these five drug 
classes were defined as the overall population size (100%) in the current research (containing 
108 brands and 37 substances). Taking into account that an expected sampling frequency of 
50% [for samples providing the required precision levels, if unknown, a value of 50% is taken 
(Rovezzi, 2002)] could be assumed, a calculation of sample size has revealed that for the 
brand level (confidence level 95%, confidence interval 5%)9, a minimum number of 84 data 
                                                 
9
 The confidence interval is described by Furlong et al. (2000, p63) as a ‘range of values, bounded by the upper 
and lower confidence limits, that is likely, at a specific level of probability (known as the confidence level), to 
contain the population parameter. A confidence interval is built around the value of a sample statistic, which 
serves as our best estimate of the population parameter’. 
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points is required [The determination of the sample size is described by Armitage et al. 
(2002); The sample size can also be determined using an online calculation tools: e.g. 
www.macorr.com/sample-size-calculator.htm]. For the substance level, a minimum 26 data 
points are required (confidence level 95%, confidence interval 10%) (please refer also to the 
statistical literature, Backhaus et al., 2003; Lenth, 2001). It can be therefore concluded that, 
regarding sample size, this dataset provides a robust basis for a statistical analysis. 
 
5.6.5.2. Multiple Regression Model Definition 
In this section, a multiple regression model was created by taking the findings from the 
previously performed data structure analysis, as well as the earlier hypothesised factor 
relations, into account. Furthermore, Paragraph 5.6.1 concluded that the slope of the sales 
[“beta sales (BS)”] should be investigated as an additional independent variable. This was 
also taken into account when creating the multiple regression models, as discussed later. 
Consequently, for each level [(A) “average sales (AS)” and (B) “beta sales (BS)” as 
dependent variables], two models were created.  
 
5.6.5.3. Regression Model Selection Method and Power 
A number of different model selection methods are described in the literature (see also 
Kleinbaum et al., 1998). Independent variables are chosen by model selection methods such 
as forwards, backwards, stepwise and simultaneous entry (see also Hair et al., 1998; 
Kleinbaum et al., 1998). However, it has been noted that stepwise entries are potentially 
problematic and should only be used for entirely predictive rather than explanatory models 
(Hair et al., 1998; Cohen and Cohen, 1975). Consequently, taking into account that the 
purpose was to test hypotheses and not to predict any dependent variables, simultaneous entry 
methods were applied. 
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5.6.5.4. Multiple Regression Analysis of the First Level Model  
with Average Sales (A1) 
In this section, the actual analysis will be performed and their results discussed. The 
hypothesised antecedents to average sales (revenue) and their expected direction of influence, 
as well as their hypotheses and its support by the statistical analysis (please see also Chapter 
6), are shown in Table 5-3. 
Hypotheses Independent Variable Expected Direction of Relationship 
(Sales) 
Support of 
Hypotheses 
H1 Order-of-market Entry (OE)  - N 
H2 Drug Interaction (IA)  - Y 
H3 Drug Side-effects (SE)  - N 
H4 Perceived Quality (PQ)  + Y 
H5 Packaging Alternatives (PA) + N 
H6 Average Price (AP)  - N 
H7 Average Marketing 
Expenditure (AM)  
+ Y 
Table 5-3: Hypothesised independent variables of average sales 
 
In order to test these variables for multicollinearity10, tolerance values  
(all above 0.658 > 0.1) and variance inflation factors (all below 1.519 < 30.0) were calculated 
by entering them simultaneously into the regression equation (see also Hair et al., 1998; 
Kleinbaum et al., 1998; Kaplan, 1995). The results did not display any obvious problems. The 
following first-level model using average sales (revenue) as a dependent variable was then 
investigated applying the multiple linear regression function on SPSS (see Table 5-4): 
ASi = β0 + β1*(OEi) + β2*(APi) + β3*(PAi) + β4*(AMi) + β5*(PQi) + β6*(IAi) + β7*(SEi)  
Whereas, in the regression equation, “average sales (AS)” is the dependent variable, the 
independent variables “order-of-market entry (OE)”, “average price (AP)”, “number of 
                                                 
10
 ‘When two predictor variables are highly correlated with each other, the analysis may misleadingly indicate 
that only one of those predictor variables significantly contributes to the prediction of the criterion variable’ 
(Furlong et al., 2000, p11). 
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packaging alternatives (PA)”, “average marketing expenditure (AM)”, “perceived quality 
(PQ)”, “drug interaction (IA)” and “drug side-effects (SE)” were loaded with factors β1 to β7. 
Furthermore, the intercept β0 was introduced.  
Multiple R = 0.551   R2 = 0.330   Adjusted R2 = 0.241   F = 4.854 (Sig. 0.000; Fcritical = 2.129) 
Independent Variable Beta t Sig. Hyp. 
Order-of-market Entry (OE) -0.083 -0.798 0.427 H1 
Drug Interaction (IA) 0.092 0.932 0.354 H2 
Drug Side-effects (SE) 0.103 0.943 0.349 H3 
Perceived Quality (PQ) 0.075 0.746 0.458 H4 
Packaging Alternatives (PA) 0.114 1172 0.245 H5 
Average Price (AP) 0.210 1.804 0075 H6 
Average Marketing Expenditure (AM) 0.423 4.147 0.000 H7 
Table 5-4: Results of the first-level multiple regression A1 model 
 
The results derived an adjusted R2 of 0.241. This means that 24.1% of the variance can be 
explained by the elements of the equation and that the independent variables are related by 
24.1% to the dependent variable. The rather low number can be justified by the complex 
nature of the sales process (see also Cohen and Cohen, 1975). It has to be noted at this point 
that other studies within sociology, having conducted regression analysis, have also derived 
similar variance values (see also McKee et al., 2001; Wild et al., 2004). The equation is 
significant (sig = 0.000) and the F-value (4.854; explained variance divided by unexplained 
variance) is above the calculated critical F-value (2.129). For H6, support for this hypothesis 
could be found (beta = 0.114; sig = 0.075). For H7, strong support can be afforded by the 
results (beta = 0.423; sig = 0.000). This means that an increase in “average marketing 
expenses (AM)” will lead to higher sales (revenue). This is supported by previous research, as 
discussed in Chapter 2. Moving to product property variables, it can be seen that H2 to H5 do 
not find support. In other words “side-effects (SE)”, “drug interaction (IA)”, “perceived 
quality (PQ)” and “packaging alternatives (PA)” do not influence the prescribing decision. 
This seems to be quite surprising, especially because it is in disagreement with the literature 
discussed in Paragraph 2.6. Furthermore, H1 also did not find any support. This is not what 
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one would expect according to the theory discussed in Paragraph 2.5. However, it was 
revealed by the descriptive data analysis (see Paragraph 5.4) that there is variation between 
actual sales (revenue) and order-of-market entry. These results and their implications will be 
discussed in the next chapter. 
In a next step, a test for linearity and homoscedasticity11 was performed, using residual plots. 
No clear patterns could be found, so the assumption of linearity and homoscedasticity is 
applied. In order to detect the presence of autocorrelation [a relationship between values 
separated from each other by a given time lag (Bhargava et al., 1983)], a Durbin-Watson test 
derived a value of 1.979. According to the rule of thumb (see also Gujarati, 2003), the 
Durbin-Watson value should not be below 1.0. Therefore, it can be assumed that no 
autocorrelation is present and a valid statistical test can be performed. 
 
5.6.5.5. Multiple Regression Analysis of the Second-Level Model  
with Average Sales (A2) 
For the second-level (substance) multiple regression model (A2), using aggregated data, the 
variables were tested for multicollinearity. Tolerance values (all above 0.895 > 0.1) and 
variance inflation factors (all below 1.117 < 30.0) were calculated by entering them 
simultaneously into the regression equation (see also Hair et al. 1998; Kleinbaum et al., 1998; 
Kaplan, 1995). The results do not display any obvious problems. In a next step, the model, 
containing only level two (substance)-relevant variables, was investigated by applying the 
multiple linear regression function on SPSS (see Table 5-5).  
 
 
                                                 
11
 ‘In regression analysis, we see a situation where the amount of variance in Y (the criterion variable) remains 
constant across different values of X (the predictor variable)’ (Furlong et al., 2000, pG8)  
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Multiple R = 0.584   R2 = 0.341   Adjusted R2 = 0.255   F = 3.962 (Sig. 0.021; Fcritical=2.544) 
Independent Variable Beta t Sig. Hyp. 
Drug Interaction (IA) -0.056 -0.316 0.755 H2 
Drug Side-effects (SE) 0.423 2.364 0.027 H3 
Perceived Quality (PQ) 0.368 2.158 0.042 H4 
Table 5-5: Results of the second-level multiple regression A2 model  
 
The results produced an adjusted R2 of 0.255. This means that 25.5% of the variance can be 
explained by the elements of the equation and that the independent variables are related by 
25.5% to the dependent variable. As previously stated, the rather low number can be justified 
by the rather complex nature of the sales process (see also Cohen and Cohen, 1975). The 
equation can be considered as being significant (0.021) and the F-value (3.962; explained 
variance divided by unexplained variance) is above the calculated critical F-value (2.544). 
The results do not display any obvious statistical problems. Again, the regression statistics 
above are basically in support of the previously discussed results, as well as the theory (see 
Chapter 2). The analysis has shown that “drug side-effects (SE)” (beta = 0.423; sig = 0.027) 
and “perceived quality (PQ)” (beta = 0.368; sig = 0.042) are significantly positively related to 
the sales (revenue) slope. On the other hand, no significant relations were found for “drug 
interaction (IA)”. These results and their implications will be discussed in the next chapter. 
A test for linearity and homoscedasticity was performed, using residual plots. No clear 
patterns could be found, so the assumption of linearity and homoscedasticity is applied. In 
order to detect the presence of autocorrelation, a Durbin-Watson test derived a value of 1.963. 
Therefore, it can be assumed that no autocorrelation is present and a valid statistical test can 
be performed. 
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5.6.5.6. Multiple Regression Analysis of the First-Level Model with Beta Sales (B1) 
The third run analysed the relationship between marketing factors and the beta of sales 
(revenue) on the first level (brand), as suggested in Paragraph 5.6.1. The model was 
investigated by applying the multiple linear regression function on SPSS (see Table 5-6). 
The following equation was computed: 
BSij = β0j + β1j*(OEij) + β2j*(APij) + β3j*(PAij) + β4j*(AMij) + β5j*(PQij) + β6j*(IAij) + β7j*(SEij)  
The results produced an adjusted R2 of 0.275. This means that 27.5% of the variance can be 
explained by the elements of the equation and that the independent variables are related by 
27.5% to the dependent variable. As already stated, the rather low number can be justified by 
the rather complex nature of the sales process (see also Cohen and Cohen, 1975).  
Multiple R = 0.579   R2 = 0.335   Adjusted R2 = 0.275   F = 5.608 (Sig. 0.000; Fcritical = 2.129) 
Independent Variable B t Sig. Hyp. 
Order-of-market Entry (OE) 0.188 1.840 0.070 H1 
Drug Interaction (IA) -0.060 -0.622 0.536 H2 
Drug Side-effects (SE) -0.036 -0.335 0.738 H3 
Perceived Quality (PQ) 0.455 4.611 0.000 H4 
Packaging Alternatives (PA) 0.081 0.853 0.396 H5 
Average Price (AP) 0.052 0.458 0.648 H6 
Average Marketing Expenditure (AM) 0.217 2.176 0.033 H7 
Table 5-6: Results of the first-level multiple regression B1 model  
 
A test for multicollinearity was performed. Tolerance values (all above 0.752 > 0.1) and 
variance inflation factors (all below above 1.519 < 30.0) were calculated by entering them 
simultaneously into the regression equation (see also Hair et al., 1998; Kleinbaum et al., 1998; 
Kaplan, 1995). The equation is significant (sig = 0.000) and the F-value (5.608; explained 
variance divided by unexplained variance) is above the calculated critical F-value (2.129). 
The results do not display any obvious problems. The analysis shows that “order-of-market 
entry (OE)” (beta = 0.188; sig = 0.070), “perceived quality (PQ)” (beta = 0.455;  
sig = 0.000) and “average marketing expenditure (AM)” (beta = 0.217; sig = 0.033) are 
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significantly positively related to sales (H1, H4, H6). On the other hand, no significant 
relations were found for “average price (AP)”, “packaging alternatives (PA)”, “drug 
interaction (IA)” and “drug side-effects (SE)”. These results and their implications will be in 
discussed the next chapter. 
A test for linearity and homoscedasticity was then performed, using residual plots. No clear 
patterns could be found, so the assumption of linearity and homoscedasticity is applied. In 
order to detect the presence of autocorrelation, a Durbin-Watson test derived a value of 1.989. 
According to the rule of thumb (see also Gujarati, 2003), the Durbin-Watson value should not 
be below 1.0. Therefore, it can be assumed that no autocorrelation is present and a valid 
statistical test can be performed. 
 
5.6.5.7. Multiple Regression Analysis of the Second-Level Model  
with Beta Sales (B2) 
The fourth run analysed the relationship between marketing factors and the beta of sales 
(revenue) on the second level (substance), using aggregated data as suggested in Paragraph 
5.6.5.1. Therefore, the variables of the aggregated data were tested for multicollinearity. 
Tolerance values (all above 0.895 > 0.1) and variance inflation factors (all below  
1.117 < 30.0) were calculated by entering them simultaneously into the regression equation 
(see also Hair et al., 1998; Kleinbaum et al., 1998; Kaplan, 1995). The results do not display 
any obvious problems. In a next step, the model containing only level two (substance)-
relevant variables was investigated by applying the multiple linear regression function on 
SPSS (see Table 5-7).  
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Multiple R = 0.790   R2 = 0.625   Adjusted R2 = 0.576   F = 12.771 (Sig. 0.000; Fcritical = 2.129) 
Independent Variable B t Sig. Hyp. 
Drug Interaction (IA) -0.276 -2.056 0.051 H2 
Drug Side-effects (SE) 0.316 2.341 0.028 H3 
Perceived Quality (PQ) 0.666 5.172 0.000 H4 
Table 5-7: Results of the second-level multiple regression B2 model  
 
The results produced an adjusted R2 of 0.576. This means that 57.6% of the variance can be 
explained by the elements of the equation and that the independent variables are related by 
57.6% to the dependent variable. As already stated, the rather low number can be justified by 
the rather complex nature of the sales process (see also Cohen and Cohen, 1975). The 
equation is significant (sig = 0.000) and the F-value (12.771; explained variance divided by 
unexplained variance) is above the calculated critical F-value (2.129). The results do not 
display any obvious statistical problems. The analysis indicates that “drug side-effects (SE)” 
(beta = 0.316; sig = 2.341), “drug interaction (IA)” (beta = -.276; sig = -2.056), as well as 
“perceived quality (PQ)” (beta = 0.666; sig = 0.000), are significant related to the sales 
(revenue) slope. These results and their implications will be discussed in the next chapter. 
Finally, a test for linearity and homoscedasticity was performed, using residual plots. No clear 
patterns could be found, so the assumption of linearity and homoscedasticity is applied. In 
order to detect the presence of autocorrelation, a Durbin-Watson test derived a value of 2.122. 
According to the rule of thumb (see also Gujarati, 2003), the Durbin-Watson value should not 
be below 1.0. Therefore, it can be assumed that no autocorrelation is present and a valid 
statistical test can be performed. 
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5.7. Conclusions  
In this chapter the previously derived hypotheses were statistically tested. For this purpose 
secondary market data provided by the Swiss market research company on twelve Excel files 
containing various different formats were combined. However, product-related data were 
missing and had to be collected from additional sources. This resulted in a dataset containing 
ten research-relevant variables. In a next step, the dataset was cleaned. For this purpose, 
missing values were indicated, a check for outliers was performed and descriptive statistical 
properties such as arithmetic mean, variance, standard deviation, skewness and kurtosis of the 
dataset were calculated. Unfortunately, these tests revealed that, in most of the cases, no 
normal distribution was present.  
The data were then further explored, using descriptive statistics. This determined that order-
of-entry does not seem to take place. Furthermore, it was recognised that different sales slopes 
(beta) take place. Interestingly, it seems that this aspect has not been covered so far in 
marketing-related research, whereas it is widely used in the price-demand theory in 
economics. Consequently, it was decided to include beta sales (revenue) as dependent 
variable in the research. An analysis of the data structure revealed a multi-level arrangement, 
containing a brand (first) and substance (second) level. In order to be able to proceed with 
further analysis, this data had to be reorganised. For this purpose, the mean averages of the 
required variables per product (brand) and beta sales (revenue) were calculated, which 
produced a dataset containing 86 data points.  
For the analysis of this multi-level data structure, it was intended to use a hierarchical linear 
model (HLM). However, the dataset did not fulfil the minimum requirement of 30 samples 
per group, as noted in the literature (Bell et al., 2008; Hox and Maas, 2002; Moineddin et al., 
2007). An HLM test run also highlighted the instability of the results. It was therefore decided 
to conduct a multiple regression analysis instead.  
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The data were then prepared for analysis. A test for multicollinearity was performed, 
revealing a multicollinearity problem between three marketing variables. As a result, these 
variables were combined (all marketing expenses were added up) into one new marketing 
variable. A check for outliers and missing values was performed. It appeared that outliers 
were present and contained extreme values. Although they were justifiable, it appeared that 
these products are exceptions on the market. Since no generalisation regarding these products 
could be made, these outliers were removed. The missing values were then replaced by 
estimates derived from a multiple imputation (EM algorithm). In order to enable statistically 
robust results, normally distributed data are required. In the present case, a logarithmic 
transformation had to be conducted in order to reach normal distribution. As data analysis 
using multiple regression needs to be conducted for every single level separately, the data had 
to be aggregated (see also Hox, 2010) for the second level (substance), resulting in a dataset 
of 26 data points. However, for the second level (substance), only the relevant variables were 
included. A calculation of the sample size indicated that robust results could be derived from 
the analysis.  
Finally, the analysis was performed, calculating both levels (brand and substance) using both 
depended variables (average and beta sales). All models were tested successfully for their 
statistical robustness in the first instance. For average sales (revenue), the results showed a 
strong positive relation with “marketing expenditure (MA)” (beta = 0.752; sig = 0.000) on the 
first (brand) level and with “side-effects (SE)” (beta = 0.423; sig = 0.027) and “perceived 
quality (PQ)” (beta = 0.368; sig = 0.042) on the second (substance) level. For beta sales 
(revenue), the results indicated a strong positive relation with “perceived quality (PQ)”  
(beta = 0.463; sig = 0.000) as well as the “order-of-market entry (OE)” (beta = 0.218; sig = 
0.054) on the first (brand) level and with “side-effects (SE)” (beta = 0.316; sig = 0.028), 
“perceived quality (PQ)” (beta = 0.666; sig = 0.000) and a negative interaction with “drug 
interactions (IA)” (beta = -.276; sig = 0.051) on the second (substance) level.  
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In the next chapter, these results will be critically interpreted and the most important findings 
and contributions of this research will be established. In addition, the managerial implications 
and limitations of this work will be presented. Furthermore, some directions for future 
research will be provided.  
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6. Evaluation of the Statistical Results 
In this chapter, the hypotheses that were presented in the third chapter are investigated on the 
basis of the statistical results of the multivariate analysis that was performed in Chapter 4, in 
order to examine the conceptual model explicated in Chapter 3. The conclusions are then 
discussed and the recent scientific findings that were presented in the second chapter, as well 
as the results from the qualitative studies (focus and Delphi) shown in Chapter 3, are taken 
into account. Finally, the implications of these findings in regard to their theoretical 
implications are analysed, highlighting the study’s contribution to research on “physician-
targeting”. Based on these findings, a final updated conceptual model is presented. 
 
6.1. Evaluation of the Statistical Results 
In this section, the previously proposed seven hypotheses will be examined in the light of the 
statistical results, and then conclusions will be drawn. 
In order to be able to interpret the previously presented results, a discussion of the relation 
between the two variables “beta sales (BS)” and “average sales (AS)” is required at this point. 
The “beta sales (BS)” variable indicates the slope and captures the overall trend, whereas the 
“average sales (AV)” variable indicates mean average sales (revenue) over the whole sales 
(revenue) period. Consequently, this might be thought to imply that a higher “beta sales (BS)” 
results in higher “average sales (AS)”. However, the interpretation of the statistical results 
showed that this is not necessarily true for every hypothesis, as will be discussed later. This 
unexpected observation can be explained in a general sense by the “lucas critique” theory 
(Robert, 1976), suggesting that an effect that occurs by changing an economic policy cannot 
be entirely predicted on the basis of historical data. In other words, a causal relationship 
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between an independent and a dependent variable that has been observed on the basis of past 
data might not necessarily take place in the future.  
In Chapter 4 it was shown that a multi-level structure, containing a brand (first) level and a 
substance (second) level, is present. In a practical sense, this distinction is highly relevant 
because companies are only able to influence actively non-substance level-related variables 
through their marketing measures (promotion, pricing and packaging). In other words, this 
means that the prescription pharmaceutical marketer can only actively influence brand-related 
factors, whereas substance-related factors are mainly given by companies’ outcomes from 
their research and development (R&D), and therefore they generally are not under the control 
of marketers. This finding leads to the implication that the overall “marketing concept”, 
containing the four “marketing mix” instruments, has to be reconsidered. Therefore it can be 
concluded that the classical ‘4Ps’ approach (see Paragraph 1.1.2.) is not necessarily applicable 
in prescription pharmaceutical marketing, but a ‘3Ps’ approach can be suggested instead, as 
will be discussed further in the next chapter.   
 
6.1.1. The Importance of Order-of-Entry  
For the H1 hypothesis “the earlier a market entrant enters the market, the higher sales will 
be”, the statistical results indicated that there is not a significant relationship between the 
brand (first level)-related variable “order-of-market entry (OE)” and “average sales (AS)” 
(beta = -0.083; sig = 0.427), but there is a positive significant relation to “beta sales (BS)”  
(beta = 0.218; sig = 0.054). This means that a later market entrant is more likely to enjoy a 
higher increase in sales (revenue) than an earlier entrant. Generally speaking, market entry 
will increase sales (revenue) immediately, but once a product is established on the market, no 
effect can be observed. Even more interesting is the fact, as indicated by the results, that 
“average sales (AS)” is not related to order-of-market entry. These findings are also illustrated 
  
196 
in the following diagrams (see Figures 6-1 and 6-2, the same diagrams (5-11, 5-12) are 
presented in Chapter 5 as well).  
 
Figure 6-1: Sales of ATIIR-antagonists 
 
Figure 6-2: Sales of Statins 
 
At first glance, it appears that these results are in contrast to the findings presented in the 
scientific literature. Berndt et al. (1997, p37) concluded that, as in many markets, the ‘order-
of-market entry is very substantial for the sales (revenue) result’. In particular, Berndt et al. 
(1997, p37) stated that ‘holding price, marketing efforts and product quality constant, relative 
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to the nth product, the (n+1)th entrant can expect about 40% lower sales (revenue)’. Similar 
findings from other authors were also found (see also Urban et al., 1986; Berndt et al., 1997; 
Kalyanaram and Urban, 1992; Lean and Bond, 1977; Golder and Tellis, 1993). On the other 
hand, it was highlighted by Brown and Lattin (1994) that late market entry is a possible 
strategic alternative (see also Paragraph 2.5.5). Consequently, the results show that order-of-
market entry is not necessarily a decisive factor for market success (sales). In addition to this 
point, it has to be stated that such results have primarily been investigated in markets with 
little regulation (please see Paragraph 1.1.3). However, in the present context, as described in 
the first chapter, governmental bodies are involved in the medicines launching process by 
approving negotiated prices with the Swiss Federal Office of Public Health (BAG) – the 
regulatory Swiss agency for the authorisation and supervision of therapeutic products 
(Swissmedic) regarding medical drug quality, effectiveness and safety, as well as the Federal 
Office for Social Insurance (BSV), by placing the medical drug onto the approved list. As a 
result, medical products cannot be introduced freely into the market by pharmaceutical 
companies, as will be discussed later. This means that it is difficult to plan the time of market 
entry. 
In summary it is evident that early Swiss prescription pharmaceutical market entrants do not 
benefit from early mover advantage. This means that, overall, early entry does not necessarily 
lead to higher sales (revenue), as discussed in Chapter 2. The causes and resulting 
implications will be discussed later. Thus, no support for hypothesis H1 can be given. 
Furthermore, the results indicate that during the market introduction phase an extraordinary 
sales (revenue) increase takes place. This phenomenon will be discussed in the next 
paragraph. 
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6.1.2. The Relevance of Promotion 
In a next step, the marketing-related H7 hypothesis “more promoted medical drugs are more 
likely to be prescribed by physicians (costumers)” was investigated. For the “average 
marketing expenditure (MA)” variable, a highly significant positive relation to “average sales 
(AS)” (beta = 0.423; sig = 0.000) and “beta sales (BS)” (beta = 0.217; sig = 0.033) was found. 
These findings are supported by several researchers, who concluded that ‘promotional 
expenditure have a significant and positive effect on sales (revenue) in pharmaceutical 
markets’ (Kremer et al., 2008, p244, see also Brassington and Pettit, 2007; Bond and Lean, 
1977). This was also confirmed by the focus and Delphi group studies presented herein. The 
group members indicated the high relevance of promotion in prescription pharmaceutical 
marketing, in order to ensure that the specific product is present in the prescriber (costumer)’s 
mind and prescriptions are made. It should be emphasised at this point that promotional 
activities such as direct-to-consumer (DTC) promotion, as well certain physician (costumer)-
directed promotional measures, are heavily restricted in the Swiss state-regulated market. 
Furthermore, one should also take into account that pharmaceutical companies do not tend to 
market slow-selling medical drugs. As a result, these products will be removed from the 
product range in the long term. Consequently, the H7 hypotheses could be supported. 
In the previous paragraph the order-of-market entry effect and its implications on sales 
(revenue) were discussed. In the literature it was highlighted by Vakratsas and Kolsaricis 
(2008) that companies can overcome the disadvantage of being late with promotional 
measures. This means that ‘later (new) entrants would have to shout louder in order to be 
heard on the market’, as stated by (Robinson and Fornell, 1985, p316). These conclusions can 
also be justified from the marketer’s perspective. Over time, marketers of early entrants gain 
marketing experience within specific markets (see also Vakratsas and Kolsarici, 2008). On the 
other hand, the effectiveness of marketing measures will decrease over time (see also 
Shankar, 1997). As a result, higher marketing efforts are needed when launching a new 
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product. These conclusions can also be supported by the findings derived from the descriptive 
analysis, as illustrated in Figures 6-3 and 6-4, indicating the patterns of the actual marketing 
expenses of two different state-regulated prescription pharmaceutical markets (ATIIR-
antagonists and Statins). As clearly interpreted from these illustrations, there is a tendency for 
a higher proportion of marketing expenditure to be made within the first (product launch) 
phase and the later stage of a medical drug’s introduction. However, it should be pointed out 
that marketing activities are restricted as well. It was mentioned earlier that pharmaceutical 
companies, due to regulatory reasons, can only conduct direct-to-physician (costumer) (DTP) 
and opinion leaders, as well as word-of-mouth-directed, marketing.  
This also leads to the conclusion that the market failure of “imperfect information” (see 
Arnold, 2008) (in this case a supplier-induced demand that results when a producer with 
superior product knowledge is in the position to influence demand (see also Elliott and Payne, 
2005, p100) is present. 
 
Figure 6-3: Marketing Expenses of ATIIR-antagonists 
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Figure 6-4: Marketing Expenses of Statins 
 
Despite the fact that the order-of-market entry effect does not appear to be relevant, it was 
revealed that promotional efforts in general are of importance during the medical drug 
introduction phase. Furthermore, the analysis revealed a high multicollinearity (see Table 5-1) 
between “detailing expenses (DE)”, “mailing expenses (ME)” and “advertising expenses 
(AE)” data. This suggests that no distinction in regard to spending on marketing activities 
appears to be made by the pharmaceutical companies in the studied market. The reasons for 
these unexpected results are outside the scope of this study and require further research. 
Therefore, it is also not possible to analyse the individual effect of these promotional 
marketing measures on sales (revenue).  
Based on the presented results, it has to be concluded that sales (revenue) success cannot be 
fully influenced by pharmaceutical companies employing marketing instruments, but they are 
influenced by external factors, as already indicated by the marketing model (see Figure 1-4). 
Nevertheless, the results show that marketing expenditure have a strong influence on “beta 
sales (BS)” and “average sales (AS)”, indicating that marketing expenditure lead to a sales 
(revenue) increase and maintain the sales (revenue) level as well.  
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6.1.3. The Role of Product Mix Attributes 
The product mix-related H2 hypothesis “medical drugs with fewer drug interactions (product 
quality measure) with other drugs are more likely to be prescribed by practitioners 
(costumers)” was tested. For the substance (second level)-related variable “drug interaction 
(IA)” the analysis did not reveal a significant relation to “average sales (AS)” (beta = 0.056; 
sig = 0.755) but a negative relation to “beta sales (BS)” (beta = -0.276; sig = 0.051) for the 
aggregated substance level. This means that more indicated “drug interactions” would result 
in a lower sales (revenue) increase. These findings are in support of the scientific literature. 
According to Berndt et al. (1997), sales (revenue) will increase if the approved product has an 
advantage relative to other products. The relevance of the product related attributes for sales 
(revenue) was also emphasised by the focus and Delphi groups. This is also in support of 
other researchers, who have highlighted that product differentiation is an essential 
discriminator and key to successful marketing (see also Cooper and Kleinschmidt, 1993; 
Kotler, 2006 and 1998; Sharp et al., 2001), resulting in higher product sales (revenue). 
Therefore, support for the H2 hypothesis can be given. 
In addition, the H3 hypothesis “medical drugs with lower side-effects (product quality 
measure) are more likely to be prescribed by practitioners (costumers)” was evaluated. The 
findings of the multiple regression analysis show a positive relationship between the 
substance (second level)-related variable “side-effects (SE)” and “average sales (AS)” (beta = 
0.423;  
sig = 0.027) as well as “beta sales (BS)” (beta = 0.316; sig = 0.028) for the aggregated 
substance level. On first impressions, these unexpected results appear to be quite 
contradictory. However, a further interpretation reveals that this is not necessarily true. Not 
very much research has been conducted in this field (please see Paragraph 7.3.). Denig et al. 
(1988, p82) revealed that ‘serious side-effects are the most important factor when choosing a 
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drug for a relatively harmless disorder according to the physicians (costumers)’. However, on 
the other hand, as stated by Denig et al. (1988, p82), ‘for the acute disorder, efficacy is valued 
the most, followed by experience and only then are side-effects taken into account’. 
Furthermore, Denig et al. (1988, p83) deduced that ‘mild side-effects seem to play a minor 
role in the assessment of medical drugs’. Nevertheless, it should be added that no distinction 
between serious and mild side-effects was made in the present research. Furthermore, it has to 
be emphasised that medical drugs containing a serious harmful side-effect profile are not 
normally introduced by Swissmedic to the market in the first place. Therefore, it can be 
assumed that no medical substances with really serious side-effects are being marketed.  
However, it should be emphasised that the reliability of the results derived from Denig et al. 
(1988) can be questioned because of the applied research methodology. The data were 
collected by using questionnaires directed towards physicians (costumers), but this was 
indicated as a limitation by Denig et al. (1988, p84). They stated that only general 
expectancies about treatment outcomes were measured. According to the code of medical 
ethics (please refer to the American Medical Association, www. ama-assn.org), ‘physicians 
(costumers) should prescribe drugs, devices, and other treatments based solely upon medical 
considerations and patients (consumers)’ need and reasonable expectations of the 
effectiveness of the drug, device or other treatment for the particular patient (consumer)’. On 
the other hand, Corrigan (1995, p4) writes in his proposal to the FDA (U.S. Food and Drug 
Administration, www.fda.gov) that ‘physicians (costumers) are not always making informed 
decisions when determining the medication’. They are either uninformed or do not view side-
effects as being a relevant criterion. The interpretations of these results suggest that, in 
practical usage, practitioners (costumers) do not take side-effects into account when 
prescribing a medical drug, and therefore there is a case that the correlation uncovered here 
could be considered spurious. This results in some doubt as to whether or not the H3 
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hypothesis is supported, despite significant correlation, so further research in this area should 
be conducted to examine this issue more deeply. 
In a next step, the H4 hypothesis “the better the medical drug’s perceived product quality 
(product quality measure), the more likely the medical drug will be prescribed” was 
investigated. A positive significant relation between the substance (second level)-related 
variable “perceived quality (PQ)” and “average sales (AS)” (beta = 0.368; sig = 0.042) as well 
as “beta sales (BS)” (beta = 0.666; sig = 0.000) was indicated for the aggregated substance 
level. These findings are in line with Flechter’s (1989) conclusion that product confidence is 
relevant for the physician (costumer)’s prescription decision (sales). A similar conclusion was 
drawn by the focus group as well. Consequently, support for the H4 hypothesis can be given.  
In addition, the H5 hypothesis “medical drugs with more packaging alternatives are more 
likely to be prescribed by practitioners (costumers)” was tested. In this case, no significant 
relationship for the brand (first level) related variable “packaging alternatives (PA)” and 
“average sales (AS)” (beta = 0.114; sig = 0.245) as well as “beta sales (BS)” (beta = 0.081; 
sig = 0.396) on the aggregated substance level was found. These finding are not surprising for 
the Swiss markets. As already discussed, many Swiss physicians (costumers) also sell medical 
drugs (self-dispensing doctors (costumers); see also Kocher and Oggier, 2007). Therefore, the 
number of packaging alternatives does not really play a role. As a result, the H5 hypothesis 
could not be supported. 
At this point, a discussion about the results and the implications of the product design-related 
variables should be made. In Chapter 4 it was shown that a multi-level structure is in place, 
containing a brand (first) and a substance (second) level. This means, as will be discussed 
later, that “drug interaction (IA)” and “drug side-effects (SE)” are purely substance-related 
variables, whereas “perceived quality (PQ)” may partly also be influenced by marketing 
activities. This might also provide another explanation for these, as they appear to be, 
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contradictory results. Despite an unfavourable “drug side-effects (SE)” profile, the medical 
drug’s “perceived quality (PQ)” might increase due to marketing activities conducted by the 
pharmaceutical company.  
Furthermore, in the light of the conclusion that was derived from the third hypothesis, it 
appears that “drug interaction (IA)” and the number of “packaging alternatives (PA)” are not 
relevant when a drug prescription is made. This would imply that prescribers (costumers) 
make decisions based on their knowledge regarding effectiveness, side-effects and interaction 
profiles with other drugs. However, this does not necessarily mean that their knowledge is 
correct. So far, studies based on surveys conducted with doctors (costumers) (see also Berndt 
et al., 1997; Denig et al., 1988), as well as the results derived from the focus and Delphi 
groups herein, imply that effectiveness, side-effects and the interaction profile are relevant 
decision-making factors. Consequently, it seems that drug prescription decisions are made on 
a prevailing misconception (lack of knowledge, wrong or biased information, as well as 
prescription habit, as might be the case (see also Denig et al., 1988) in regard to medical drug 
quality). In other words, it appears that practitioners (costumers) are not always well-informed 
and therefore do not prescribe the most suitable medical drug for the patient (consumer)’s 
requirements. This might be the case for “side-effects (SE)” and “drug interaction (IA)”. 
Assuming a spurious relationship, these variables will be removed from the model (please see 
Figure 5-3 and 5-4). Furthermore, it was revealed that the “perceived quality (PQ)” variable 
has a positive relation to “beta sales (BS)” (increase of revenue) as well as “average sales 
(AS)”.  
In the first chapter, according to Elliot and Payne (2005, p10), we found that within a 
healthcare pharmaceutical market, the market failure of “imperfect/asymmetric information” 
(agency relationship) is typically present. Akerlof (1970) defined the market failure of 
“imperfect/asymmetric information” as an effect that takes place when sellers have better 
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information about the product being sold, so they are able to swindle consumers easily. 
However, it was also stated by DiLorenzo (2011, p252) that in ‘successful capitalist 
economies, all information about products is asymmetrical because of the division of 
knowledge’. As a result, the presence of “imperfect/asymmetric information” can be assured 
in the Swiss prescription pharmaceuticals market. Furthermore, this phenomenon can also be 
justified through the complex tripartite relationship (3P triangle) that takes place between a) 
the party who pays for the drug, b) the patient (consumer) who actually uses the drug and c) 
the prescriber (costumer) of the drug, as discussed in the first chapter.  
 
6.1.4. The Role of Pricing 
Next, the H6 hypothesis “medical drugs with a lower price (price level) are more likely to be 
prescribed by practitioners (costumers)” was tested. As a result, a significant relation between 
the brand (first level)-related variable of “average price (AP)” and “average sales (AS)” (beta 
= 0.210; sig = 0.075), but a non-significant relation to “beta sales (BS)” (beta = 0.052; sig = 
0.648), was found. This means that a higher price level leads to higher sales (revenue).  
Again, at this point a further discussion is required in order to view the wider reasons for 
these unexpected results. According to the price elasticity of demand theory (see also Arnold, 
2008), in a market with freely available substitutable products, a higher price should lead to 
lower sales (revenue). However, so far it has been revealed that higher “medical drug prices” 
result in higher sales (revenue). Despite ‘minor consensus on the price elasticity of demand’ 
(Kremer et al., 2008, p236) that takes place in the literature, the results of the present study 
revealed a positive price elasticity. 
This can be explained by the fact that prescribers (costumers) seem not to be motivated to 
prescribe cheaper medical drugs. These results are also supported by Lexchin’s (2009, p145) 
findings, revealing that ‘doctors (costumers) are generally ignorant both about the relative and 
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absolute prices of medications’. These results are also supported by Cooper and Kleinschmidt 
(1993, p109), who expounded that a low-price strategy is generally not effective. However, 
this statement was questioned by Rice (2009, p184), who demonstrated that HMO (Health 
Maintenance Organisation; a group of physicians (costumers) that has an agreement with 
health insurance(s) and provides care for a previously fixed fee) physicians (costumers) are 
more price-sensitive when prescribing brand name substitutes than non-HMO physicians 
(costumers). In addition, the focus group concluded that financial reward (seller’s margin) is 
relevant when it comes to the medical drug prescription decision. Consequently, in order to 
maximise a physician (costumer)’s profit, self-dispensing doctors (costumers) (Kocher and 
Oggier, 2007; Sutherland et al., 2008) are highly motivated to prescribe more expensive 
medical drugs. This is also supported by the fact that they do not really consider packaging 
alternatives, e.g. by choosing the most economical option for their patients (consumers).  
In addition, it was stated by the focus and Delphi groups that the patient (consumer)’s price 
sensitivity is of relevance (see also Brassington and Pettit, 2007; Dogramatzis, 2002). 
However, this conclusion is questioned by the actual results. Furthermore, it appears that 
patients (consumers) are usually not very cost-sensitive, as they do not have to cover the 
costs. As indicated by Newhouse (1978), the insured consumer may be unwilling to search for 
lower prices because he obtains at best only a fraction of the benefit from finding a lower 
priced seller. In other words, some form of insurance tends to make the consumers less 
careful. This phenomenon has been described as the “moral hazard” (Elliot and Payne, 2005, 
p10). Consequently, market failure is present (see also Arnold, 2008).  
The results revealed that average price does not have an effect on “beta sales (BS)”, but it 
does so on “average sales (AS)”. This means that a sales (revenue) increase does not take 
place immediately. As a result, the H6 hypothesis is not supported. 
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In the next and final chapter of this thesis, managerial implications are examined and 
limitations are indicated. As a consequence, directions for future research are proffered and 
the most important findings and contributions are highlighted. 
  
208 
7. Discussion and Conclusions 
 
7.1. Introduction 
In this chapter the main findings derived by the Systematic Literature Review (see Chapter 2), 
the qualitative studies, the focus (see Chapter 3) and Delphi group (see Chapter 4) as well as 
the quantitative analysis will be interpreted and discussed. For this purpose, reference to the 
initial three research objectives that are stated in the first chapter (see Paragraph 1.3.) is given. 
It will within the chapter be shown that this research has fulfilled these objectives (see below). 
4. To conceptualise and delineate the dimensionality of pharmaceutical marketing mix 
instruments that are used when physicians (costumers) are targeted. 
5. To investigate the influence of product- (especially quality) and promotion-mix 
related factors on “physician-targeting”, thus leading to an increase in sales (revenue). 
6. To develop a valid and reliable model of “physician-targeting” in the sector of 
prescription pharmaceuticals for marketing managers. 
 
Based on the findings derived by this research that is based on these initial objectives, a 
summary of the main study’s results will be given, the theoretical, methodological as well as 
managerial implications of the research, with particular relevance to prescription 
pharmaceuticals marketers, are provided. The conceptual “physician-targeting” model is then 
presented and discussed. Based on this, the outcome of the hypotheses test that was conducted 
by the qualitative study (see Chapter 5 and 6) is then critically discussed and a number of 
theoretical, methodological and practical recommendations are proposed. Furthermore, the 
limitations of the study are discussed and an agenda for future research is provided. Finally, 
conclusions are drawn, highlighting the major contributions of the present work.  
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7.2. Deriving the Conceptual Models 
Going back to the first chapter of this dissertation, in support of the present scientific 
literature it was concluded that there is little explicit knowledge regarding actual success 
factors in pharmaceuticals marketing. The systematic literature review and qualitative studies 
provided a first insight into this issue and a conceptual model was hypothesised. These 
methods were then utilised to develop a set of operational measures, in order to test the 
conceptual model and to enable the development of a “physician-targeting” model. 
Quantitative secondary data were then used in order to evaluate and validate empirically the 
conceptual model presented in the following section. Taking the previously discussed 
statistical results into account, a conceptual model for beta sales (revenue) and average sales 
(revenue) was derived. The conceptual model containing “beta sales (BS)” as a dependent 
variable is shown in Figure 7-1.  
SUBSTANCE  - LEVEL
Product Policy (Features) 
Quality
Beta Sales (BS)
Marketing Categories
Promotion Policy (DTP)
H1 (0.218)
H7 (0.217)
Order of
Market Entry (OE)
Perceived Quality (PQ)
Average Marketing 
Expenditures (AM)
H4 (0.666)
BRAND - LEVEL
 
Figure 7-1: Conceptual model containing Beta Sales as a dependent variable 
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Next, the conceptual model containing “average sales (AS)” as a dependent variable was 
created, as shown in Figure 7-2.  
SUBSTANCE  - LEVEL
Product Policy (Features) 
Quality
Average Sales (AS)
Marketing Categories
Pricing Policy
H6 (0.210)
Perceived Quality (PQ)
Average Price (AP)
H4 (0.368)
Promotion Policy (DTP)
H7 (0.423)Average Marketing 
Expenditures (AM)
BRAND - LEVEL
 
Figure 7-2: Conceptual model containing Average Sales as a dependent variable 
 
As revealed in Chapter 4, a two-level structure distinguishes between the brand (first) level 
and substance (second) level. From the marketing point of view, this is a very interesting 
perspective, as it provides a theoretical contribution to other research studies which do not 
take a two-level structure into account. In practical terms, this means that pharmaceutical 
companies can only differentiate themselves on the brand level by actively influencing 
marketing-related measures such as “order-of-market-entry (OE)”, “packaging alternatives 
(PA)”, “average price (AP)” and “average marketing expenditure (MA)”. On the other hand, 
the substance-related factor “perceived quality (PQ)” is given by the substance and cannot be 
influenced by companies’ marketing activities.  
In addition, this research revealed two market failures in relation to healthcare 
(“imperfect/asymmetric information” and “moral hazard”), as described by Elliott and Payne 
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(2005, p10), in a state-regulated market. Firstly, imperfect information on the quality and 
price of healthcare goods (service) is in evidence. The patient (consumer) is usually not 
informed about the quality, price or possible alternatives to the medical drug. Since a certain 
proportion of the medical drug price is covered by health insurance, this reveals the patient 
(consumer)’s lack of awareness (see also Jaakkola and Renko, 2007). At this point we should 
refer to Harm et al.’s (2002, p147) statement that ‘the ones who make the decisions are not 
identical with those who receive the service and/or pay for it’. Secondly, there is an agency 
relationship (leading to “imperfect information”) between patient (consumers) and healthcare 
providers (physicians (costumers), pharmacists and pharmaceutical companies), which leads 
to an asymmetry of information [typically, the doctor knows more than the patient 
(consumer)]. Although DTC (direct-to-consumer advertising) is strictly restricted but DTP 
[direct-to-physician (costumer) advertising] is allowed in Switzerland (Kocher and Oggier, 
2007), there is still “supplier-induced demand”, resulting in the fact that providers with 
superior knowledge about health and healthcare interventions are in a position to influence 
demand.  
The implications of these market failures can be observed by the unusual market behaviour 
that takes place. As previously discussed, this research revealed that the order-of-market entry 
effect does not really take place. However, ‘later entrants are at a disadvantage in competing 
with price’, as it would be beneficial, at least according to Bowman and Gatignon (1996, 
p238). This occurs because the medical price has to be agreed with the Swiss Federal Office 
of Public Health (www.admin.bag.ch). Furthermore, the results show that promotional 
marketing activities have a positive influence on the medical drug prescription rate. This is 
despite the fact, as the first chapter highlighted, that pharmaceutical companies distributing 
their products in the state-regulated Swiss market are faced with certain marketing-related 
restrictions. As a result, pharmaceutical companies are limited in employing their marketing 
activities and are not able to vary their channel-related promotional tactics. 
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By deriving this conceptual (“physician-targeting”) model the 3rd research objective was 
reached. However, the prerequisite was the 1st as well as the 2nd research objective. This 
leads to the theoretical, methodological and managerial implications that are proposed in the 
next section of this chapter. 
 
7.3. Theoretical and Methodological Implications  
This dissertation makes a theoretical contribution to the following main areas aiming to 
improve the quality of scholarly and applied research conducted by marketing researchers.  
Firstly, the order-of-market entry effect was evaluated from the perspective of a strongly 
state-regulated prescription drug market. It was shown that the first mover effect does not take 
place in such a context. Furthermore, it was revealed that in addition to marketing-related 
factors that can mainly be influenced by the company, additional external factors play a role, 
thus leading to unusual market behaviour which contrasts with the models already described 
in the scientific literature (see also Kalyanaram et al., 1995), as discussed in Chapter 2. As 
discussed in the first chapter and highlighted by Copper and Kleinschmidt (1993, p91), ‘it is 
viewed as a problem that studies tend to have a one-country (or even one-region) focus’, 
usually the non-state-regulated US market.  
 
Secondly, a marketing mix proportion, containing the marketing instruments “product”, 
“price”, “place” and “promotion” policy, was proposed. Furthermore, it was shown that these 
marketing instruments have a different relevance and that their use is restricted by 
governmental authorities, leading to unusual market behaviour. Despite the fact that the 
present study makes a number of significant contributions to existing research, the work done 
in this study also contributes to existing theory due to the empirical assessment of numerous 
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existing constructs. Referring to the research objectives described in the first chapter, this 
work provides a conceptualisation and delineates the dimensionality of pharmaceutical 
marketing instruments used for “physician-targeting”. Furthermore, the influence of 
pharmaceutical marketing instruments leading to sales (revenue) is investigated, and finally a 
valid and reliable “physician-targeting” model is developed.  
It has to be emphasised at this point that different marketing mix concepts have been 
discussed in the first chapter. Nevertheless, a further discussion is required at this stage of the 
research.  
In addition to McCarthy’s ‘4Ps’ marketing mix concept (McCarthy and Perreault, 1960) that 
is generally applied for consumer goods, the ‘7Ps’ marketing concept was introduced by 
Booms and Bitner (1981) for service marketing. According to their definition, the ‘7Ps’ refer 
to the ‘product’, ‘price’, ‘promotion’, ‘place’, ‘process’, ‘physical evidence’ and ‘people’ that 
make up the marketing mix. They are an extension of the more basic '4Ps': ‘product’, ‘place’, 
‘price’ and ‘promotion’. The structure of the present research is based on the ‘4Ps’ marketing 
mix model. This can be reasoned by the fact that prescription pharmaceutical are more likely 
consumer goods than services. This statement can be supported by the fact that most of the 
recent pharmaceutical marketing literature relates to the idea of the ‘4Ps’ as it has been 
revealed by the Systematic Literature Review (see Chapter 2.). The focus and Delphi group 
studies have came to similar conclusions. Despite of this, a few authors (Liberman and 
Rotarius, 2001; Harms et al., 2002) have proposed additional ‘Ps’. On the other hand it can be 
argued that the additional ‘3Ps’ (process, physical evidence and people) are already included 
within McCarthy’s ‘4Ps’ as it is discussed in the following. Firstly, the ‘process’ attribute is 
an important factor when it comes to deliver a quality service (in this case the medical drug) 
and is already included in the product policy that has been investigated in the present research 
(perceived quality, drug interaction, drug side effects). Secondly, ‘physical evidence’ affects 
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the customer’s satisfaction and refers to the way the product, service, and everything of the 
company, appears from the outside. In this case, it is included in the product policy by 
packaging and branding measures as well as by the promotional policy by the sales 
representative, mailing and advertising measures. Thirdly, ‘people’, on the other hand, are a 
crucial factor when it comes to deliver a service (in this case the medical drug) and is already 
included in the distributional (place) policy. However, as it has been in Chapter 4.4. reasoned, 
the distributional (place) policy was not investigated in the present research. 
Finally it can be summarised that the ‘4Ps’ concept is commonly used in the prescription 
pharmaceutical marketing field. Furthermore it can be concluded that the additional ‘3Ps’ are 
already included within the ‘4Ps’ and do therefore not need to be separated. 
 
Furthermore, it was revealed that two market failures are present (see also Elliot and Payne, 
2005, p10 and Arnold, 2008). Firstly, it was shown that “imperfect/asymmetric information” 
(agency relationship) is present, which takes place when sellers (in this case physicians 
(costumers) and pharmacists) are more informed about a product than their patients) (see also 
Akerlof, 1970). Secondly, the market failure of “moral hazard” (see also Elliot and Payne, 
2005, p10 and Arnold, 2008) was observed, as some form of insurances tends to make 
consumers less careful.  
 
7.4. Managerial Implications  
Although it is important to generate a substantive theoretical contribution in a doctoral 
dissertation, different demands are made by the marketing discipline on scholarly research. 
According to Hunt (1976 and 1994), marketing can be considered at least in part as an 
“applied” or “normative” field, as well as a “scientific” one. Consequently, marketing can be 
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considered as a discipline that provides practical “in the field” advice to marketers. The 
properties of “managerial-relevant” research were defined by Thomas and Tymon (1982, 
p348) as the ‘ability of practitioners (costumers) to implement action implications of a theory 
by manipulating its causal variables’. In addition, managerial relevance has been defined by 
Jaworski (2011, p211) as the ‘degree to which a specific manager in an organisation perceives 
academic knowledge to aid his or her job-related thoughts or actions in the pursuit of 
organisational goals’. Furthermore, it was highlighted in Chapter 1 that, according to Brinik 
and Bowman (2007, p316), Kremer et al. (2008) and Stremersch (2008), studies aiming to 
derive managerial descriptions are welcomed. This can also be supported by the fact that 
‘managers are increasingly under pressure to justify the impact of their marketing 
expenditures’ (Lehmann, 2004, p75). According to Varadarajan (2003), marketing research 
outcomes aimed at marketing managers and policymakers therefore has to satisfy different 
requirements in regard to their relevance:   
• Marketing managers - Research that makes a contribution to making better marketing 
decisions in organisations. The evaluation of the findings derived from this research 
has lead six practical recommendations for prescription pharmaceutical drug 
marketers operating in state-regulated markets such as the Swiss context of this study. 
These recommendations aim to increase the efficacy of marketing measures and sales 
in an increasingly competitive healthcare market (see also Hollon, 1999) by benefiting 
two market failures (“imperfect/asymmetric information” and “moral hazard”). 
• Policymakers - Research that is of value to decision-makers affiliated with 
governmental institutions. The analysis of the study results has led to four 
recommendations for policymakers within a state-regulated prescriptions 
pharmaceuticals market. These measures aim to reduce the ‘rising healthcare costs 
that have become a major public concern over the last couple of years’ (Gonzalez et 
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al., 2008, p247) by reducing or eliminating the two market failures 
(“imperfect/asymmetric information” and “moral hazard”) that take place. 
 
Therefore, a substantial proportion of the contribution of any marketing research should be 
the direct application of research findings to marketing practice, as presented in the following 
section. The managerial implications of the present study fall into the strategic marketing area 
of “order-of-market entry” and the operational marketing area of “marketing instruments”. 
As suggested by Stremersch and Van Dyck (2009), the derived model contributes to 
pharmaceutical marketing research and ‘contributes to the need of managerial prescriptions 
for medical drugs marketers’ (Birnik and Bowman, 2007, p316), in order to improve 
management decision-making and the ‘justification of the amount and allocation of 
companies’ marketing budgets’ (Kremer et al., 2008, p236). Furthermore, these findings will 
enable pharmaceutical companies to adapt their current “physician-targeting” concept based 
on market and strategic requirements (Stremersch and Van Dyck, 2009).  
 
7.5. Implications of Physician-targeting Model 
The research outcomes as well as the derived conceptual model (see Paragraph 7.1.), 
indicating the “physician-targeting” process, have already been in the previous paragraphs 
discussed. In the present paragraph, the four main positively tested hypotheses (please see 
Figure 7-3) and their theoretical as well as managerial contributions, affecting the decisions of 
marketing managers, policy maker as well as marketing researchers (scholars), are presented 
leading to the following practical recommendations.  
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Figure 7-3: Conceptual model of “physician-targeting” in a state-controlled prescription pharmaceuticals 
market  
 
7.5.1. The Order-of-Entry is not of Importance 
In the fourth chapter (see Paragraph 4.4.) the H1 hypothesis “the earlier a market entrant 
enters the market, the higher the sales (revenue) will be” was proposed and positively 
supported by the quantitative data analysis. The evaluation of the research findings has lead to 
the following practical recommendation for marketing managers. 
1. Marketing managers - It is not essential to be first to market 
The results of this dissertation have revealed that, within a state-regulated prescription 
pharmaceutical market, order-of-market entry is not of high relevance. As discussed in 
the first chapter, the scientific pharmaceutical marketing literature suggests 
fundamental marketing strategic concepts based on the order-of-entry effect (see also 
Castro and Chrisman, 1995; Rodriquez-Pinto et al., 2008), thus enabling companies to 
follow two strategies: (1) early market entry or (2) late market entry. Despite not 
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having been covered by this research, the literature provides some practical guidelines 
for early as well as late market entrants. It has been suggested by Kardes and 
Kalyanaram (1992) that an early market entrant should emphasise a high level of 
promotional measures, in order to ensure the formation of a physician (costumer)’s 
prescription as well the patient (consumer)’s usage habit. Furthermore, to meet the 
market requirements of an early entrant and to ensure a successful product 
introduction, a specific marketing mix has to be created and pursued, as by Trim and 
Hao (2005). On the other hand, a late market entry strategy is a strong alternative. A 
late market entrant will have to implement a differentiated, adapted marketing mix 
according to market requirements (see also Comanor, 1986), as discussed in Chapter 
2. However, we can refer to Harms et al’s (2002) conclusion that there is no generally 
applicable strategic approach in the pharmaceutical industry, but there are nonetheless 
factors that should be considered to achieve company success.  
 
7.5.2. The Doctors’ Perceived Quality is relevant 
In the fourth chapter (see Paragraph 4.4.) the H4 hypothesis “the better the medical drug’s 
perceived product quality, the more likely the medical drug will be prescribed” was proposed 
and positively supported by the quantitative data analysis. The evaluation of the research 
findings has lead to the following two practical recommendations. 
1. Marketing managers - Enhance the prescriber (costumer)’s perceived quality 
This research has shown that, in order to ensure high sales (revenue), marketers 
should ensure that doctors (costumers) think highly of the quality of a specific medical 
drug. However, factors leading to an increase in the perceived quality were not 
investigated by the research. Nevertheless, some practical advice was provided by the 
focus group and the literature (see also Chapter 2). The focus group participants 
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suggested that marketers should seek to enhance the product/company brand image 
(producer’s reputation) by communicating quality criteria. This includes good medical 
documentation as well as a good product presentation. Furthermore, it was pointed out 
by the focus group (see also Jaakkola and Renko, 2007) that a good drug has to ensure 
superiority over competitive drugs through high efficacy. 
2. Policy makers - Educational programmes and systems providing medical drug 
information for prescribers (costumers) should be implemented  
The results indicate that there is a lack of product knowledge among doctors 
(costumers) regarding medical drug properties, especially side-effects. Furthermore, 
there is a chance of a biased medical drug perception because of the pharmaceutical 
company’s marketing activities leading to “imperfect information” market failure. 
Consequently, an independent medical drug education programme should be set up 
(see also Angell, 2005). Currently, further educational programmes take place, but 
they are often not delivered by producers or independent institutions. Again, one 
should seek to set up an educational programme conducted independently, in order to 
avoid a conflict of interests.  
 
7.5.3. Higher Price Level leads to Sales Increase 
In the fourth chapter (see Paragraph 4.4.) the H6 hypothesis “medical drugs with a lower price 
(price level) are more likely to be prescribed by practitioners (costumers)” was proposed and 
significantly negative rejected by the quantitative data analysis. The evaluation of the research 
findings has therefore lead to the following three practical recommendations. 
1. Marketing managers - A high price policy is sales beneficial 
This research has revealed that a higher price results in a sales (revenue) increase. 
This can be explained by “moral hazard” market failure, as well as by “imperfect 
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information” on offer. The circumstances in which those who receive a service and/or 
pay for it are not identical with those who make the decision (Harms et al., 2002) 
justify this effect. Furthermore, because self-dispensing prescribing physicians 
(costumers) can increase their profits by selling the prescribed medication, they are 
motivated to prescribe more expensive medical drugs. This phenomenon takes place 
even in the case of governmentally-fixed prescription drugs pricing due to the 
negotiability of the price by pharmaceuticals companies. 
2. Policy makers - Inhibit prescribers (costumers)’ price-related prescription practice by 
banning the practice of self-dispensing physicians (costumers)  
This research shows that, in order to remove a prescriber’s (costumer) motivation to 
profit from prescribing more expensive medical drugs, the practice of self-dispensing 
doctors (costumers) should be banned. This would lead to a reduction in “moral 
hazard” market failure. In other words policymakers should ensure that prescribers 
(costumers) (decision-makers) are not involved in any way in medical drugs sales or 
the distribution process and that they remain independent from pharmaceutical 
companies, in order to prevent a conflict of interests. 
3. Policy makers - Negotiate lower medical prices 
The results have indicated that a higher price leads to a sales increase. In order to 
reduce rising costs within the healthcare sector, one focus of policymakers should be 
on the costs of medical drugs. As a result, policymakers should try to negotiate a 
lower price. They can achieve this goal by increasing purchasing power (purchasing in 
bulks), and competitive pressure could be actively applied where more than one 
supplier (producer) for a certain medication is present. In addition, it should also be 
ensured that no conflict of interest (e.g. employers/directors from the authority being 
involved in a pharmaceutical business) is present. 
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7.5.4. Promotion plays an important Role 
In the fourth chapter (see Paragraph 4.4.) the H7 hypothesis “better promoted medical drugs 
are more likely to be prescribed by physicians (costumers)” was proposed and positively 
supported by the quantitative data analysis. The evaluation of the research findings has lead to 
the following three practical recommendations. 
1. Marketing managers - Apply specifically promotional measures 
The findings of this dissertation imply that it would be beneficial if promotional 
measures [e.g. detailing (personal selling), mailing and advertising] were applied more 
specifically. It was concluded that there is room for an increase in the efficacy of 
marketing expenditure by implementing more specifically directed marketing 
measures in the Swiss market. In other words, marketing instruments need to be 
target-oriented. Regarding personal selling, it is suggested by the literature that, in 
order to ‘increase the effectiveness of individual representatives’ (Mizik and 
Jacobson, 2004, p1714), pharmaceutical companies should aim to foster good 
relationships between the salesperson and prescribers (costumers) (Hill, 1999). The 
sales-relevant criteria of the sales relationship are characterised by the 24-item SOCO 
(Sales Orientation-Customer Orientation) scale (Saxe and Weitz, 1982). Some further 
advice is given by Gonul et al. (2001, p89), who concluded that the ‘scope of personal 
selling should be carefully scheduled in terms of frequency, length of visits, and 
number of free samples given away to optimize the company’s effectiveness of direct 
promotion efforts and expenses’. Regarding mailing and advertising, there is not very 
much research available within pharmaceutical marketing. However, it has been 
highlighted by Wong-Rieger (2009) that mailing and advertising should aim to 
increase “disease awareness” as well as “drug awareness”. Nevertheless, specific 
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pharmaceutical marketing literature such as Berkowitz (1996), Dogramatzis (2002) 
and Smith (1983) can be recommended at this point.  
2. Marketing managers - Maintain strong marketing activities during the launch phase 
This research has revealed that strong marketing activities during the launch phase are 
beneficial, even in a state-regulated market. Furthermore, it was shown that a higher 
increase in sales (revenue) is usually gained during the product launch phase. This 
finding is supported by Jaakkola and Renko (2007, p342), who stated that ‘marketers 
of new medical drugs should not underestimate the importance of gaining publicity 
and positive word-of-mouth’. In addition, it was emphasised by Kardes and 
Kalyanaram (1992, p355) that the ‘habit formation (learning) effect is of importance 
for long-lasting sales success’. Consequently, it can be concluded that, because the 
launch phase is of high relevance for the further sales (revenue) success, prescription 
drugs marketers need to ensure that strong (effective) marketing measures are 
employed during the product launch phase. 
3. Policy makers - Inhibit companies’ promotional activities 
Another approach would be a further limitation on companies’ medical drug 
marketing expenditure by introducing adequate policies, especially for marketing 
activities that take place during the launch phase. As a result, the market failure 
“imperfect information” would be reduced. Furthermore, this would also reduce a 
company’s marketing spending, the widening gap between research and development 
and marketing expenditure (see also Angell, 2005). The most effective way to achieve 
this end may be to implement a total ban on any promotional activities and to 
distribute the required technical medical drug information through a controlled 
independent channel, in order to avoid a conflict of interests. 
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7.6. Conflicting Interests between Marketing managers and Policymakers  
There is a conflict between pharmaceutical marketers and policymakers. Two main areas are 
in conflict in this situation, namely “pricing” and “marketing”. 
First of all, on the one hand marketers should aim to increase the price level of medical drugs 
in order to increase sales (revenues), while on the other hand, policymakers should try to 
reduce the price level, in order to reduce healthcare spending. Together, these two opposing 
strategies lead to a “pricing policy” conflict. Furthermore, marketers should try to increase 
marketing expenditure, whereas policymakers should try to inhibit this area, thus resulting in 
a “marketing policy” conflict. 
As already highlighted, healthcare costs are on the rise (Gonzalez et al., 2008) and will lead, if 
no countermeasures are taken, in the long term to financial problems for society. Taking into 
account that the current monthly healthcare insurance cost of 365 Swiss francs will rise  by an 
average of 5.4% per year (figures taken from www.bfs.admin.ch) and a low inflation rate is 
present (it has been almost 0% in Switzerland for the last couple of years, see 
www.lik.bfs.admin.ch), healthcare insurance costs in 50 years’ time will be approximately 
equal to the average monthly salary of 5,979 Swiss francs (www.bfs.admin.ch). However, at 
this point it should be mentioned that, according to governmental statistical data (see 
www.bfs.admin.ch), only 10 per cent of the healthcare costs can be attributed to medication 
costs. Nevertheless, despite its unpopularity among specific interest groups (pharmaceutical 
companies, pharmacists, doctors (costumers) and even health insurance providers), it can be 
concluded that, sooner or later, regulatory measures will have to be implemented by 
policymakers, in order to limit rising healthcare expenditure.  
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7.7. Study Limitations 
The methodology conducted for this dissertation ensures the minimisation of bias caused by 
reliability12 and validity13. Nevertheless, some limitations are present, as will be discussed in 
the following. 
The systematic literature review discussed in Chapter 2 has several limitations. The method 
was applied as systematically as possible to ensure the principal limitation of the present 
study lay in the fact that no literature review could guarantee an absolutely distortion-free 
picture. Petticrew and Roberts (2006) described six possible biases of systematic reviews. 
One aim of the study design was to minimise these biases as described below: (1) Studies 
with statistically significant results are more likely to get published than those with non-
significant results. Therefore, unpublished work and alternative sources were considered. (2) 
The publication could be affected by the source of funding. Therefore, conclusions derived 
from the systematic literature review were based on 528 publications. (3) Authors may be 
more likely to report positive findings in international, English language journals, and 
negative findings in a journal from their own country. Therefore, Swiss and German sources 
were included as well. (4) Many studies are published in journals that are not indexed in any 
of the major electronic databases. Therefore, it was ensured that alternative sources gathered 
via Google and expert recommendations were included. (5) Studies that are supportive of a 
beneficial effect may be cited more frequently than unsupportive trials. Therefore, the final 
conclusions’ findings were based on 528 publications, in order to minimise this bias.  
(6) Studies with significant results are more likely to lead to multiple publications. The 
significance of the results was not a criterion.  
                                                 
12
 The reliability of a measure is its degree of consistency: a perfectly reliable measure gives the same result 
every time it is applied to the same person or thing, barring changes in the variable being measured’ (Whitley, 
1995, p100) 
13
 ‘The validity of a measure is its degree of accuracy: A perfectly valid measure assesses the trait it is supposed 
to assess, assesses all aspects of the trait, and assesses only that trait’ (Whitley, 1995, p100) 
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The qualitative focus and Delphi groups described in Chapter 3 had the following limitations. 
The main limitation lay in the fact that the methods used can never guarantee a distortion-free 
picture. Although the methods used strive to produce consensus among experts, even an 
expert judgement may not always be objective (see also Glitz, 1997). However, because of 
their broad professional and academic experience, valid and reliable responses can be 
assumed from the participants (see also Glitz, 1997). Furthermore, it is the nature of the 
Delphi and focus group techniques that the sample size is relatively small and therefore not 
broadly representative (focus group n = 5, Delphi group n = 11) (see also Bortz and Doering, 
2006). Consequently, the results cannot be interpreted as definitive or as representative of the 
industry due to the limitations caused by the small number of acknowledged Swiss experts 
providing prescriptive advice. However, it should be emphasised at this point that quantitative 
methods can provide new findings or different views, as they might gather more in-depth 
information, whereas the statistically more robust qualitative methods containing bigger 
sample sizes are based on retrospective data and structured questionnaires (see also Bortz and 
Doering, 2006). 
The quantitative market data analysis discussed in Chapter 4 has the following limitations. 
This dissertation was designed so that individual medications could be compared effectively 
with each other (same product class and same indication). This naturally limits the number of 
medications. As a result, a total of 37 substances and 108 brands (products) were recorded. 
Furthermore, this dataset covered five prescription medical markets (Beta Blockers, ACE 
Inhibitors, Angiotensin II Antagonists, PDE5 Inhibitors, and Statins). The assumption was 
made that these results could be generalised for the prescription pharmaceuticals market. 
However, it was stated by the focus group, as well as by Kremer et al. (2008), that this is not 
necessarily true. Consequently, additional research will be required in order to clarify this 
uncertainty (see also Paragraph 6.3). In order to investigate the multi-level structure of this 
dataset, applying hierarchical linear model (HLM) analysis would have been ideal. However, 
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because of the small sample size, a multiple regression analysis was applied instead. The 
availability of data in Switzerland was an advantage – marketing data was available from 
1995 – but since data records containing all the required information were difficult to find for 
this period of time, additional data had to be gathered from multiple sources. Some of these 
data were taken from another secondary data source, while other information (primary data) 
was collected via an online survey that was especially conducted for this dissertation. 
Consequently, it can be considered a strength that the dataset contained information gathered 
from different sources, as this enhanced representativity. 
However, this does not mean that these findings can automatically be generalised to markets 
other than Switzerland, although it is in line with Steenkamp’s (2005) suggestion that context-
related research should be performed. As stated by Steenkamp (2005, p6), ‘theories are 
usually developed without an explicit reference to their socioeconomic institutional and 
cultural context. However, a cross-national generalization should in many cases not be 
assumed’. This can also be reasoned by the fact that, as pointed out by Steenkamp (2005, p6), 
‘cultural norms and beliefs are powerful forces shaping people’s perceptions, dispositions, 
and behaviours’. Consequently, generalising existing strategies to other markets is one of the 
most important challenges facing companies today. As a result, ‘companies’ business models 
must often be recast’, as concluded by Steenkamp (2005, p7). This is in support of Bolton’s 
(2003) editorial note in the Journal of Marketing (JM) that international marketing research is 
underrepresented  
 
7.8. Directions for Future Research 
The effects of pharmaceutical marketing within a regulated prescription drug market are 
interesting and important to study, but often answers to the research questions regarding 
marketing factors lead to new research questions. Consequently, this dissertation delivers 
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implications from which academics and marketers can benefit. However, this work has also 
revealed research gaps that interested scholars can follow in their research. Nevertheless, it 
should be highlighted at this point that the ‘primary goal of scholarship in pharmaceutical 
marketing should perhaps not be to derive theories that can be generalised perfectly to all 
situations’, as suggested by Stremersch (2008, p233). Rather, the goal should be to develop 
theories and reveal findings with explicit reference to the context (Steenkamp, 2005). In 
addition, academics should also gain unique overall and independent knowledge about a state-
regulated pharmaceutical market and its specific behaviour, in order to be able to deliver 
recommendations to marketers and policymakers (Steenkamp, 2005). As a result, the 
following five research gaps are indicated. 
• Factors influencing perceived quality 
It was revealed that the prescriber (costumer)’s perception of quality is of high 
relevance. However, the actual factors influencing this factor still remain unclear. 
Consequently, additional research regarding the role and the guiding criteria behind 
perceived quality should be conducted. 
• Price elasticity of prescription pharmaceutical marketing demand models 
This research provided a positive price elasticity for the investigation. However, 
further research covering more markets and relevant guiding factors could be 
performed. This in support of Kremer et al. (2008, p236), who concluded that, in the 
literature, there is ‘little consensus on the price elasticity of demand’. 
• Generalisation of the research results 
This research is based on data taken from five prescription pharmaceutical medication 
classes. Further research could investigate if the presented findings relate only to these 
five investigated medical classes or if they can be generalised to the total market. 
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However, according to Kremer et al. (2008, p244), the ‘effects of the promotional 
instruments vary considerably across disease categories’. 
• The role of distribution and order-of-market entry 
There is room for further research regarding distribution and the relationship between 
order-of-market entry and distribution in prescription pharmaceutical marketing, as 
this is widely uncovered by the scientific literature (e.g. to be in hospital first).  
• Relevant product policy factors  
There is room for research regarding the role of product policy-related factors such as 
product properties. Furthermore, product differentiation by product alteration using 
the same substance (such as different types of Paracetamol (pain killer) products: 
Panadol Children, Panadol 500mg, Max Strength, Night-time, Day & Night, 
Blackcurrant Flavour, Lemon Sachet, etc.) or by branding (product and company 
brand) (see also Vakratsas and Kolsaricis, 2008) could be investigated.  
 
In addition to these five suggested research directions, it might be worth reconsidering the 
validity of the ‘4Ps’ marketing mix concept for prescription pharmaceuticals marketing. 
Alternatively, concepts such as ‘3Ps’ or ‘2Ps+1’ might be suggested. However, although 
several marketing mix concepts have been suggested in the scientific literature, as discussed 
in the first chapter of the present study, the need for an additional marketing mix concept and 
its contribution to marketing science can be questioned. 
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7.9. Conclusions 
This research has investigated factors leading to higher sales (revenue) of prescription 
pharmaceutical drugs when physicians (costumers) are targeted in a state-controlled market. 
The research has also revealed that the vast majority of the literature has investigated specific 
marketing-related factors within the non-state-regulated U.S. market. In addition, focus and 
Delphi group studies were conducted with Swiss healthcare professionals (state-regulated 
market). On the basis of these results, a conceptual model (see Figure 3-5) and seven 
hypotheses were derived. These hypotheses were then tested in the light of state-controlled 
(Swiss) prescription pharmaceutical markets data, resulting in the following conceptual model 
(see Figure 7-3). 
The research has revealed several marketing instruments that are not applicable in a state-
controlled market. For “order-of-market entry” it was shown that this effect is not of high 
relevance. For “product policy”, no differences could be found. Furthermore, it was shown 
that there are restrictions on applicable promotional instruments as a result of initiatives and 
regulations imposed by governmental authorities, which ultimately lead to a reduction in the 
amount of marketing that can be employed by pharmaceutical companies. In addition, a 
distinction has to be made between the “brand-level”-related variable (promotional activities 
that can be directly influenced by companies) and the “substance-level”-related variable (can 
only partly be influenced by companies’ promotional activities). Furthermore, there was also 
a difference in the behaviour of factors related to “average sales (AS)” and “beta sales (BS)”. 
In general, it was concluded that prescription drugs “marketers” should place emphasis on 
their marketing activities through promotional measures during the product introduction 
phase. Furthermore, it also appears that there is room for a more efficient application of 
promotional measures. In addition, a higher pricing level should be the goal and measures 
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should be taken in order to increase the prescriber (costumer)’s perceived quality. However, it 
is not necessarily relevant to be first to market. 
On the other hand, healthcare “policymakers” should aim to reduce prescription drug pricing 
levels and restrict companies’ promotional activities. In addition, the practice of self-
dispensing doctors (costumers) (which takes place in the Swiss market) should be banned and 
educational product-related measures for doctors (costumers) should be more comprehensive 
and independently delivered. 
The analysis of the effects of pharmaceutical marketing will remain an interesting challenge 
for researchers worldwide, taking into account the ideas and concepts presented within this 
dissertation. The author hopes that this dissertation provides a starting point for further work 
in this fascinating and important area. 
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9. Appendices 
 
Appendix 1 – Kuehn Market Model 
 
Competitors
External Opinion 
Leaders
External Opinion 
Leaders
Own Company
Market
Distributors
Consumers
External Competition Forces
Substitution Products
Potential Competitors
Suppliers Influences
External Market Factors
Economical Factors
Social and Cultural Issues
Technological Advances
Political and Legal Factors
Market Environment
Marketing-Mix
Marketing-Mix Marketing-Mix
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Appendix 2 – Literature Rating Criteria 
 
Type Description Ranking Criteria 
five star Indicated as a core paper within 
the subject area, shows high 
relevance regarding to the 
research question. 
Findings give a relevant contribution 
regarding to prescription pharmaceutical 
marketing in general. 
Methodology meets the requirements of 
objectivity, reliability and validity. 
four star Paper has some important 
findings and good methodology. 
Findings partly contribute to 
pharmaceutical marketing, investigate 
aspects such as order-of-entry, marketing 
mix, especially product, place, promotion 
and price and provide in depth findings 
regarding these instruments. 
Methodology meets the requirements of 
objectivity, reliability and validity. 
three 
star 
Some interesting, but less 
essential findings and figures can 
be found. 
Findings partly investigate aspects such 
as order-of-entry, marketing mix, 
especially product, place, promotion and 
price and provide some limited, additional 
findings.  
Methodology meets the requirements of 
objectivity, reliability and validity. 
two star Regarding for the ongoing 
research, only interesting 
research methods applied 
Provides only interesting methodology 
that meets the requirements of objectivity, 
reliability and validity. 
one star Not relevant to subject at all No contribution at all. 
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Appendix 3 - Focus Group Transcript 
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Appendix 4 – Meta Matrix Focus Group 
Category  Seller Buyer Group 
Marketing   
SA 3: Pharmacists often give 
a generic substitute  
BB 10-11: patient asks 
the doctor for a 
prescription of a drug that 
has been recommended 
by the pharmacists 
GD 50: Life style drugs, 
however, are better 
advertised via patients 
who ask the doctor for 
the preparation 
    
SA 5-6: scientifically oriented 
physicians decide on the 
basis of the medical scientific 
documentation, n, clinical 
study results, independent 
studies 
BB 11-12: physician 
prescribes a drug usually 
on the basis of his 
personal experience, 
historical data  
GD 50-52: organises an 
event covering a non-
pharmaceutical topic 
once per year. This 
enables to reach doctors 
who normally would not 
take part. 
    
SA 6-7: economically 
orientated doctors decide on 
the basis of a price to 
performance ratio and the 
best customer service. best 
margins  
BD 17-18: medication 
has been introduced first. 
Good previous 
experience will cause 
hesitation in changing the 
drug. 
GD 53: Information 
“pushing” is another 
strategy 
    
SC 15: Physicians do have 
preferences 
BD 19: disadvantage 
when a drug is seldom 
prescribed 
GD 54-55: , patients are 
increasingly gathering the 
relevant information and 
asking doctors for a 
specific medication 
    
SA 26-27: prescription drug 
can only be prescribed by a 
doctor. Personal 
acquaintanceship with a 
BE 24: consumers often 
go to the pharmacy and 
ask for a drug they have 
encountered on the 
GD 55-56: customers do 
ask in the pharmacy for 
additional information 
about a product they 
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physician is a major criterion 
for access 
Internet.  have already heard about 
    
SA 29: multiplication effect is 
also a good approach 
BB 32-34: A regional 
relation network that 
endorses the medication 
... has a positive effect 
GD 153: A prescription 
habit seldom changes 
    
SA 29-30: Opinion leaders 
are the main target group 
BB 34-35:  important ...  
to be in a hospital first 
GD 154-155: market 
introduction of Viagra 
would have been very 
difficult without laymans’ 
involvement and an 
enormous marketing 
effort 
    
SA 63: doctors’ 
specialisation is of relevance  
BB 35-36: General 
practitioners usually have 
little reason to change 
the patients’ hospital 
prescription 
GD 155-157: Serotonin 
inhibitors were 
unsuccessfully introduced 
because of their wrong 
positioning and a poor 
marketing performance. 
Their potential has not 
been realised. 
    
SA 103-104: Physicians are 
the decision makers when 
purchasing prescription 
drugs 
BD 42-43: convince the 
relevant opinion leaders’ 
one or two years before a 
new product will be 
launched 
GD 255: an opinion 
leader can be a a head 
doctor in a regional 
hospital providing regular 
seminars or a specialist 
    
SA 104-106: Classical sales 
approach: influencing the 
physician: to show the 
benefit and make sure that 
the drug is being distributed 
at the pharmacy 
BE 48: product 
information and sales 
strategy has to go via the 
doctor 
GD 257: the person that 
has shown exceptional 
vocational competence is 
recognised as an opinion 
leader 
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SC 110: depends on the 
product properties, 
application area and target 
group 
BE 48-49: Life style 
drugs are better 
advertised via patients 
who ask the doctor for 
the preparation   
    
SC 110-111: marketing 
strategy and especially the 
pre-launch activities have to 
be set-up accordingly 
BD 115-116: substance 
has been presented at a 
scientific congress 
previous to the market 
introduction   
    
SC 112-113: Marketing 
performed after the market 
introduction phase has to be 
extremely target group 
orientated 
BE 122-123: market 
customs. In Europe, 
advertising is performed 
via physicians whereas 
drugs are marketed via 
patients in America 
  
 
 
 
 
 
 
Product   
SC 41: good product 
presentation 
BB 129: effectiveness, 
side effect profile, 'my 
own experience'  
GD 146: A frequent query 
is whether the drug has 
been produced in 
Switzerland. 
    
SA 125-126: indication 
(application area), 
compliance (once, twice or 
three times daily) and 
possible side effects  ... 
safety  
BB 129-130: medication 
documentation 
GD 148: difference (of 
drugs) is usually 
exaggerated by the 
competitors 
    
SA 126-127: producers’ 
reputation are other relevant 
issues. Large companies 
have an advantage over 
small companies 
BD 132-133: drug 
delivery .. imodern image  
GD 152: medication has 
to show good 
effectiveness  
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SC 131: Safety and side 
effects 
BE 134: compliance is 
relevant 
GD 159: sum of the 
experience you have of a 
firm also gives a certain 
impression 
    
SA 137-138: compliance is 
relevant 
BB 139: choose the 
company me (physician) 
and the patient has more 
confidence in   
    
SA 138: In case of an 
unknown producer, the larger 
one will be chosen 
BB 139-140: In case of 
problems, the larger 
company will be more 
likely able to pay    
    
SC 141: two similar products, 
the branded product will be 
chosen 
BD 142: I would definitely 
choose a product from a 
well-known firm   
    
SA 176: There is a switch to 
generics     
Price   SC 41: price policies  
BB 13-14: purchase 
conditions are also 
relevant   
    
SA 104: Financial incentives 
are relevant 
BB 32: Reasonable 
pricing is necessary   
    
SA 168-170: Until recently, 
the price did not have any 
relevance. However, since 
the government has 
implemented a new 
regulation, that 20% of the 
price has to be paid directly 
by the patient, the price is 
more relevant.  
BD 143: I would 
recommend a generic 
product to my patients 
because of lower price   
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SA 173-174: The new 
regulation has raised the 
patients’ price sensitivity. 
Consequently, physicians 
are also confronted more 
frequently with this issue.  
BB 178: price plays an 
important role for me   
    
SC 181: There are 
differences in price sensitivity 
world wide 
BE 184-185: However, 
preparation without a 
generic substitute still 
has a high price   
     
BE 185-186: The patient 
considers the price when 
he has to pay out of his 
own pocket   
     
BE 186-187: Patients ... 
are increasingly asking 
for them (generic drugs) 
when purchasing 
medication   
          
Place     
BD22-23: Consumers 
purchase prescription 
drugs via the internet as 
a grey channel    
         
Promotion Advertising 
SA 215: I usually search for 
information about a 
competitors’ product in the 
internet 
BD 18-19: scientific 
medical documentation is 
relevant 
GD 56-57: Despite the 
circumstance that direct -
to -customer advertising 
is illegal in Switzerland, 
this is becoming more 
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and more popular. 
However, there are other 
ways a drug can be 
promoted 
   
SC 222: The online trading 
platforms usually provide 
information 
BB 32: Convincing 
documentation is 
essential   
     
BD 46: There can also be 
too much promotion   
     
BB 108-109: Sales 
person, printing material, 
presentations at scientific 
congresses   
     
BD 114: Good scientific 
medication 
documentation is relevant   
     
BD 115: A good slogan 
mentioning the key 
therapeutic problem is 
also essential   
     
BD 117: lay press should 
be involved   
     
BE 121-122: the quality 
of medical information 
shows the company 
standard   
     
BB 218-219: I do have to 
consult the producers’ 
information. However, I 
do not know if the 
complete information has 
been provided   
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BB 219-221: I read the 
critical pharmaceutical 
information from Etzel 
Gisling, consult the 
Compendium and also 
ask colleagues on 
congresses.   
     
BD 223: sales figures of 
a substance are a very 
important indicator   
     
BD 223-224: A rise in 
share prices is usually 
related to the product. 
This is official, unbiased 
information.   
     
BE 226: information from 
Compendium, Internet 
and companys’ 
information   
          
  Personal Selling 
SA 27-28: Many physicians 
do not accept any sales 
visits, especially from small 
firms 
BD 20-21: in case similar 
products, personal 
contacts with sales 
executives are essential 
GD 90-91: Certain groups 
of specialised doctors 
more likely welcome 
sales representatives 
than others 
    
SA 28-29: relevant to meet 
the physicians, primarily at a 
congress 
BB 72-74: I do not have 
any preferences when 
arranging (sales) 
appointments. This gives 
me the chance to get 
acquainted with a new 
GD 93-94: A reason for 
cancelling a sales visit 
might also be the doctor's 
fear of showing that he is 
not up to date.  
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medicine. There are also 
chances for meetings at 
a congress. It works by 
coincidence 
    
SC 39-41: frequent sales 
visits ... information of 
opinion leaders 
BD 81-84: They do not 
take the opportunity to 
receive information from 
sales reps. The sales 
person is in general quite 
well informed, also gives 
information about 
possible side effects, but 
is a little bit biased. If you 
listen to them on a 
regular basis, it is an 
easy way to gain further 
education. 
GD 94-95: Some of my 
doctor’ colleagues do not 
welcome sales reps at all, 
but are informed by 
independent resources.  
    
SC 75-76: Will I like the main 
matter of the sales visit? Will 
I benefit from the sales visit? 
How will I interact with the 
sales person? 
BE 86-88: I try to reduce 
the time of a sales visit. 
The conversation might 
give me some first 
information. If necessary, 
I might seek better 
founded information.  
GD 95-96: Others advise 
their medical practice 
assistant only to welcome 
representatives from 
certain companies or 
areas of interest  
    
SA 193-194: good product, 
the sales person has an 
influence on the doctor ... as 
an information supplier 
BB 197-199: I do expect 
reliable information and a 
convincing personal 
appearance. However, 
this influences my 
decision only to a minor 
extent. I do read clinical 
studies, attend seminars, 
GD 97-100: It is very 
difficult to access 
objective information. 
Therefore, 
pharmaceutical 
representatives still 
remain an acceptable 
information source. 
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and exchange 
information with 
colleagues. I do also 
consider the opinion 
leader’s point of view. 
Information from the 
relevant specialist 
literature is usually too 
critical and deters from 
trying new medical 
approaches.  
    
SA 194-196: if sales person  
... is being tripped up all the 
time, the physician will be 
influenced, but negatively. 
BD 204-205: The 
pharmaceutical 
representative cannot 
provide me with any new 
vocational subject 
orientated information 
GD: 228-229: It should 
always be the same sales 
person you are in charge 
with 
    
SC 202-203: As more 
products for a certain 
treatment are on the market, 
sympathy for and or 
antipathy of a sales rep 
becomes even more 
important. 
BD 208-210: Almost 
every piece of 
information provided by 
sales reps is biased. A 
sales visit is only useful 
for me when some 
helpful information is 
given. I do not look at the 
accompanying 
documents. 
GD 232-233: A good 
sales person is 
competent in vocational 
matters, knows the 
medicines’ 
documentation, has a 
good appearance and 
appropriate 
communication skills 
     
BE 2111-212: The sales 
reps only give me some 
inspiration. I will seek 
additional information in 
cases involving 
interesting information   
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Appendix 5 – Delphi Group Round -1-Mailing 
Dear Expert 
 
In the course of an ongoing international scientific study of methods for an accelerated 
market introduction of pharmaceutical products, we are conducting a Delphi-Group survey.  
 
For this current qualitative survey we have defined a small group of chosen healthcare 
professionals involved on the buy or sell side of pharmaceutical marketing.  
 
• In a first step, you are asked a few general questions. 
• In a second step ( a few weeks later), you will be asked a couple of additional, more 
specific questions based on your answers.  
• As a last step, the summarised results of this opinion poll will be sent to you and you 
will be asked whether your assumptions comply with the survey’s conclusion.  
 
Thus, we would like to ask you your personal opinion regarding the importance of various 
factors that might influence the sales of prescription drugs. 
 
 
1. What are the most important key factors leading to successful sales?  
(Please justify your statement) 
 
____________________________________________________________________________ 
2. What are the greatest challenges for you in the "product" area? So far we identified 
issues such as branding, efficacy, sales reps, etc. 
 
____________________________________________________________________________ 
3. Why do many products struggle to reach their financial expectations?  
 
____________________________________________________________________________ 
 
Thank you for taking part in this study. Please remember to return the completed 
questionnaire by means of the return-addressed, pre-paid envelope provided. 
 
Your responses will be treated confidentially and collated with those of other experts. As 
mentioned above, we will provide you with a summary of the results within the next weeks. 
 
Thank you for your cooperation 
 
Yours Faithfully 
 
Michael Stros 
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Appendix 6 – Delphi Group Round -2- Covering Letter 
 
 
 
 
 
Dear Expert 
 
As already mentioned, further questions, as follows, have arisen from your previously 
handed-in questionnaire. 
 
Instructions: 
 
• Firstly, we would like to learn of your opinion with regard to the relevance of some 
specific criteria associated with the sales process: Please tick the most appropriate 
box in column (A). 
• Secondly, please rank in columns (B and C)  
(1 = unimportant, high number = very important) the above-mentioned criteria 
according to their importance to the sales process. 
 
 
Thank you for taking part in this study. Please remember to return the completed 
questionnaire by means of the return-addressed, pre-paid envelope provided. 
 
Your responses will be treated confidentially and collated with those of other experts and we 
will provide you with a summary of the results within the next weeks. 
 
 
Thank you for your cooperation 
 
 
 
Yours Faithfully 
 
 
Michael Stros 
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Appendix 7 – Delphi Group Round -3- Covering Letter 
 
 
 
 
 
Dear Expert 
 
As already mentioned, further questions, as follows, have arisen from your previously 
handed-in questionnaire. 
 
Instructions: 
 
• Please tick the most appropriate box in the right column  
 
 
Thank you for taking part in this study. Please remember to return the completed 
questionnaire by means of the return-addressed, pre-paid envelope provided. 
 
Your responses will be treated confidentially and collated with those of other experts and we 
will provide you with a summary of the results within the next weeks. 
 
 
Thank you for your cooperation 
 
 
 
Yours Faithfully 
 
 
Michael Stros 
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Appendix 8 – Delphi Group Transcript 
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Appendix 9 – Meta Matrix Delphi Group 
Category Statement Participant Line 
Marketing Awareness at a) med. Doc. b) pharmacies, c) patient - generally at the prescriber 1 2 
  Product + Marketing + Sales have to fit fully for the given market segment 1 4-5. 
  product itself: -high efficacy, less side effects  2 6 
  Targeting: see the right doctor (high potential physician);  2 8 
  marketing mix: mailings, journal ads, congresses 2 9 
  
Customer type. Customer perceives the problem as such and is willing to take the drug; 
Customer buying power. The customer must able to pay for the drug (either through 
health care insurance or by personal assets) 3 13-15 
  
Timing. The first drug on the market even with lower efficacy can collect more sales and is 
more present in the minds of the customers; Customer mind share 3 15-17 
  
Product life cycle management. How well the overall product lifecycle is managed. It can 
shorten the time to market and increase the revenues generated throughout the lifetime of 
a product. 3 21-23 
  Targeting: knowing who are the accessible potential clients;  4 24 
  
a good story / business logic to sell the drug > business strategy > activities for target; 
prelaunch activities / launch activities in strong line with the strategy (levers / indicators); 
dedicated team / sales force incentives 5 28-30 
  
Establish Customer Relationship Management in an early stage. Establish cooperation 
concepts with pharmacies, drugstores etc. 6 36-37 
  
Corporate Culture / Branding: - The producing company stands with its company name 
and culture responsible for the product and thus creates general public trust.  6 40-41 
  To become "top of mind". 6 42 
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Strategic long-term clinical development plan (only promotion if steady flow of clinical 
results); Strategic positioning & messaging plan building on clinical plan (strategy avoid 
operational “missing up”); Strong pre-launch activities (accelerates take-up); “Stable” 
marketing / sales / medical / regulatory team (fluctuation leads to knowledge drain); 
Efficient marketing mix (sounds like common sense, but isn’t due to high turn-over in 
marketing management) 7 44-49 
  Know your customers needs 9 52 
  Targeting model, 20/80; Know your competitors well 9 53 
  Handling of real or possible side effects 4 62-63 
  Packaging and labelling. 30-40% of drug recalls  4 64 
  
no over- or under spending; Marketing excellence: differentiation to competitors basing on 
really relevant parameters 5 65-66 
  Simple, logic, story  6 68 
  
easy to tell; emotional branding, different from others; me too products are not even worth 
to launch - portfolio; 6 68-70 
  
Differentiation: - To be perceivable different and unique: no “me too” product concept; 
Positioning: - To define a clear-cut positioning statement and market segmentation 
amongst direct - Competitors; Time to Market: - Shortening the product development 
process from the idea-finding stage to the marketable - Product phase;  7 71-74 
  Continuous management of current and future competitors 8 81-82 
  To be in line with regulatory / legal laws 9 84-85 
  late market entry 3 98 
  Lack of differentiation to competitors 4 101 
  
Lack of real customer focus; Lack of creativity and the will to find new innovative ways to 
sell 4 101-102 
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does not fit to target group; young, inexperienced team not dedicated sales force and 
management  5 104-105 
  time parameters are under estimated 5 105 
  focus on launch product 5 106 
  "critical" volume 6 109 
  
Insufficient Marketing Strategy and Concepts: - To ambitious objectives, underestimation 
of time to market, lack of clear positioning, differentiation, segmentation, branding and 
sales policy 6 111-113 
  
Often insufficient, profound market and consumer patient insight = important challenge in 
the future; Appearance of new product categories 6 113-114 
  
Alternative medicine substitute the classical pharmaceutical market (no prescription by a 
doctor necessary)  6 114-115 
  Sub-optimal (pre-) launch - hard to regain momentum 7 117 
  High turnover of national / international business teams (HR!) 7 117-118 
  risk for customer interface, strategic consistency, knowledge transfer 7 118-119 
  
Not the products struggle but … are based on wrong assumptions, products are often not 
understood or wrong positioned 9 123-124 
  
understand the product, the environment (political, economical, legal, etc. constraints), the 
company 9 124-125 
Product The product itself 1 2-3. 
  
Drug relevance. The drug has to solve the biological problem; Perceived drug behaviour. 
If the drug reduces or heals the issue faster or more comfortably then a comparable drug 
then preference is given to the first;  3 11-14. 
  A good drug (efficacy, side effect, medications);  5 28 
  
Product quality: - Achievement of high therapeutic efficacy for the patients. - The quality 
performance has to be maintained in the long run on a constantly high level 6 31-32 
  Branding: 6 40 
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  To achieve quickly a high product brand awareness and image 6 41-42 
  
Develop a highly innovative and differentiated product (unethical Rx e.q. AIDS/Oncology 
the product and corresponding “disease management” solution are keys);  7 43-44 
  products to cover these needs 9 52 
  product efficacy must convince 1 55 
  Are there USP’s to the product? 1 56 
  high efficacy perception of your product is a must 2 58 
  Having the ‘right’ drug at the right time 4 61-62 
  advantages for patients and doctors in focus  6 68 
  
Product Convenience: - Work-out consumer-friendly product conception, packaging and 
strong design. Avoid over-packaging.  7 74-75 
  Efficacy, novelty (drugs and targets) 8 83 
  product is not so effective 3 95 
  product shows undesired side effects  3 96 
  not every product is worth to launch 5 105-106 
  
Product efficacy: - Many products don't meet consumer expectations or create new 
medical problems in the long term application 6 107-108 
  Most are “me too” preparations; No advantage over well known, accepted drugs 8 121 
Price justifiable price (competitive);  2 6 
  Price will become the most important issue in future; 1 55-56 
  
Margins. - To maintain economically defendable margins. Get sufficient profit to generate 
further research funds and thus assure the company’s economic existence. - Margins 
under pressure due to increased price control and pressure from governments, consumer 
protection organisations, parallel imports and generic products. 7 76-79 
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  Expiring patents lead to low cost imitations and price pressure 6 108-109 
Place 
Accessibility. How well the drug is accessible i.e. in a respective territory or can the 
production meet the demand. For a biotech this includes the right partnering with a larger 
company 3 19-21 
  
Selling: - Fast and complete distribution, availability and visibility at the sales channels. 
Fast and high penetration among the target audience;  6 38-39 
Promotion Promotion, if allowed, may support above statements and develop to a broad acceptance 1 3-4. 
  
Professional sales force: - high/top product knowledge, -enthusiastic, emotional, highly 
motivated sales rep 2 7-8. 
  Frequency: high number of sales force contracts 2 8-9. 
  
How present the drug is in the customer’s mind (doctor or patient) as in classical 
marketing understanding (through advertisement or sales force etc.);  3 17-18 
  
Sales Force Excellence: skills of the sales force and implementation of the strategy (call 
number, frequency);  4 24-25 
  
Implementation of an integrated call plan: number of calls, frequency, accompanying 
other activities (mails, e-detailing, etc.) 4 26-27 
  
Scientific documentation: - The producer has to document the scientific outcomes and 
proven evidence of seriously conducted medical trials, particularly for the medical 
"milieus"; Communication: - Public relations aimed at doctors. specialised trade and 
potential end-users to call early high interest.  6 32-36 
  Transparent. understandable and complete patient information; 6 37-38 
  
Well proven and documented efficacy; Low or tolerable side effects; Superiority over 
competition drugs (efficacy, side effects, prize, pharmacokinetics) 8 50-51 
  Have convincing arguments  9 52 
  high number of appointments is another challenge 2 58-59 
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Getting doctors doors open for the REPs (by offering services besides the product itself, 
for expl …..) 5 66-67 
  
Human resources turn-over in marketing (every 1,5 - 2 years) can impact customer 
interface and knowledge transfer - people business!;  8 80-81 
  
Promotion & sales in 100% compliance with stricter national, international and internal 
guidelines 8 82-83 
  To accurate, uncensored data 9 84 
  To get Dr. appointments for your reps 9 84 
  less noise - less prescriptions 2 93 
  lead to image problems and possible withdrawing from the market 3 96-97 
  Conservative attitude to sales & marketing methodology 4 103 
  Success by marketing has a short life time, after a few months the truth comes trough 8 121-122 
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Appendix 10 – Overview of Delivered Secondary Market Data Files 
Data File Indication Product Available Data
File_1 Betablockers 17 Sales (pharmacy & practitioners), Cummulated Sales
ACE Inhibitors 13
Sales (pharmacy & practitioners), Cummulated Sales, 
Detailing, Non-Detailing, Marketing, Cummulated 
Detailing, Cummulated Non-Detailing, Cummulated 
Marketing
Statins 7
Sales (pharmacy & practitioners), Cummulated Sales, 
Detailing, Non-Detailing, Marketing, Cummulated 
Detailing, Cummulated Non-Detailing, Cummulated 
Marketing
File_2 Betablockers 45 Sales (pharmacy & practitioners)
Betablockers 22 Sales (pharmacy & practitioners)
ACE Inhibitors 38 Sales (pharmacy & practitioners)
ACE Inhibitors 31 Sales (pharmacy & practitioners)
Statins 45 Sales (pharmacy & practitioners)
PDE5 Inhibitors 7 Sales (pharmacy & practitioners)
File_3 Betablockers 165
Medical Promotion Index (total promotion costs, 
detailing costs, mailing costs, advertising costs)
ACE Inhibitors
Statins
File_4 Statins 618 Launch date
Ulcustherapeuticals
Angiotensin II-Antagonists
Betablockers
ACE Inhibitors
PDE5 Inhibitors
File_5 Angiotensin II-Antagonists 11 Medical Promotion Index (total promotion costs, 
File_6 Betablockers
Medical Promotion Index (total promotion costs, 
detailing costs, mailing costs, advertising costs)
ACE Inhibitors
Statins
PDE5 Inhibitors
File_7 mixed (approved drugs) 6960 + 1584 (generics) Launch date, Factory price, Sales price, Indication group
File_8 mixed (approved drugs) Broad range of products Monthly sales price, Amount per product, Package size
File_9 Betablockers
Medical Promotion Index (total promotion costs, 
detailing costs, mailing costs, advertising costs)
ACE Inhibitors
Statins
PDE5 Inhibitors
File_10 Betablockers Broad range of products Launch date, (Medical Promotion Index) total promotion 
ACE Inhibitors
Statins
PDE5 Inhibitors
File_11 Betablockers Broad range of products
Launch date, Medical Promotion Index (total promotion 
costs, detailing costs, mailing costs, advertising costs)
ACE Inhibitors
Statins
PDE5 Inhibitors
File_12 PDE5 Inhibitors 7
Sales (pharmacy & practitioners), Cummulated Sales, 
Detailing, Non-Detailing
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Appendix 11 – Coding of Variables for Analysis 
VARIABLE NAME CODE DESCRIPTION
product_name 1 - 109 none
order_of_entry number of market entry order, starting with 1
drug_class_code 1 ANGIOTENSIN II ANTAGONISTS, PLAIN
2 PDE5 Inhibitors
3 BETA BLOCKING AGENTS
4 BETA BLOCKING AGENTS AND THIAZIDES
5 ACE INHIBITORS, PLAIN
6 ACE INHIBITORS, COMBINATIONS
7 LIPID MODIFYING AGENTS, PLAIN
8 BETA BLOCKING AGENTS AND OTHER DIURETICS
substance_code 1 Atenolol
2 atorvastatin
3 Bisoprolol
4 Captoprilum
5 carvedilol
6 cerivastatin 
7 Enalapril
8 Ezetimibum
9 fenofibrate
10 fluvastatin
11 fosinopril
12 Lisinoprilum
13 Metoprololi
14 moexipril
15 nebivolol
16 nicotinic acid
17 Perindopril
18 Pindolol
19 pravastatin
20 Propranolol
21 quinapril
22 Ramipril
23 simvastatin
24 sotalol
25 Trandolapril
26 Zofenopril
27 candesartan 
28 eprosartan 
29 Irbesartan
30 losartan 
31 olmesartan medoxomil 
32 Sildenafil
33 Tadalafil
34 telmisartan 
35 valsartan 
36 varapamili
37 Vardenafil
daily_drug_dose in gramm 
drug_application_range total number of approved drug applications
drug_interaction total number of drug interactions
drug_side_effects total number of drug side effects
rating_of_drug_properties 1 bad (equalized 1.0)
2 average (equalized 5.5)
3 good (equalized 10.0)
personal selling_costs Producers' monthly product personal selling costs in Swiss Francs
mailing_costs Producers' monthly product mailing costs in Swiss Francs
advertising_costs Producers' monthly advertising costs in Swiss Francs
promotion_costs Cummulated monthly product promotion costs
drug_type_code 1 tablets
2 filmtablets
3 capsules
4 ampules
5 retard tablets
6 retard capsules
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Appendix 12 – Questionnaire for Primary Data Collection 
<< INTRODUCTION >> 
 
Dear Expert 
 
I am writing to enlist your assistance in completing an online survey for a doctoral research in Pharmaceutical Marketing at 
the Aston Business and Life and Health Sciences School, Aston University in the United Kingdom.  
 
Thus, we would like to ask you your personal opinion regarding the efficacy of medical drug substances. This online survey 
will take you only 5-10 minutes to complete. Furthermore, a price draw will be made for an Ipod Shuffle, from all the 
completed entries. 
 
I assure you that any information you give will be treated with complete confidentiality. If you would find it useful, I am 
happy to provide you with a summary of the findings upon completion of the research. Please also note, that the information 
you provide is not used for any other purpose than testing theories about pharmaceutical marketing strategies. 
 
I look forward to hearing from you. A link of the online survey is given below. 
 
Yours sincerely 
 
Michael Stros 
 
 
<< PAGE ONE >> 
 
1) Sex (male/female) 
 
2) Occupation (pharmacist/doctor) 
2a) if doctor, what is your specialisation? (general practitioner; inner medicine; cardiology; diebetology; endocrinology) 
 
3) Years of experience? (less than 1y; 1-5; 6-10; 11-15; 16-20; more than 20y) 
 
4) Where are you located (list of Swiss cantons) 
 
 
<< PAGE TWO >> 
 
5)  Please rate the following medical substances for their efficacy 
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Medical Drug 
Class 
Substance Valuation No valuation 
made 
Comments 
  Not efficient – highly efficient Tick box Optional 
ACE Inhibitors  
 
Captoprilum 
 
1    2    3    4    5    6    7    8    9 
□    □    □    □    □    □    □    □    □ 
  
 Enalapril □    □    □    □    □    □    □    □    □   
 Fosinopril □    □    □    □    □    □    □    □    □   
 Lisinoprilum □    □    □    □    □    □    □    □    □   
 Moexipril □    □    □    □    □    □    □    □    □   
 Quinapril □    □    □    □    □    □    □    □    □   
 Trandolapril □    □    □    □    □    □    □    □    □   
Angiotensin II 
Antagonists 
 
 
Candesartan 
 
1    2    3    4    5    6    7    8    9 
□    □    □    □    □    □    □    □    □ 
  
 Losartan □    □    □    □    □    □    □    □    □   
 Olmesartan Medoxomil □    □    □    □    □    □    □    □    □   
 Telmisartan □    □    □    □    □    □    □    □    □   
 Valsartan □    □    □    □    □    □    □    □    □   
Beta Blockers   
1    2    3    4    5    6    7    8    9 
  
 Atenolol □    □    □    □    □    □    □    □    □   
 Bisoprolol □    □    □    □    □    □    □    □    □   
 Carvedilol □    □    □    □    □    □    □    □    □   
 Metoprololi □    □    □    □    □    □    □    □    □   
 Nebivolol □    □    □    □    □    □    □    □    □   
 Propranolol □    □    □    □    □    □    □    □    □   
 Sotalol □    □    □    □    □    □    □    □    □   
Statins   
1    2    3    4    5    6    7    8    9 
  
 Atorvastatin □    □    □    □    □    □    □    □    □   
 Cerivastatin □    □    □    □    □    □    □    □    □   
 Fluvastatin □    □    □    □    □    □    □    □    □   
 Pravastatin □    □    □    □    □    □    □    □    □   
 Simvastatin □    □    □    □    □    □    □    □    □   
PDE5 Inhibitors   
1    2    3    4    5    6    7    8    9 
  
 Sildenafil □    □    □    □    □    □    □    □    □   
 Tadalafil □    □    □    □    □    □    □    □    □   
 Vardenafil □    □    □    □    □    □    □    □    □   
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<< PAGE THREE >> 
 
6)  Please leave your email address, in case you are interested to participate on the price draw and would like to receive a 
summary of the study (optional) 
 
7)  Feel free to add additional comments (optional) 
 
 
<< PAGE FOUR >> 
 
Thank you for your participation 
If you require further information, you can contact me under 
strosm@aston.c.uk 
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Appendix 13 – Mailing 
Falls dieses e-Mail nicht korrekt dargestellt wird, klicken Sie bitte hier  
 
Sehr geehrter Herr Stros  
 
Für meine Dissertation benötige ich Ihre Unterstützung. 
 
Im Rahmen meiner wissenschaftlichen Arbeit an der 
Aston Business sowie Life & Health Sciences School, 
Aston Universität in Birmingham, Grossbritannien, 
untersuche ich Pharma Marketing Modelle.  
 
Für die Umfrage, welche lediglich 5 Minuten Ihrer Zeit in 
Anspruch nehmen wird, möchte ich Sie bitten, 
medizinische Substanzen aus fünf Wirkstoffklassen nach 
ihrer Wirksamkeit zu bewerten. 
 
Falls Sie möchten, können Sie am Ende der Befragung an einer Verlosung teilnehmen und einen Ipod Shuffle gewinnen. 
Ich kann Ihnen versichern, dass Ihre Informationen vertraulich behandelt und nur zur Überprüfung der Theorie verwendet 
werden. Falls Sie es wünschen, werde ich Ihnen gerne eine Zusammenfassung der Erkenntnisse zustellen. 
Vielen Dank für Ihre Teilnahme.  
 
Bitte beachten Sie, dass Sie während der Umfrage nicht mehr zurück kehren können. 
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Mit freundlichen Grüssen  
 
 
    
Michael Stros 
Aston Business School 
E mail: strosm@aston.ac.uk 
    
 
 
*Teilnahmeschluss ist der 22.07.2011. Ihre Angaben werden vertraulich behandelt. 
 
Ihr Team von just-medical! 
 
 
 
Unsubscribe  
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Appendix 14 – Histograms 
 
 
Figure 5-1: Histogram of Order-of-market Entry 
 
  
Figure 5-2: Histogram of Sales 
 
 304 
 
Figure 5-3: Histogram of Interaction with other Drugs 
 
 
Figure 5-4: Histogram of Side-effects 
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Figure 5-5: Histogram of Perceived Quality 
 
 
Figure 5-6: Histogram of Packaging Alternatives 
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Figure 5-7: Histogram of Average Price 
 
 
Figure 5-8: Histogram of Detailing Expenditure 
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Figure 5-9: Histogram of Mailing Expenditure 
 
 
Figure 5-10: Histogram of Advertising Expenditure 
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